NZ710648B2 - Therapy involving antibodies against claudin 18.2 for treatment of cancer - Google Patents
Therapy involving antibodies against claudin 18.2 for treatment of cancer Download PDFInfo
- Publication number
- NZ710648B2 NZ710648B2 NZ710648A NZ71064814A NZ710648B2 NZ 710648 B2 NZ710648 B2 NZ 710648B2 NZ 710648 A NZ710648 A NZ 710648A NZ 71064814 A NZ71064814 A NZ 71064814A NZ 710648 B2 NZ710648 B2 NZ 710648B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- patients
- patient
- cells
- cancer
- Prior art date
Links
- 102000004965 antibodies Human genes 0.000 title claims abstract description 379
- 108090001123 antibodies Proteins 0.000 title claims abstract description 379
- 201000011510 cancer Diseases 0.000 title claims abstract description 124
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 22
- 102000002029 Claudin Human genes 0.000 title description 11
- 108050009302 Claudin Proteins 0.000 title description 11
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims abstract description 15
- 201000006974 gastroesophageal cancer Diseases 0.000 claims abstract description 15
- 210000002966 Serum Anatomy 0.000 claims description 137
- 238000001802 infusion Methods 0.000 claims description 116
- 239000003814 drug Substances 0.000 claims description 104
- 230000027455 binding Effects 0.000 claims description 103
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 84
- 239000003795 chemical substances by application Substances 0.000 claims description 82
- 229940079593 drugs Drugs 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 60
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 59
- 108091007172 antigens Proteins 0.000 claims description 58
- 102000038129 antigens Human genes 0.000 claims description 58
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 52
- 230000014509 gene expression Effects 0.000 claims description 52
- -1 antispasmodics Substances 0.000 claims description 34
- 230000009089 cytolysis Effects 0.000 claims description 25
- 230000002934 lysing Effects 0.000 claims description 23
- 108010002350 Interleukin-2 Proteins 0.000 claims description 22
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 230000003474 anti-emetic Effects 0.000 claims description 20
- 239000002111 antiemetic agent Substances 0.000 claims description 20
- 238000001990 intravenous administration Methods 0.000 claims description 19
- 230000001404 mediated Effects 0.000 claims description 19
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 18
- 239000000812 cholinergic antagonist Substances 0.000 claims description 17
- 150000002500 ions Chemical class 0.000 claims description 17
- 206010061289 Metastatic neoplasm Diseases 0.000 claims description 16
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims description 15
- 230000001394 metastastic Effects 0.000 claims description 15
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 14
- ATALOFNDEOCMKK-OITMNORJSA-N Aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims description 13
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 230000002921 anti-spasmodic Effects 0.000 claims description 13
- 229960001372 aprepitant Drugs 0.000 claims description 13
- 210000001156 Gastric Mucosa Anatomy 0.000 claims description 12
- 229950009846 scopolamine butylbromide Drugs 0.000 claims description 12
- HOZOZZFCZRXYEK-GSWUYBTGSA-M Butylscopolamine Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 claims description 11
- 101710043956 CEACAM5 Proteins 0.000 claims description 11
- 101710040537 TNF Proteins 0.000 claims description 11
- 102000003812 Interleukin-15 Human genes 0.000 claims description 10
- 108090000172 Interleukin-15 Proteins 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 229960005019 pantoprazole Drugs 0.000 claims description 10
- 230000003482 proton pump inhibitor Effects 0.000 claims description 10
- 239000000612 proton pump inhibitor Substances 0.000 claims description 10
- 229960003727 Granisetron Drugs 0.000 claims description 9
- 229960005343 Ondansetron Drugs 0.000 claims description 9
- 230000002633 protecting Effects 0.000 claims description 9
- CPZBLNMUGSZIPR-NVXWUHKLSA-N Palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims description 8
- 229960003668 docetaxel Drugs 0.000 claims description 8
- 229960002131 palonosetron Drugs 0.000 claims description 8
- 150000003058 platinum compounds Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 7
- 230000002445 parasympatholytic Effects 0.000 claims description 7
- 239000002464 receptor antagonist Substances 0.000 claims description 7
- 150000003230 pyrimidines Chemical class 0.000 claims description 6
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 claims description 6
- 229960003571 butylscopolamine Drugs 0.000 claims description 5
- 102000002038 Claudin-18 Human genes 0.000 claims description 4
- 108050009324 Claudin-18 Proteins 0.000 claims description 4
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 claims description 4
- 230000000306 recurrent Effects 0.000 claims description 4
- 101710043948 CEACAM7 Proteins 0.000 claims description 3
- 229940075527 Detoxifying agents for antineoplastic treatment Drugs 0.000 claims description 3
- 101700086956 IFNG Proteins 0.000 claims description 3
- 101700004495 PSG2 Proteins 0.000 claims description 3
- 101700065588 TAC1 Proteins 0.000 claims description 3
- 102100002996 TAC1 Human genes 0.000 claims description 3
- 229940035295 Ting Drugs 0.000 claims description 3
- 230000036765 blood level Effects 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- GRHYHJAAOJVRSZ-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2N=C3[CH]C(OC(F)F)=CC=C3N=2)=C1OC GRHYHJAAOJVRSZ-UHFFFAOYSA-N 0.000 claims 1
- 241000282414 Homo sapiens Species 0.000 abstract description 86
- 201000010099 disease Diseases 0.000 abstract description 67
- 230000000694 effects Effects 0.000 abstract description 44
- 230000000259 anti-tumor Effects 0.000 abstract description 17
- 210000004027 cells Anatomy 0.000 description 286
- 206010028980 Neoplasm Diseases 0.000 description 74
- 238000004166 bioassay Methods 0.000 description 58
- 235000001014 amino acid Nutrition 0.000 description 46
- 206010047700 Vomiting Diseases 0.000 description 44
- 231100000494 adverse effect Toxicity 0.000 description 44
- 150000001413 amino acids Chemical class 0.000 description 42
- 230000004044 response Effects 0.000 description 42
- 108010045030 monoclonal antibodies Proteins 0.000 description 41
- 102000005614 monoclonal antibodies Human genes 0.000 description 41
- 150000001875 compounds Chemical class 0.000 description 40
- 210000001519 tissues Anatomy 0.000 description 35
- 206010027476 Metastasis Diseases 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 29
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 28
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 28
- 229960000060 monoclonal antibodies Drugs 0.000 description 28
- 210000001744 T-Lymphocytes Anatomy 0.000 description 27
- 238000002512 chemotherapy Methods 0.000 description 26
- 230000003902 lesions Effects 0.000 description 24
- 206010028813 Nausea Diseases 0.000 description 23
- 229960002949 Fluorouracil Drugs 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000002496 gastric Effects 0.000 description 21
- 238000000034 method Methods 0.000 description 21
- 210000004881 tumor cells Anatomy 0.000 description 21
- 102000000588 Interleukin-2 Human genes 0.000 description 20
- 230000001965 increased Effects 0.000 description 20
- 101710027851 C1orf56 Proteins 0.000 description 19
- 210000002784 Stomach Anatomy 0.000 description 19
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 18
- 229960001756 oxaliplatin Drugs 0.000 description 18
- 210000004369 Blood Anatomy 0.000 description 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 17
- 206010017758 Gastric cancer Diseases 0.000 description 17
- 210000004408 Hybridomas Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 201000011549 stomach cancer Diseases 0.000 description 17
- 239000000439 tumor marker Substances 0.000 description 17
- 208000000675 Krukenberg Tumor Diseases 0.000 description 16
- 201000009210 Krukenberg carcinoma Diseases 0.000 description 16
- 206010027462 Metastases to ovary Diseases 0.000 description 16
- 230000000295 complement Effects 0.000 description 16
- 239000000523 sample Substances 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- 230000004083 survival Effects 0.000 description 15
- 102000018358 Immunoglobulins Human genes 0.000 description 14
- 108060003951 Immunoglobulins Proteins 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 230000001939 inductive effect Effects 0.000 description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 14
- 239000011780 sodium chloride Substances 0.000 description 14
- 229960001904 EPIRUBICIN Drugs 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 208000009956 Adenocarcinoma Diseases 0.000 description 12
- 230000037242 Cmax Effects 0.000 description 12
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 12
- 210000001165 Lymph Nodes Anatomy 0.000 description 12
- 238000009104 chemotherapy regimen Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 229960004117 Capecitabine Drugs 0.000 description 11
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 11
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 108091006028 chimera Proteins 0.000 description 11
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 11
- 230000036961 partial Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 210000003238 Esophagus Anatomy 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 230000003247 decreasing Effects 0.000 description 10
- 239000000890 drug combination Substances 0.000 description 10
- 229960001691 leucovorin Drugs 0.000 description 10
- IQPSEEYGBUAQFF-UHFFFAOYSA-N pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 10
- 238000010186 staining Methods 0.000 description 10
- 230000001225 therapeutic Effects 0.000 description 10
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 10
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 9
- 239000000969 carrier Substances 0.000 description 9
- 229960004316 cisplatin Drugs 0.000 description 9
- 235000008191 folinic acid Nutrition 0.000 description 9
- 239000011672 folinic acid Substances 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 200000000025 progressive disease Diseases 0.000 description 9
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 8
- 206010020751 Hypersensitivity Diseases 0.000 description 8
- 108010010691 Trastuzumab Proteins 0.000 description 8
- 238000007792 addition Methods 0.000 description 8
- 230000022131 cell cycle Effects 0.000 description 8
- 230000030833 cell death Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 210000004602 germ cell Anatomy 0.000 description 8
- 230000028993 immune response Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 8
- 229960005249 misoprostol Drugs 0.000 description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 8
- 210000000056 organs Anatomy 0.000 description 8
- 230000000087 stabilizing Effects 0.000 description 8
- 229960000575 trastuzumab Drugs 0.000 description 8
- 210000002472 Endoplasmic Reticulum Anatomy 0.000 description 7
- 210000000987 Immune System Anatomy 0.000 description 7
- 102000004851 Immunoglobulin G Human genes 0.000 description 7
- 108090001095 Immunoglobulin G Proteins 0.000 description 7
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 7
- 108060001084 Luciferase family Proteins 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 210000001672 Ovary Anatomy 0.000 description 7
- 230000037165 Serum Concentration Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 7
- 229960004768 irinotecan Drugs 0.000 description 7
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 7
- 230000002147 killing Effects 0.000 description 7
- 230000003211 malignant Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 230000000069 prophylaxis Effects 0.000 description 7
- 101700043375 sing Proteins 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000002194 synthesizing Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 229960004276 zoledronic acid Drugs 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 206010003445 Ascites Diseases 0.000 description 6
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 6
- 229960004679 Doxorubicin Drugs 0.000 description 6
- 229940108890 Emend Drugs 0.000 description 6
- 108010087819 Fc receptors Proteins 0.000 description 6
- 102000009109 Fc receptors Human genes 0.000 description 6
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 210000004698 Lymphocytes Anatomy 0.000 description 6
- 108091008153 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 229940072018 Zofran Drugs 0.000 description 6
- 229940045698 antineoplastic Taxanes Drugs 0.000 description 6
- 230000001419 dependent Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000036231 pharmacokinetics Effects 0.000 description 6
- 229910052697 platinum Inorganic materials 0.000 description 6
- 231100000486 side effect Toxicity 0.000 description 6
- 230000004936 stimulating Effects 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- KSEYRUGYKHXGFW-UHFFFAOYSA-N Alizapride Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 5
- 229940088506 Buscopan Drugs 0.000 description 5
- 208000005156 Dehydration Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101700010262 GLIS2 Proteins 0.000 description 5
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 5
- 206010027457 Metastases to liver Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 210000003995 blood forming stem cell Anatomy 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 125000005647 linker group Chemical group 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000003389 potentiating Effects 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 230000003248 secreting Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 4
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 4
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 4
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 4
- 206010059512 Apoptosis Diseases 0.000 description 4
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 4
- MJIHNNLFOKEZEW-UHFFFAOYSA-N Dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 210000003236 Esophagogastric Junction Anatomy 0.000 description 4
- 210000004907 Glands Anatomy 0.000 description 4
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 241000229754 Iva xanthiifolia Species 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 4
- 210000004072 Lung Anatomy 0.000 description 4
- 230000036917 MEAN CMAX Effects 0.000 description 4
- MBKDYNNUVRNNRF-UHFFFAOYSA-N Medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 4
- 210000001616 Monocytes Anatomy 0.000 description 4
- 206010028334 Muscle spasms Diseases 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 229960001592 Paclitaxel Drugs 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 208000002151 Pleural Effusion Diseases 0.000 description 4
- 229940077718 Proton pump inhibitors for peptic ulcer and GORD Drugs 0.000 description 4
- 230000036191 S Phase Effects 0.000 description 4
- 230000018199 S phase Effects 0.000 description 4
- 229940059160 Sancuso Drugs 0.000 description 4
- 210000001578 Tight Junctions Anatomy 0.000 description 4
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 4
- 231100000765 Toxin Toxicity 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000001640 apoptogenic Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000003115 biocidal Effects 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 201000009030 carcinoma Diseases 0.000 description 4
- 230000022534 cell killing Effects 0.000 description 4
- 230000001085 cytostatic Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000000378 dietary Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940000406 drug candidates Drugs 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940079866 intestinal antibiotics Drugs 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000002777 nucleoside Chemical class 0.000 description 4
- 150000003833 nucleoside derivatives Chemical class 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrugs Drugs 0.000 description 4
- 230000002035 prolonged Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229930003347 taxol Natural products 0.000 description 4
- 229960000303 topotecan Drugs 0.000 description 4
- 108020003112 toxins Proteins 0.000 description 4
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 3
- 108060000679 ATG12 Proteins 0.000 description 3
- 102100004996 ATP12A Human genes 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 229940022659 Acetaminophen Drugs 0.000 description 3
- 229960004176 Aclarubicin Drugs 0.000 description 3
- 229940014175 Aloxi Drugs 0.000 description 3
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 3
- 229960000396 Atropine Drugs 0.000 description 3
- 102100004931 CALR Human genes 0.000 description 3
- 101700033040 CALR Proteins 0.000 description 3
- 102100006400 CSF2 Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 229940109239 Creatinine Drugs 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- 229960000975 Daunorubicin Drugs 0.000 description 3
- 101700025368 ERBB2 Proteins 0.000 description 3
- 102000027760 ERBB2 Human genes 0.000 description 3
- 229940088598 Enzyme Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 210000000981 Epithelium Anatomy 0.000 description 3
- 230000035521 G2 Phase Effects 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 241000126130 Ganymedes Species 0.000 description 3
- 208000008032 Gastrointestinal Hemorrhage Diseases 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- 229960001156 Mitoxantrone Drugs 0.000 description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
- 210000004693 NK cell Anatomy 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 108010083204 Proton Pumps Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108010001645 Rituximab Proteins 0.000 description 3
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 3
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003110 anti-inflammatory Effects 0.000 description 3
- 150000004663 bisphosphonates Chemical class 0.000 description 3
- 230000000903 blocking Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 235000011180 diphosphates Nutrition 0.000 description 3
- 230000002708 enhancing Effects 0.000 description 3
- 230000001747 exhibiting Effects 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 229960004503 metoclopramide Drugs 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 229920005589 poly(ferrocenylsilane) Polymers 0.000 description 3
- 230000000750 progressive Effects 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 231100000730 tolerability Toxicity 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1R,2R)-1,2-dimethanidylcyclohexane;5-fluoro-1H-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 2
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- MJIHNNLFOKEZEW-RUZDIDTESA-N 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 description 2
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical class FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 2
- 101700027111 3SA0 Proteins 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 108010005144 Bevacizumab Proteins 0.000 description 2
- 108010071919 Bispecific Antibodies Proteins 0.000 description 2
- 230000036868 Blood Concentration Effects 0.000 description 2
- 210000001772 Blood Platelets Anatomy 0.000 description 2
- 102100001239 CLDN18 Human genes 0.000 description 2
- 101710026502 CLDN18 Proteins 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 2
- 210000000170 Cell Membrane Anatomy 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 2
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 2
- 108010022830 Cetuximab Proteins 0.000 description 2
- 210000001072 Colon Anatomy 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229940072645 Coumadin Drugs 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- 102000003915 DNA Topoisomerases Human genes 0.000 description 2
- 108090000323 DNA Topoisomerases Proteins 0.000 description 2
- 229960000640 Dactinomycin Drugs 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 2
- 208000006922 Drug-Related Side Effects and Adverse Reaction Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 229960001433 Erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- CNZOFNMWZBNPLL-OSKRVHINSA-L FLOT Regimen Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@H]1CCCC[C@@H]1[NH-].FC1=CNC(=O)NC1=O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)C(O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 CNZOFNMWZBNPLL-OSKRVHINSA-L 0.000 description 2
- JYEFSHLLTQIXIO-SMNQTINBSA-N FOLFIRI regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 2
- 230000035693 Fab Effects 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 210000004211 Gastric Acid Anatomy 0.000 description 2
- 206010018065 General disorders and administration site conditions Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 206010073069 Hepatic cancer Diseases 0.000 description 2
- 208000006454 Hepatitis Diseases 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006822 Human Serum Albumin Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 229940050492 Leucovorin 200 MG Drugs 0.000 description 2
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 2
- DLBFLQKQABVKGT-UHFFFAOYSA-L Lucifer yellow Chemical compound [Li+].[Li+].[O-]S(=O)(=O)C1=CC(C(N(C(=O)NN)C2=O)=O)=C3C2=CC(S([O-])(=O)=O)=CC3=C1N DLBFLQKQABVKGT-UHFFFAOYSA-L 0.000 description 2
- 230000036882 MTD Effects 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 210000004379 Membranes Anatomy 0.000 description 2
- 206010051676 Metastases to peritoneum Diseases 0.000 description 2
- RONZAEMNMFQXRA-UHFFFAOYSA-N Mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N Mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000010125 Myocardial Infarction Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010028817 Nausea and vomiting symptom Diseases 0.000 description 2
- 241001182492 Nes Species 0.000 description 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 2
- 229920001850 Nucleic acid sequence Polymers 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 229940072417 Peroxidase Drugs 0.000 description 2
- 108090000437 Peroxidases Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J Pyrophosphate Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 206010038435 Renal failure Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 206010068760 Ulcers Diseases 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- 229940002005 Zometa Drugs 0.000 description 2
- URRBLVUOXIGNQR-HXUWFJFHSA-N [(1R)-1-phenylethyl] N-(2-aminoethyl)-N-[(3-methoxy-4-phenylmethoxyphenyl)methyl]carbamate Chemical class C1([C@@H](C)OC(=O)N(CCN)CC=2C=C(C(=CC=2)OCC=2C=CC=CC=2)OC)=CC=CC=C1 URRBLVUOXIGNQR-HXUWFJFHSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 231100000367 adverse event profile Toxicity 0.000 description 2
- 229960003687 alizapride Drugs 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000000890 antigenic Effects 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000002146 bilateral Effects 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002490 cerebral Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000973 chemotherapeutic Effects 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000002254 contraceptive Effects 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 101700067609 ctx Proteins 0.000 description 2
- 230000001461 cytolytic Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 229960003568 dexlansoprazole Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N dilactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003292 diminished Effects 0.000 description 2
- 229960003413 dolasetron Drugs 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 description 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 description 2
- 210000002919 epithelial cells Anatomy 0.000 description 2
- 230000001605 fetal Effects 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000001861 immunosuppresant Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 229960003174 lansoprazole Drugs 0.000 description 2
- 230000001665 lethal Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral Effects 0.000 description 2
- 230000000275 pharmacokinetic Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000000770 pro-inflamatory Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 231100000191 repeated dose toxicity Toxicity 0.000 description 2
- 230000003362 replicative Effects 0.000 description 2
- 231100000247 serious adverse effect Toxicity 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 101700082413 tant Proteins 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 229960003688 tropisetron Drugs 0.000 description 2
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- OGAPHRMCCQCJOE-BNTLRKBRSA-N (1R,2R)-cyclohexane-1,2-diamine;oxalic acid;platinum Chemical compound [Pt].OC(=O)C(O)=O.N[C@@H]1CCCC[C@H]1N OGAPHRMCCQCJOE-BNTLRKBRSA-N 0.000 description 1
- SSJXIUAHEKJCMH-WDSKDSINSA-N (1S,2S)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@@H]1N SSJXIUAHEKJCMH-WDSKDSINSA-N 0.000 description 1
- IJKBFKGHBSORFS-HPTNQIKVSA-N (1S,3S)-3-acetyl-11-amino-1-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-3,6-dihydroxy-10-methoxy-2,4-dihydro-1H-tetracene-5,12-dione Chemical compound O([C@@H]1C2=C(C[C@](O)(C1)C(C)=O)C(=O)C=1C(O)=C3C=CC=C(C3=C(N)C=1C2=O)OC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 IJKBFKGHBSORFS-HPTNQIKVSA-N 0.000 description 1
- OMJKFYKNWZZKTK-UXBLZVDNSA-N (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1\N=CN=C1C(N)=O OMJKFYKNWZZKTK-UXBLZVDNSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical class CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- QDVBKXJMLILLLB-UHFFFAOYSA-N 1,4'-bipiperidine Chemical compound C1CCCCN1C1CCNCC1 QDVBKXJMLILLLB-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 2-benzhydryloxy-N,N-dimethylethanamine;8-chloro-1,3-dimethyl-7H-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- KKRAMGIVRBZVCD-UHFFFAOYSA-N 2-benzhydryloxyethyl(dimethyl)azanium;8-chloro-1,3-dimethyl-2-oxopurin-6-olate Chemical compound CN1C(=O)N(C)C([O-])=C2N=C(Cl)N=C21.C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 KKRAMGIVRBZVCD-UHFFFAOYSA-N 0.000 description 1
- WUIABRMSWOKTOF-OCBSMOPSSA-N 3-[[2-[2-[2-[[2-[[4-[[2-[[6-amino-2-[3-amino-1-[(2,3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxym Chemical compound OS([O-])(=O)=O.N=1C(C=2SC=C(N=2)C(=O)NCCC[S+](C)C)=CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OCBSMOPSSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-ABYLTEMBSA-N 4-[(2S,3S,4S)-3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]morpholine-3-carbonitrile Chemical compound N1([C@H]2CC(O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-ABYLTEMBSA-N 0.000 description 1
- PQUGCKBLVKJMNT-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 description 1
- 102000035257 5-HT3 receptors Human genes 0.000 description 1
- 108091005518 5-HT3 receptors Proteins 0.000 description 1
- 102000037085 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091019276 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N ABTS Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 101710034857 ATIC Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 206010059837 Adhesion Diseases 0.000 description 1
- 229940009456 Adriamycin Drugs 0.000 description 1
- 229940064305 Adrucil Drugs 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 229940062527 Alendronate Drugs 0.000 description 1
- 229960004343 Alendronic acid Drugs 0.000 description 1
- 210000004141 Ampulla of Vater Anatomy 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 206010002383 Angina pectoris Diseases 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N Anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 229940059707 Anzemet Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229940009098 Aspartate Drugs 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- 210000002469 Basement Membrane Anatomy 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000000013 Bile Ducts Anatomy 0.000 description 1
- 210000003445 Biliary Tract Anatomy 0.000 description 1
- 230000037177 Biodistribution Effects 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 208000003432 Bone Disease Diseases 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000000481 Breast Anatomy 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 102100003755 CCNO Human genes 0.000 description 1
- 101700047412 CCNO Proteins 0.000 description 1
- 210000001266 CD8-Positive T-Lymphocytes Anatomy 0.000 description 1
- YBCNXCRZPWQOBR-WVHCHWADSA-N CHEMBL1618102 Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 YBCNXCRZPWQOBR-WVHCHWADSA-N 0.000 description 1
- 101700050822 CKX1 Proteins 0.000 description 1
- 102000004082 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229940001981 Carac Drugs 0.000 description 1
- 210000002318 Cardia Anatomy 0.000 description 1
- 206010007515 Cardiac arrest Diseases 0.000 description 1
- 206010007554 Cardiac failure Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 210000003855 Cell Nucleus Anatomy 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 210000003679 Cervix Uteri Anatomy 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
- 210000000349 Chromosomes Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L Cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- YIIZDEFVEBNFGA-UHFFFAOYSA-N Cl.C1=C(O)C=C2C=C(CN3C4=CC=5C(O)C(=O)OC(C=5C3=O)CC)C4=NC2=C1 Chemical compound Cl.C1=C(O)C=C2C=C(CN3C4=CC=5C(O)C(=O)OC(C=5C3=O)CC)C4=NC2=C1 YIIZDEFVEBNFGA-UHFFFAOYSA-N 0.000 description 1
- 208000009060 Clear Cell Adenocarcinoma Diseases 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N Clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002286 Clodronic Acid Drugs 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 108009000280 Complement Activation Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229940095074 Cyclic AMP Drugs 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N DL-aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229940029964 DRUGS FOR ACID RELATED DISORDERS Drugs 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 208000000264 Deglutition Disorders Diseases 0.000 description 1
- 210000004443 Dendritic Cells Anatomy 0.000 description 1
- 229940008871 Dexilant Drugs 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N Diatrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
- 229960004993 Dimenhydrinate Drugs 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 229940099182 Dramamine Drugs 0.000 description 1
- 229940075060 Driminate Drugs 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010013950 Dysphagia Diseases 0.000 description 1
- 210000003981 Ectoderm Anatomy 0.000 description 1
- 229940099302 Efudex Drugs 0.000 description 1
- 208000000292 Ehrlichiosis Diseases 0.000 description 1
- 229940087477 Ellence Drugs 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 210000001900 Endoderm Anatomy 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- 229960004585 Etidronic Acid Drugs 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940064300 Fluoroplex Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108090000045 G-protein coupled receptors Proteins 0.000 description 1
- 102000003688 G-protein coupled receptors Human genes 0.000 description 1
- 230000035520 G1 Phase Effects 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 101700043945 GLBB Proteins 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 206010049438 General physical health deterioration Diseases 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- IUAYMJGZBVDSGL-UHFFFAOYSA-N Gramicidin Chemical compound N1C(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCN)NC(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C1CC1=CC=CC=C1 IUAYMJGZBVDSGL-UHFFFAOYSA-N 0.000 description 1
- 101700083699 HIS6 Proteins 0.000 description 1
- 208000005721 HIV Infections Diseases 0.000 description 1
- 108010001860 HMGB Proteins Proteins 0.000 description 1
- 102000000849 HMGB Proteins Human genes 0.000 description 1
- 206010018830 Haematemesis Diseases 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failure Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010012104 Heterophile Antibodies Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 240000006600 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- 102100016020 IFNG Human genes 0.000 description 1
- 102100008982 IL17A Human genes 0.000 description 1
- 101710003110 IL17A Proteins 0.000 description 1
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 1
- 101710004172 INPP1 Proteins 0.000 description 1
- 102100004930 INPP1 Human genes 0.000 description 1
- 229940015872 Ibandronate Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N Incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 1
- 229940100601 Interleukin-6 Drugs 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022694 Intestinal perforation Diseases 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- FHFHNVHRVKQQHN-UHFFFAOYSA-N Islandicin Chemical compound C1=CC=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O FHFHNVHRVKQQHN-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 210000004759 MCP Anatomy 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241001446467 Mama Species 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 210000003716 Mesoderm Anatomy 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N Metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 210000004688 Microtubules Anatomy 0.000 description 1
- 102000028664 Microtubules Human genes 0.000 description 1
- 108091022031 Microtubules Proteins 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N Minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 1
- 229960001785 Mirtazapine Drugs 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 208000003420 Nasal Septal Perforation Diseases 0.000 description 1
- 206010028765 Nasal septum perforation Diseases 0.000 description 1
- 229940112641 Nexium Drugs 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
- 229950004969 Olpadronic acid Drugs 0.000 description 1
- 229940100688 Oral Solution Drugs 0.000 description 1
- 229940096978 Oral Tablet Drugs 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010058823 Ovarian mass Diseases 0.000 description 1
- 101700051812 PPA1 Proteins 0.000 description 1
- 102100002896 PSG2 Human genes 0.000 description 1
- 101710040931 PTGS1 Proteins 0.000 description 1
- 102100006335 PTGS1 Human genes 0.000 description 1
- 101710040930 PTGS2 Proteins 0.000 description 1
- 102100015381 PTGS2 Human genes 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 210000000277 Pancreatic Ducts Anatomy 0.000 description 1
- 210000001002 Parasympathetic Nervous System Anatomy 0.000 description 1
- 210000001914 Parietal Cells, Gastric Anatomy 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 210000004303 Peritoneum Anatomy 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N Phencyclidine Chemical class C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N Phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- 229940032668 Prevacid Drugs 0.000 description 1
- 229940089505 Prilosec Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 229940061276 Protonix Drugs 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 210000004915 Pus Anatomy 0.000 description 1
- 210000001187 Pylorus Anatomy 0.000 description 1
- 229940083082 Pyrimidine derivatives acting on arteriolar smooth muscle Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N Ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 Ranitidine Drugs 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 229940080693 Reglan Drugs 0.000 description 1
- 229940023942 Remeron Drugs 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 108060008443 TPPP Proteins 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 241001116500 Taxus Species 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229960002372 Tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N Tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 206010007867 Tissue disorder Diseases 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 206010045146 Tularaemia Diseases 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 210000003803 Urachus Anatomy 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229940019333 Vitamin K antagonists Drugs 0.000 description 1
- 229940053867 Xeloda Drugs 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229930000525 aclacinomycin A Natural products 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional Effects 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-M alendronate(1-) Chemical compound NCCCC(O)(P(O)(O)=O)P(O)([O-])=O OGSPWJRAVKPPFI-UHFFFAOYSA-M 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- RGHILYZRVFRRNK-UHFFFAOYSA-N anthracene-1,2-dione Chemical class C1=CC=C2C=C(C(C(=O)C=C3)=O)C3=CC2=C1 RGHILYZRVFRRNK-UHFFFAOYSA-N 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001754 anti-pyretic Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940058303 antinematodal Benzimidazole derivatives Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites Pyrimidine analogues Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000091 biomarker candidate Substances 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 229960005331 calcium folinate Drugs 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 230000003399 chemotactic Effects 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000001010 compromised Effects 0.000 description 1
- 201000006233 congestive heart failure Diseases 0.000 description 1
- 230000001268 conjugating Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000001627 detrimental Effects 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010870 diseases of metabolism Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229950008597 drug INN Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108060002971 flz Proteins 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- REHUGJYJIZPQAV-UHFFFAOYSA-N formaldehyde;methanol Chemical compound OC.O=C REHUGJYJIZPQAV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 210000004475 gamma-delta T lymphocyte Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 101700020815 hbp2 Proteins 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 101710008935 hisHF Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000001506 immunosuppresive Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 201000008255 invasive lobular carcinoma Diseases 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229950000257 metamizole Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- KJBLQGHJOCAOJP-UHFFFAOYSA-N metoclopramide hydrochloride Chemical compound O.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC KJBLQGHJOCAOJP-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial Effects 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000001613 neoplastic Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 230000003364 opioid Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000001936 parietal Effects 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000023 polynucleotide Polymers 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000009101 premedication Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- KRCQSTCYZUOBHN-UHFFFAOYSA-N rabeprazole sodium Chemical compound [Na+].COCCCOC1=CC=NC(CS(=O)C=2[N-]C3=CC=CC=C3N=2)=C1C KRCQSTCYZUOBHN-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000001690 radiotoxic Effects 0.000 description 1
- 231100000336 radiotoxic Toxicity 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 235000018770 reduced food intake Nutrition 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000000198 serotonin 5-HT3 receptor agonist Substances 0.000 description 1
- 230000001568 sexual Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 230000002048 spasmolytic Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960005324 tiludronic acid Drugs 0.000 description 1
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000224 toxic side effect Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 201000005485 toxoplasmosis Diseases 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 230000001228 trophic Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 230000001755 vocal Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Abstract
The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained. patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.
Description
TREATMENT
THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR
OF CANCER
the malignancies
Cancers of the stomach and the esophagus (gastroesophageal; GE) are among
of cancer death
with the highest unmet medical need. Gastric cancer is the second leading cause
with
worldwide. The incidence of esophageal cancer has sed in recent s, ding
arcinoma of the esophagus is now
a shift in histological type and primary tumor location.
more prevalent than squamous cell carcinoma in the United States and Western Europe, with
survival rate for GE cancer is
most tumors located in the distal esophagus. The overall five-year
associated with ntial
20-25%. despite the aggressiveness of established standard treatment
side effects.
and have to be
The majority of patients presents with y advanced or metastatic disease
of platinum
subjected to first—line chemotherapy. Treatment ns are based on a backbone
taxane or
and pyrimidine derivatives mostly combined with a third compound (e.g.
anthracyclines). Still, median progression free survival of 5 to 7 months and median l
survival of 9 to 11 months are the best that can be expected.
The lack of a major benefit from the s newer generation combination chemotherapy
regimens for these cancers has stimulated research into the use of targeted agents. Recently,
Her2/neu—positive gastroesophageal cancers Trastuzumab has been approved. However, as only
need is still
~20% of patients express the target and are eligible for this treatment, the medical
high.
member
The tight junction molecule Claudin )8 splice variant 2 (Claudin 18.2 (CLDN18.2)) is a
of the claudin family of tight junction proteins. CLDN18.2 is a 27.8 kDa embrane protein
comprising four ne spanning domains with two small ellular loops.
In normal tissues there is no detectable expression of CLDN18.2 by RT-PCR with exception
stomach. Immunohistochemistry with CLDN18.2 specific antibodies reveals stomach as the only
positive tissue.
CLDN18.2 is selective gastric lineage antigen expressed exclusively on short-lived
a highly
differentiated gastric epithelial cells. CLDN18.2 is maintained in the course of malignant
transformation and thus frequently displayed on the surface of human gastric cancer cells.
Moreover, this pan-tumoral antigen is ectopically activated at cant levels in esophageal,
pancreatic and lung adenocarcinomas. The .2 protein is also zed in lymph node
into the ovary
metastases of gastric cancer adenocarcinomas and in distant metastases especially
(so-called Krukenberg tumors).
The chimeric IgGl antibody IMAB362 which is directed against .2 has been developed
by Ganymed Pharmaceuticals AG. IMAB362 recognizes the first ellular domain (ECDl)
claudin
of CLDN18.2 with high affinity and specificity. IMAB362 does not bind to any other
family member including the closely related splice variant 1 of Claudin (CLDN18.1).
[MAB362 shows precise tumor cell specificity and bundles four independent highly potent
isms of action. Upon target g IMAB362 mediates cell killing by ADCC, CDC
direct
induction of apoptosis induced by cross linking of the target at the tumor cell surface and
inhibition of proliferation. Thus, IMAB362 lyses efficiently CLDN18.2-positive cells, including
cell
human gastric cancer cell lines in vitro and in viva. Mice g CLDN18.2—positive cancer
treated
lines have a survival benefit and up to 40% of mice show regression of their tumor when
_‘ With IMAB362.
The toxicity and PK/TK profile of IMAB362 has been ghly examined in mice and
cynomolgus monkeys including dose range finding studies, 28-day repeated dose toxicity studies
in cynomolgus and a 3-month repeated dose toxicity study in mice. in both mice (longest
treatment duration weekly administration for 3 months, highest dose levels 400 mg/kg) and
lgus monkeys (up to 5 weekly applications of up to 100 mg/kg) repeated doses of
IMAB362 i.v. are well tolerated. No signs of systemic or local toxicity are induced. Specifically,
does not induce immune
no gastric toxicity has been observed in any toxicity study. IMAB362
activation and cytokine release. No adverse effects on male or female reproductive organs were
ed. 2 does not bind to tissues lacking the target. Biodistribution studies in mice
indicate that the reason for lack of gastric ty is most likely compartimentalization of tight
junctions at the luminal site in healthy gastric epitheli'a, which s to impair accessibility of
the IMAB362 epitope profoundly. This compartimentalization is lost upon malignant
transformation rendering the epitope drugable by IMAB362.
Here we present data demonstrating that administration of an anti-CLDN18.2 antibody such as
IMAB362 to human patients with gastroesophageal cancer is safe and well—tolerated up to a dose
of at least 1000 mg/mz. Furthermore, the data presented herein demonstrate that the antibody is
fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral
activity was obtained.
Y OF THE INVENTION
The present invention generally provides a therapy for effectively treating and/or preventing
diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric
cancer, esophageal cancer, pancreatic cancer, lung cancer such as non small cell lung cancer
(NSCLC), ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the
gallbladder and metastases thereof, in particular gastric cancer metastasis such as Krukenberg
tumors, peritoneal metastasis and lymph node metastasis. Particularly red cancer diseases
are arcinomas of the stomach, the esophagus, the pancreatic duct, the bile ducts, the lung
and the ovary.
In a first aspect, the t invention provides a method of treating or preventing a cancer
disease sing administering to a patient an antibody having the ability of g to
CLDN18.2, wherein the antibody is administered so as to provide a serum level of at least 40
pg/ml. In different embodiments, the antibody is administered so as to provide a serum level of
at least 50 ug/ml, at least 150 pg/ml, at least 300 pg/ml, at least 400 11ng or at least 500 pgml.
ln different embodiments, the antibody is administered so as to provide a serum level of not
more than 800 ug/ml, 700 pg/ml, 600 ug/ml, 550 pg/ml or 500 pg/ml. In one embodiment, the
serum level provided is between 40 pg/ml and 700 pig/ml, ably 40 pg/ml and 600 pgml,
preferably 50 pg/ml and 500 11ng such as between 150 11ng and 500 pg/ml or 300 pg/ml and
500 pg/ml. By the term "serum level", as used in the present specification, it is meant a
concentration of the substance in on in the blood serum. In one embodiment, theuserum
level is provided for at least 7 days or at least 14 days. In one ment, the method
comprises stering a dose/doses of the antibody of at least 300 mg/m2 such as at least 600
mg/m2 and preferably up to 1500 mg/mz, up to 1200 mg/m2 or up to 1000 mg/mz.
in a second aspect, the present invention provides a method of treating or preventing a cancer
disease comprising administering to a t an antibody having the y of binding to
WO 46778
CLDN18.2, wherein the antibody is administered at a dose of at least 300 mg/m2 such as at least
600 mg/m2 and preferably up to 1500 mg/mz, up to 1200 mg/m2 or up to 1000 mg/mz.
In a third. aspect, the present invention provides a method of treating or preventing a cancer
disease comprising stering to a patient an antibody having the ability of binding to
.2, wherein at least 50%, preferably 60%, 70%, 80% or 90% of the cancer cells of the
patient are CLDN18.2 positive and/or at least 40%, preferably 50% or 60% of the cancer cells of
the patient are positive for surface expression of CLDN18.2. In this aspect, the present invention
also provides a method of treating or preventing a cancer disease, said method comprising: a.
identifying a t exhibiting at least 50%, preferably 60%, 70%, 80% or 90% CLDN18.2
positive cancer cells and/or at least 40%, preferably 50% or 60% cancer cells which are positive
for surface expression of CLDN18.2; and b. administering to said patient an antibody having the
ability of binding to CLDN18.2. In one embodiment, at least 95% or at least 98% of the cancer-
cells ofthe patient are CLDN18.2 positive. In one ment, at least 70%, at least 80% or at
least 90% of the cancer cells of the patient are positive for surface sion ofCLDN18.2.
In one embodiment of the method of any of the aspects bed herein, treatment of the cancer
disease s in achieving stable e. In one embodiment, stable disease is achieved for at
least 2 months, at least 3 months or at least 6 months.
In a fourth aspect, the present invention provides a method of achieving stable disease in a
cancer patient comprising stering to the patient an antibody having the ability of binding
to CLDN18.2. In one embodiment, stable disease is achieved for at least 2 months, at least 3
months or at least 6 .
In one ment of the method of any of the aspects described herein, the antibody is
administered in a single dose or in multiple doses.
In a fifth aspect, the present invention provides a method of treating or preventing a cancer
disease comprising administering to a t an antibody having the ability of binding to
CLDN18.2, wherein the antibody is administered in multiple doses.
If acccording to the invention the antibody is administered in multiple doses, the antibody is
preferably administered in at least 3 doses. at least 4 doses, at least 5 doses, at least 6 doses, at
least 7 doses, at least 8 doses, at least 9 doses or at least 10 doses and preferably
up to 30, 25, 20,
or 10 doses. The doses of the antibody are preferably administered in time intervals of at least
7 days, at least 10 days, at least 14 days, or at least 20 days. The doses of the antibody are
preferably administered in time intervals of between 7 and 30 days, 10 and 20 days and
preferably about 14 days.
In one embodiment of the method of the third, fourth or fifih aspect, the antibody is administered
so as to provide a serum level of at least 40 pg/ml. In different embodiments, the antibody is
administered so as to e a serum level of at least 50 ug/ml, at least 150 ug/ml, at least 300
ug/ml, at least 400 ug/ml or at, least 500 ug/ml. In different embodiments, the dy is
administered so as to provide a serum level of not more than 800 ug/ml, 700 pg/ml, 600 ug/ml,
550 14ng or 500 pg/ml. In one embodiment, the serum level provided is n 40 ug/ml and
700 pg/ml, preferably 40 ug/ml and 600 ug/ml, preferably 50 ug/ml and 500 ug/rnl such as
between 150 pyml and 500 pg/ml or 300 itng and 500 pg/ml. In one mebodiment, the serum
level is provided for at least 7 days or at least 14 days. In one embodiment, the method
comprises administering a dose/doses of the antibody of at least 300 mg/m2 such as at least 600
mg/m2 and preferably up to 1500 mgmz, up to 1200 mg/m2 or up to 1000 mg/mz.
In one embodiment of the method of any of the above aspects, the method r comprises
administering one or more selected from the group consisting of antiemetics, antispasmodics,
parasympatholytics and agents which protect gastric mucosa.
In a sixth aspect, the present invention es a method of treating or preventing a cancer
disease comprising administering to a patient an antibody having the ability of binding to
CLDN18.2 and one or more selected from the group consisting of antiemetics, asmodics,
parasympatholytics and agents which protect c mucosa.
If the method of the invention comprises administering one or more selected from the
group
consisting of antiemetics, asmodics, parasympatholytics and agents which protect gastric
mucosa, the method in different embodiments comprises administering: (i) an antiemetic and an
antispasmodic, (ii) an antispasmodic and an agent which protects gastric mucosa, (iii) an
etic and an agent which protects c mucosa or (iv) an antiemetic, an antispasmodic
and an agent which protects gastric mucosa.
In embodiment, administered as antiemetic
one an antiemetic is prophylaxis prior to
administration of the antibody. In one embodiment, an antiemetic is administered as antiemetic
intervention simultaneously with and/or following administration of the antibody. In one
l (NKl)
embodiment, the antiemetic comprises a 5-HT3 receptor antagonist and/or a neurokinin
(e. g. Emend)
receptor antagonist. Preferably, the NKI receptor nist comprises tant
and the 5-HT3 receptor antagonist comprises Ondansetron (e.g. Zofran), Granisetron (e.g. ,
thereof.
Sancuso) or Palonosetron (e.g. Aloxi), or a combination of two or more
In one embodiment, the antispasmodic comprises butylscopolamine (Buscopan).
which reduces
In one embodiment, the agent which protects gastric mucosa comprises an agent
production of c acid. In one embodiment, the agent which ts gastric mucosa
comprises an agent ed from the group consisting of proton pump inhibitors, Misoprostol
and Omeprazole. In one embodiment, the agent which protects gastric mucosa comprises a
, combination of a proton pump inhibitor and Misoprostol. In one embodiment, the proton pump
inhibitor comprises Pantoprazole (e.g. Pantozol).
the patient a NKI
In one embodiment, the method of the ion comprises stering to
receptor antagonist such as Aprepitant (e.g. Emend), a 5-HT3 or antagonist such as
Ondansetron (e.g. Zofran), Granisetron (e.g. Kytril, Sancuso) or Palonosetron (e. g. Aloxi), or a
combination of two or more thereof. an antispasmodic such as butylscopolamine (e. g. Buscopan)
and a proton pump inhibitor such as Pantoprazole (e.g. Pantozol).
In one embodiment of the method of any of the above aspects, the antibody is administered by
I and 4 hours,
iv infusion. In one ment, the i.v. infusion is over a time period ofbetween
preferably about 2 hours.
of a
in a sixth aspect, the present invention provides a method of determining the responsiveness
cancer patient to treatment or tion of a cancer disease comprising administering an
antibody having the ability of binding to .2, said method comprising the step of
determining the blood level of one or more markers in the patient, wherein the one or more
markers are selected from the group consisting of CA 125, CA 15-3, CA 19-9, CEA, IL-2, IL-15,
IL-6. lFNy, and TNFOL In this aspect,- prior to and following administration of an antibody
having the ability of binding to CLDN18.2, such as following administration of a single dose of
establish the
the dy, biological s such as blood may be taken from the patient to
level of the one or more markers. Multiple samples may be taken from the same
tissue to
level of the
determine average levels and to account for possible fluctuations in those levels. The
is compared with the level one or more-markers following administration of the antibody
determined prior to administration. The effect of the antibody on the patient can therefore
identified by a d change in the level of marker following administering an antibody having
of marker
the ability of g to CLDN18.2. If the patient shows a desired change in the level
with
following administering an antibody having the ability of binding to CLDN18.2 treatment
the antibody having the ability ofbinding to CLDN18.2 may be commenced.
In one embodiment, the level is determined in blood, plasma or serum.
of CA 125,
In one embodiment, the one or more markers are selected from the group consisting
ot‘ at least one
CA 15-3, CA 19-9, CEA, IL-2, lL-lS, lFNy, and TNFa and a decrease in the level
of the markers following administration of the antibody indicates that the t is responsive to
treatment or prevention of a cancer disease.
In one embodiment, the marker is lL-6 and an increase in the level of the marker following
administration of the antibody indicates that the patient is responsive to treatment or prevention
of a cancer disease.
In an eighth , the present invention es a method of determining whether a cancer
patient is amenable to treatment or prevention of a cancer disease sing administering an
antibody having the y of binding to CLDN18.2, said method comprising the step of
determining the percentage of CLDN18.2 positive cancer cells.
In this embodiment, prior to administration of an antibody having the ability of binding to
CLDN18.2. a biological sample such as a tumor sample (eg. a tumor biopsy) may be taken from
the patient to establish the level of .2 positive cancer cells. Multiple samples may be
taken to determine an average level and to account for possible fluctuations in those levels. If a
patient has the desired level of CLDNl8.2 ve cancer cells an antibody having the ability of
binding to CLDN18.2 may be administered.
least 95% or
In one ment, a level of at least 50%, prefeferably 60%, 70%, 80% or 90%, at
to treatment
at least 98% CLDN18.2 positive cancer cells indicates that the patient is amenable
least 40%, preferably at least
or prevention of a cancer disease. In one embodiment, a level of at
50%, at least 60%, at least 70%, at least 80% or at least 90% cancer cells which are positive
surface sion of CLDN18.2 indicates that the patient is amenable to treatment or prevention
of a cancer disease.
The antibody having the ability of binding to CLDN18.2 may bind to native epitopes of
CLDN18.2 present on the e of living cells. In one embodiment, the antibody having the
In one
1.0 y of binding to CLDN18.2 binds to the first extracellular loop of CLDN18.2.
embodiment. the antibody having the ability of binding to CLDN18.2 mediates cell killing by
one or more of complement dependent cytotoxicity (CDC) mediated lysis, antibody dependent
ar cytotoxicity (ADCC) mediated lysis, induction of apoptosis and inhibition of
proliferation. In one embodiment, the antibody having the ability of binding to CLDN18.2 is a
monoclonal, chimeric or humanized antibody, or a nt of an antibody. In one embodiment,
the antibody having the ability of binding to CLDN18.2 is an dy selected from the group
consisting of (i) an antibody produced by and/or Obtainable from a clone deposited under the
ion DSM
no. DSM ACC2737, DSM ACC2738, DSM ACC2739, DSM 0,
ACC2741, DSM ACC2742, DSM 3, DSM ACC2745, DSM ACC2746, DSM
ACC2747, DSM ACC2748, DSM ACC2808, DSM ACC2809, or DSM ACC2810, (ii) an
antibody which is a chimerized or zed form of the antibody under (i), (iii) an antibody
having the specificity of the antibody under (i), and (iv) an antibody comprising the antigen
binding portion or n binding site, in particular the variable region, of the antibody under (i)
and preferably having the specificity of the dy under (i). In one embodiment, the antibody
is coupled to a therapeutic agent such as a toxin, a radioisotope, a drug or a xic agent.
In one embodiment, the cancer is CLDN18.2 positive. In one embodiment, cells of the cancer
is at the surface of the cells.
express CLDN18.2. In one embodiment, expression of CLDN18.2
In one embodiment, at least 50%, prefeferably 60%, 70%, 80% or 90% of the cancer cells are
CLDN18.2 positive and/or at least 40%, preferably at least 50% of the cancer cells are positive
for surface sion of CLDN18.2. In one embodiment, at least 95% or at least 98% of the
cancer cells are CLDN18.2 positive. In one embodiment, at least 60%, at least 70%, at least
or at least 90% of the cancer cells are positive for surface expression ot‘CLDN18.2.
WO 46778 2014/000719
In one embodiment, the cancer disease is selected from the group consisting of gastric cancer,
esophageal cancer, pancreatic cancer, lung cancer, n cancer, colon cancer, hepatic cancer,
disease may
head-neck cancer, cancer of the gallbladder and the metastasis thereof. The cancer
In one embodiment,
be a Krukenberg tumor, neal metastasis and/or lymph node metastasis.
In one embodiment,
the cancer is an arcinoma, in particular an advanced adenocarcinoma.
the cancer is selected from the group consisting of cancer of the stomach, cancer of the
particular the lower esophagus, cancer of the eso-gastric junction and
esophagus, in
gastroesophageal cancer. In a particularly preferred embodiment, the cancer is gastroesophageal
cancer. The t
cancer such as atic, refractory or recurrent advanced esophageal
with HERZ/neu positive status but not eligible
may be a HER2/neu negative patient or a patient
with at least one drug
to trastuzumab therapy. In one embediment, the patient had prior therapy
and/or capecitabine),
selected from the group consisting of pyrimidine analogs (e.g. fluorouracil
platinum compounds (e.g. cisplatin and/or oxaliplatin), epirubicine, docetaxel and detoxifying
agents for antineoplastic treatment (e.g. calcium te and/or folinic acid). one
patient has performance status of between 0 and 1 and/or
embodiment, the a
an ECOG
the patient is
Kamofsky Index of between 70 and 100%. In a particularly preferred embodiment,
a human patient
According to the invention, CLDN18.2 preferably has the amino acid, sequence according
SEQ ID NO: 1.
The present invention also provides the agents described herein such as the dy having
ability ofbinding to CLDN18.2 for use in the methods described herein.
the following
Other features and advantages of the instant invention will be apparent from
ed description and .
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Mean blood concentration of IMAB362 during the study.
Figure 2. ADCC activity of patient PBMCs. (A) PBMCs were purified from 6 patient blood
samples 7 days (open square) or 14 days (black squares) after IMABB62 stration. Specific
lysis rates of NUGC-4 stomach cancer target cells, expressing CLDN18.2, obtained afier
on of 31.63 ug/ml IMAB362 and PBMCs from a healthy donor or t PBMCs (E:T_ =
: 1) for 24 h. (B) IMAB362 concentration-dependent specific lysis of NUGC-4 cells obtained
24h after addition of PBMCs of different patients (graphs display means :4: standard deviation, p
value was calculated using unpaired t-test). (C) ADCC response curves of healthy control
PBMCs in
upon addition of sing IMAB362 trations. Assays were performed
parallel to each ADCC analysis with patient PBMCs. (D) ADCC response curve of t
PBMCs upon addion of increasing IMAB362 concentrations (for patient 0202 not enough
PBMCs were obtained to generate a curve). (E) Half maximum killing rates for all patients and
healthy donors was calculated with GraphPad Prism re using the build-in non-linear
regression analysis tool.
Figure 3. Ability of patient complement components to induce 2-mediated CDC.
CDC assays were performed with CLDN18.2 and luciferase positive CHO-Kl target cells. Cells,
serum (20% v/v) and antibodies were incubated for 80 min at 37°C. Patient samples were
ed by addition of fresh 0.5 pg/ml IMAB362 in pre-infusion serum samples (grey bars).
HSC: Healthy human serum pool l spiked with 03-10 ug/ml IMAB362 (positive control).
Hi: Heat vated human serum pool spiked with 10 ug/ml IMAB362 (negative control).
Patient numbers are indicated. Error bars: :t standard deviation
Figure 4. Ability of patient complement components to interact with i.v. administered
[MAB362 over time. Normalized CDC assays were performed by adjusting the IMAB362
concentration in each sample to 0.5 )4ng using pre-infusion serum of each patient (dilution
factor 10-680fold). (A/B) CDC assays were med as described in Figure 3. (C) Each dot
represents one patient ement. Open square: 0.5 ug/ml IMAB362 in human serum. P
values obtained with paired t-test. Error bars: mean 1 standard deviation.
Figure 5. Kinetics of cytotoxicity induced by i.v. administered circulating IMAB362.
NUGC-4 target cells. PBMCs of one healthy donor (E:T = 40:1) and patient serum samples
(25% v/v) as antibody and complement source were used in a total cytotoxicity assay to measure
integrated cytotoxic activity. Of each patient, serum samples were ted 1, 7. 14 and 28-32
days after IMAB362 stration. Patients were treated with escalating doses of IMAB362
(33-1000 mg/mz). The antibody concentration present in the assay is indicated below each bar.
HSC: Human serum pool control spiked with fresh 200.0 rig/ml IMAB362 (EC80-|00). PSC:
not available.
Patient pre-infusion serum control spiked with fresh 200.0 ug/ml IMAB362). n.a.:
Figure 6. cs of ADCC activity of IMABB62 in nactivated patient serum. The
in the previous figure, except here patient complement was
assay was performed as described
bar parts) and to
heat-inactivated (56°C, 30 min) to single out ADCC activity (black and grey
calculate additive effects of serum components (white bar parts).
CDC assays were
Figure 7. CDC activity induced by IMABB62 present in patient serum.
incubated for
performed with CLDN18.2 and luciferase positive CHO—Kl target cells. They were
80 min with 20% (v/v) patient serum obtained 1, 7, l4 and 28-32 days after antibody infusion.
concentration
Patients were treated with a IMAB362 dose of 33 to 1000 mg/mz. The antibody
control
present in each assay is indicated below each bar. HSC: Healthy human serum pool
spiked with decreasing concentrations of [MAB362 as indicated. PC: ve control (patient
pre-infusion serum spiked with 10 ug/ml-IMAB3‘62).
in ts. Meanisd
Figure 8. cokinetic s of repeated infusions of IMAB362
concentration (pg/ml) of IMAB362 in serum of 4 ts treated with repeated doses of 300
mg/m2 (cohort l, lett figure) and up to 30 patients (30 patients first infusion, 12 patients fifth
infusion) treated with repeated doses of 600 mg/m2 (cohort 2 and cohort 3 together, right .
Arrows indicate the IMAB362 infusions. First on was given on day
Figure 9. Progression free survival of patients in the full analysis set (FAS).
Figure 10. Progression free survival of patients in the per ol (PP) set (n=20).
DETAILED DESCRIPTION OF THE INVENTION
this Although the present invention is described in detail below, it is to be understood that
herein
invention is not limited to the particular methodologies, protocols and reagents described
as these may vary. It is also to be understood that the terminology used herein is for the purpose
of bing particular embodiments only, and is not intended to limit the scope of the present
invention which will be d only by the appended claims. Unless defined otherwise, all
technical and scientific terms used herein have the same meanings as commonly understood by
one of ordinary skill in the art.
In the following, the elements of the present ion will be described. These elements are
listed with specific embodiments, however, it should be tood that they may be ed ‘
in any manner and in any number to create additional embodiments. The variously described
es and preferred embodiments should not be construed to limit the present invention to
only the explicitly described embodiments. This description should be understood to support and
encompass embodiments which combine the explicitly described embodiments with any number
of the disclosed and/or preferred elements. Furthermore, any ations and ations of
all described elements in this application should be considered disclosed by the description of the
present application unless the context indicates otherwise.
Preferably, the terms used herein are defined as described in "A multilingual glossary of
'15 biotechnological terms: (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H.
Kolbl, Eds., Helvetica a Acta, CH-4010 Basel, rland, .
The practice of the present invention will employ, unless otherwise indicated, conventional
methods of chemistry, biochemistry, cell biology, immunology, and recombinant DNA
ques which are explained in the literature in the field (of, e.g., Molecular Cloning: A
Laboratory , 2"d Edition, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press,
Cold Spring Harbor 1989).
hout this specification and the claims which follow, unless the context requires otherwise,
the word "comprise", and variations such as "comprises" and "comprising", will be understood to
imply the inclusion of a stated member, integer or step or group of members, integers or steps
but not the exclusion of any other member, integer or step or group of members, integers or steps
although in some embodiments such other member, integer or step or group of members, integers
or steps may be excluded, i.e. the subject-matter consists in the inclusion of a stated member,
integer or step or group of members, integers or steps. The terms "a" and "an" and "the" and
similar reference used in the context of describing the invention (especially in the t of the
claims) are to be construed to cover both the singular and the plural, unless otherwise indicated
herein or clearly dicted by context. Recitation of ranges of values herein is merely
intended to serve as a shorthand method of referring individually to each separate value falling
within the range. Unless otherwise indicated herein, each dual value is incorporated into
the cation as if it were individually recited herein. All methods described herein can be
performed in any suitable order unless otherwise indicated herein or otherwise clearly
contradicted by t. The use of any and all examples, or exemplary ge (e.g., "such
as"), provided herein is intended merely to better illustrate the invention and does not pose a
limitation on the scope of the invention otherwise claimed. No language in the cation
should be construed as indicating any non-claimed element essential to the ce of the
invention.
Several documents are cited throughout the text of this specification. Each of the documents
cited herein (including all patents, patent applications, scientific publications, cturer's
specifications, instructions, etc.), r supra or infi‘a, are hereby incorporated by reference in
their entirety. Nothing herein is to be ued as an admission that the invention is not entitled
to antedate such disclosure by virtue of prior invention.
The term "CLDN18" relates to claudin 18 and includes any variants, including claudin l8 splice
variant 1 (claudin 18.1 (CLDN18.1)) and claudin 18 splice variant 2 (claudin 18.2 (CLDN18.2)).
The term "CLDN18.2" preferably relates to human CLDN18.2, and, in particular, to a protein
2O comprising, preferably consisting of the amino acid sequence according to SEQ ID NO: 1 of the
sequence listing or a variant ofsaid amino acid ce.
The term "CLDN18.l" preferably relates to human CLDN18.1, and, in particular, to a protein
sing, preferably consisting of the amino acid sequence according to SEQ ID NO: 2 of the
sequence listing or a variant of said amino acid sequence.
The term "variant" according to the invention refers, in particular, to mutants, splice ts,
conformations, isoforms. allelic variants, species variants and species homologs, in particular
those which are lly present. An allelic variant relates to an alteration in the normal
sequence of a gene, the significance of which is often r. Complete gene sequencing often
fies numerous allelic variants for a given gene. A species homolog is a nucleic acid Or
amino acid sequence with a different species oforigin from that of a given nucleic acid or amino
acid sequence. The term "variant" shall encompass any posttranslationally modified variants and
conformation variants.
According to the invention, the term "CLDN18.2 positive " means a cancer involving
cancer cells expressing CLDN18.2, preferably on the surface of said cancer cells.
"Cell surface" is used in accordance with its normal meaning in the art, and thus includes the
outside of the cell which is accessible to binding by proteins and other molecules.
CLDN18.2 is expressed on the surface of cells if it is located at the surface of said cells and is
accessible to g by CLDN18.2-specific antibodies added to the cells.
According to the invention, CLDN18.2 is not substantially expressed in a cell if the level of
expression is lower ed to expression in stomach cells or stomach tissue. ably, the
level of expression is less than 10%, preferably less than 5%, 3%, 2%, 1%, 0.5%, 0.1% or 0.05%
of the expression in stomach cells or stomach tissue or even lower. Preferably, CLDN18.2 is not
substantially expressed in a cell if the level of sion exceeds the level of expression in non-
cancerous tissue other than stomach by no more than 2-fold, preferably 1,5-fold, and preferably
does not exceed the level of expression in said non-cancerous tissue. Preferably, CLDN18.2 is
not substantially expressed in a cell if the level of sion is below the detection limit and/or
if the level of expression is too low to allow binding by CLDN18.2-specif1c antibodies added to
the cells.
ing to the invention, CLDN18.2 is expressed in a cell if the level of expression exceeds
the level of expression in non-cancerous tissue other than stomach preferably by more than 2—
fold, preferably lO—fold, lOO-fold, IOOO-fold, or lOOOO-fold. Preferably, CLDN18.2 is expressed
in a cell if the level of expression is above the ion limit and/or if the level of expression is
high enough to allow binding by CLDN18.2-specific dies added to the cells. Preferably,
CLDN18.2 expressed in a cell is expressed or exposed on the surface of said cell.
According to the invention, the term "disease" refers to any pathological state, including ,
in particular those forms of cancer described herein. Any reference herein to cancer or particular
forms of cancer also includes cancer metastasis thereof. In a preferred embodiment, a disease to
be treated ing to the present ation involves cells expressing CLDN18.2.
' 15
"Diseases associated with cells expressing CLDN18.2" or similar expressions means according
In one
to the invention that CLDN18.2 is sed in cells of a diseased tissue or organ.
embodiment, sion of CLDN18.2 in cells of a diseased tissue or organ is increased
compared to the state in a healthy tissue or organ. An increase refers to an se by at least
%, in particular at least 20%, at least 50%, at least 100%, at least 200%, at least 500%, at least
1000%, at least 10000% or even more. In one embodiment, expression is only found in a
diseased tissue, while expression in a y tissue is repressed. According to the invention,
diseases associated with cells expressing CLDN18.2 include cancer diseases. Furthermore,
according to the invention, cancer diseases preferably are those wherein the cancer cells express
.2.
As used herein, a "cancer disease" or "cancer" includes a disease characterized by aberrantly
regulated cellular growth, proliferation, differentiation, on, and/or migration. The three
malignant properties of cancers (uncontrolled growth (division beyond the normal limits),
invasion (intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to
other locations in the body via lymph or blood)) entiate cancers from benign tumors, which
but some, like
are self-limited, and do not invade or metastasize. Most s form a tumor
leukemia, do not. By "cancer cell" is meant an abnormal cell that grows by a rapid, uncontrolled
cellular proliferation and continues to grow after the stimuli that initiated the new growth cease.
Preferably, a "cancer disease" is terized by cells expressing CLDN18.2 and a cancer cell
is a cancer cell, preferably of the
expresses CLDN18.2. A cell expressing CLDN18.2 preferably
s described herein.
According to the invention. the term "tumor" or "tumor disease" refers to an abnormal growth of
cells (called neoplastic cells, tumorigenous cells or tumor cells) preferably forming a ng or
lesion. By "tumor cell" is meant an abnormal cell that grows by a rapid, uncontrolled cellular
proliferation and continues to grow after the stimuli that initiated the new growth cease. Tumors
show l or complete lack of structural organization and fimctional coordination with the
normal tissue, and y form a distinct mass of tissue, which may be either benign, pre-
malignant or malignant.
According to the invention a tumor is preferably a ant tumor. "Malignant tumor" is used
synonymous with cancer.
"Adenocarcinoma" is a cancer that ates in glandular tissue. This tissue is also part of a
larger tissue category known as epithelial tissue. Epithelial tissue includes skin, glands and a,
variety of other tissue that lines the cavities and organs of the body. Epithelium is d
embryologically from ectoderm, endoderm and mesoderm. To be classified as arcinoma,
the cells do not necessarily need to be part ofa gland, as long as they have secretory properties.
This form of carcinoma can occur in some higher mammals, including humans. Well
differentiated adenocarcinomas tend to resemble the glandular tissue that they are derived fi'om,
while poorly differentiated may not. By staining the cells fi'om a biopsy, a pathologist will
determine whether the tumor is an adenocarcinoma or some other type of cancer.
Adenocarcinomas can arise in many tissues of the body due to the ubiquitous nature of glands
within the body. While each gland may not be ing the same nce, as long as there is
an exocrine function to the cell, it is considered lar and its malignant form is therefore
named arcinoma. Malignant adenocarcinomas invade other tissues and ofien metastasize
given enough time to do so. Ovarian adenocarcinoma is the most common type of ovarian
carcinoma. It includes the serous and us adenocarcinomas, the clear cell adenocarcinoma
and the endometrioid adenocarcinoma.
By "metastasis" is meant the spread of cancer cells from its original site to another part of the
body. The formation of metastasis is a very complex s and depends on detachment of
malignant cells from the primary tumor, invasion of the extracellular matrix, penetration of the
endothelial basement membranes to enter the body cavity and vessels, and then, after being
transported by the blood, infiltration of target organs. Finally, the growth of a new tumor at the
target site depends on angiogenesis. Tumor metastasis ofien occurs even after the removal of the
primary tumor because tumor cells or ents may remain and p metastatic potential.
In one embodiment, the term "metastasis" according to the invention relates to nt
metastasis" which relates to a metastasis which is remote from the primary tumor and the
regional lymph node system. In one embodiment, the term "metastasis" according to the
invention relates to lymph node metastasis. One particular form of metastasis which is treatable
using the therapy of the invention is asis originating from gastric cancer as primary site. In
preferred ments such gastric cancer metastasis is Krukenberg tumors, peritoneal
metastasis and/or lymph node metastasis.
Krukenberg tumor is an uncommon metastatic tumor of the ovary accounting for 1% to 2% of all
ovarian tumors. Prognosis of Krukenberg tumor is still very poor and there is no established
Krukenberg tumors. Krukenberg tumor is a metastatic Signet ring cell
treatment for
arcinoma of the ovary. Stomach is the primary site in most Krukenberg tumor cases
(70%). Carcinomas of colon, appendix, and breast (mainly invasive lobular carcinoma) are
from carcinomas
next most common primary sites. Rare cases of berg tumor ating
and urinary
of the gallbladder, biliary tract, as, small'intestine, ampulla of Vater, cervix,
bladder/urachus have been reported.
Women with Krukenberg tumors tend to be unusually young for patients with metastatic
45 years.
carcinoma as they are typically in the fifih decade of their lives, with an average age of
This young age of distribution can be related in part to the increased frequency of c Signet
ring cell carcinomas in young women. Common presenting symptoms are usually related to
ovarian ement, the most common of which are abdominal pain and distension (mainly
have
because of the usually bilateral and often large ovarian masses). The remaining patients
In addition, Krukenberg tumor is nonspecific gastrointestinal symptoms or are asymptomatic.
reportedly associated with virilization resulting from hormone production by ovarian stroma.
Ascites is t in 50% of the cases and usually reveals malignant cells.
Krukenberg tumors are bilateral in more than 80% of the reported cases. The ovaries are usually
asymmetrically enlarged, with a bosselated r. The sectioned surfaces are yellow or white;
they are usually solid, although they are occasionally cystic. antly, the capsular surface
the ovaries with Krukenberg tumors is lly smooth and free of adhesions or peritoneal
deposits. Of note, other metastatic tumors to the ovary tend to be ated with surface
implants. This may explain why the gross morphology of Krukenberg tumor can deceptively
bilateralism in Krukenberg tumor is consistent
appear as a primary n tumor. However,
[\J U“! with its metastatic nature.
Patients with Krukenberg tumors have an overall mortality rate that is significantly high. Most
patients die within 2 years (median al, 14 months). Several studies show that the prognosis
is poor when the primary tumor is identified afier the metastasis to the ovary is discovered. and
the sis becomes worse if the primary tumor remains covert.
By "treat" is meant to administer a nd or composition or a combination of compounds or
compositions to a subject in order to prevent or eliminate a disease, including reducing the Size
ofa tumor or the number of tumors in a subject; arrest or slow a disease in a subject; inhibit or
slow the development of a new disease in a subject; decrease the frequency or severity of
has or who previously has had a disease;
symptoms and/or recurrences in a subject who currently
and/or prolong, i.e. increase the lifespan of the subject.
duration,
In particular, the term "treatment of a disease" es , shortening the
ameliorating, preventing, slowing down or inhibiting progression or worsening, or preventing or
delaying the onset of a disease or the symptoms thereof.
The term "patient" means according to the invention a subject for treatment, in particular a
in- particular
diseased t, including human beings, nonhuman primates or another animals,
mice and rats.
mammals such as cows, horses, pigs, sheeps, goats, dogs, cats or rodents such as
In a particularly preferred embodiment, a patient is a human being.
CLDN18.2 may be
ing to the invention, an an antibody having the ability of binding to
- administered in ation with, i.e. simultaneously with, followed by and/or following, an
agent stabilizing or increasing expression ofCLDN 18.2.
The term "agent stabilizing or sing expression of CLDN18.2" refers to an agent or a
and/or protein
combination of agents the provision of which to cells s in increased RNA
cell surface,
levels of CLDN18.2, preferably in increased levels of CLDN18.2 protein on the
ed to the situation where the cells are not provided with the agent or the combination
cell expressing CLDN18.2, such
agents. Preferably, the cell is a cancer cell, in particular a cancer
or sing expression
as a cell of the cancer types desribed herein. The term "agent stabilizing
of which
ofCLDNlS.2" refers, in particular, to an agent or a combination of agents the ion
cells compared to the
to cells results in a higher density of CLDN18.2 on the surface of said
of agents.
situation where the cells are not provided with the agent or the combination
"Stabilizing expression of CLDN18.2" includes, in particular, the situation where the agent or
ation of agents prevents a decrease or reduces a decrease in expression ofCLDN18.2, e. g.
sion of CLDN18.2 would se without provision of the agent or the combination
said decrease or reduces
agents and provision of the agent or the combination of agents prevents
said decrease of CLDN18.2 expression. "Increasing expression of CLDN18.2" includes, in
ular, the situation where the agent or the ation of agents increases expression
CLDN18.2, expression of CLDN18.2 would decrease, remain essentially nt or
e.g.
the agent
increase without provision of the agent or the combination of agents and provision of
to the situation without
or the combination of agents increases CLDN18.2 expression compared
provision of the agent or the combination of agents so that the resulting expression is higher
ed to the situation where expression of CLDN18.2 would decrease, remain essentially
constant or se without provision of the agent or the combination of agents.
According to the invention, the term "agent izing or increasing sion of CLDN18.2"
includes chemotherapeutic agents or combinations of chemotherapeutic agents such as cytostatic
. Chemotherapeutic agents may affect cells in one of the following ways: (1) Damage
DNA of the cells so they can no longer reproduce, (2) Inhibit the synthesis of new DNA strands
the cells so that the cells
so that no cell replication is possible, (3) Stop the mitotic processes of
cannot divide into two cells.
ing to the invention, the term "agent stabilizing or increasing expression of CLDN18.2"
preferably relates to an agent or a combination of agents such a cytostatic compound or a
combination of cytostatic compounds the provision of which to cells, in ular cancer cells,
results in the cells being arrested in or accumulating in one or more phases of the cell cycle,
preferably in one or more phases of the cell cycle other than the G1- and GO-phases, preferably
other than the Gl-phase, preferably in one or more of the G2- or S-phase of the cell cycle such as
the Gl/G2-, S/G2—, 02— or S—phase of the cell cycle. The term "cells being arrested in or
accumulating in one or more phases of the cell cycle" means that the precentage of cells which
are in said one or more phases of the cell cycle increases. Each cell goes through a cycle
comprising four phases in order to replicate itself. The first phase called G1 is when the cell
is prepares to replicate its chromosomes. The second stage called S, and in this phase DNA
synthesis occurs and the DNA is duplicated. The next phase is the G2 phase, when the RNA and
protein duplicate. The final stage is the M stage, which is the stage of actual cell division. In this
final stage, the duplicated DNA and RNA split and move to te ends of the cell, and the cell
actually divides into two identical, onal cells. Chemotherapeutic agents which are DNA
damaging agents usually result in an accumulation of cells in the G1 and/or G2 phase.
herapeutic agents which block cell growth by interfering with DNA synthesis such as
antimetabolites usually result in an accumulation of cells in the S-phase. Examples of these drugs
are 6-mercaptopurine and 5-fluorouracil.
ing to the invention, the term "agent stabilizing or increasing expression of CLDN18.2"
includes anthracyclines such as epirubicin, platinum compounds such as oxaliplatin and
cisplatin, nucleoside analogs such as S-fluorouracil or prodrugs thereof, taxanes such as
docetaxel. and camptothecin analogs such as irinotecan and topotecan,'and combinations of
drugs such as combinations of drugs comprising one or more of anthracyclines such as
epirubicin, oxaliplatin and S-tluorouracil such as a combination of drugs comprising oxaliplatin
and 5-fluorouracil or other drug combinations described herein.
In one preferred embodiment, an "agent stabilizing or increasing sion of CLDN18.2" is an
"agent inducing immunogenic cell death".
In specific circumstances, cancer cells can enter a lethal stress y linked to the emission of
a spatiotemporally defined combination of signals that is d by the immune system to
activate tumor-specific immune responses (Zitvogel L. et al. (2010) Cell 140: 798—804). In such
scenario cancer cells are triggered to emit signals that are sensed by innate immune effectors
such as dendritic cells to trigger a e immune response that involves CD8+ T cells and IFN—
anticancer immune response. These
7 signalling so that tumor cell death may elicit a productive
signals include the pre-apoptotic exposure of the endoplasmic reticulum (ER) chaperon
iculin (CRT) at the cell surface, the pre-apoptotic secretion of ATP, and the post-apoptotic
release of the nuclear protein HMGBI. Together, these processes constitute the molecular
determinants of genic cell death (1CD). Anthracyclines, oxaliplatin, and y irradiation are
able to induce all signals that define 1CD, while cisplatin, for example, which is deficient in
inducing CRT translocation from the ER to the surface of dying cells - a process requiring ER
stress - requires complementation by gargin, an ER stress inducer.
ing to the invention, the term "agent inducing immunogenic cell death" refers to an agent
of
or a ation of agents which when provided to cells, in particular cancer cells, is capable
inducing the cells to enter a lethal stress y which finally results in tumor-specific immune
In particular, an agent inducing immunogenic cell death when provided to cells
responses.
induces the cells to emit a temporally defined combination of s, including, in
ular, the pre-apoptotic exposure of the endoplasmic reticulum (ER) chaperon calreticulin
Lu 0 (CRT) at the cell surface, the pre-apoptotic secretion of ATP, and the post-apoptotic release of
the nuclear protein HMGB 1.
According to the invention, the term "agent inducing genic cell death" includes
anthracyclines and oxaliplatin.
Anthracyclines are a class of drugs commonly used in cancer chemotherapy that are also
antibiotics. Structurally, all anthracyclines share a common four-ringed 7,8,9,10-
tetrahydrotetracene—S,lZ-quinone structure and usually e glycosylation at specific sites.
Anthracyclines preferably bring about one or more of the following mechanisms of : 1.
Inhibiting DNA and RNA synthesis by intercalating between base pairs of the DNA/RNA strand,
thus preventing the ation of rapidly-growing cancer cells. 2. Inhibiting topoisomerase II
DNA transcription and
enzyme, preventing the relaxing of supercoiled DNA and thus blocking
replication. 3. Creating iron-mediated free oxygen radicals that damage the DNA and cell
membranes.
According to the invention, the term "anthracycline" preferably relates to an agent, preferably an
anticancer agent for inducing apoptosis, preferably by inhibiting the rebinding of DNA in
topoisomerase II.
Preferably, according to the invention, the term "anthracycline" lly refers to a class of
compounds having the ing ring structure
0 OH
O OH
including analogs and tives, pharmaceutical salts, hydrates, , conjugates and prodrugs
thereof.
Examples of anthracyclines and cycline analogs include, but are not limited to,
daunorubicin (daunomycin), doxorubicin (adriamycin), icin, idarubicin, rhodomycin,
pyrarubicin, valrubicin, N-trifluoro-acetyl doxorubicin- l 4—valerate, aclacinomycin,
morpholinodoxorubicin (morpholino-DOX), cyanomorpholino-doxorubicin (cyanomorpholino-
DOX), olino-doxorubicin (2-PDOX), 5-iminodaunomycin, mitoxantrone and
aclacinomycin A (aclarubicin). Mitoxantrone is a member of the anthracendione class of
compounds, which are anthracycline s that lack the sugar moiety of the anthracyclines but
retain the planar polycylic aromatic ring structure that permits intercalation into DNA.
Particularly preferred as anthracyline according to the invention is a compound of the following
formula:
wherein
R. is selected from the group consisting ofH and OH, R2 is selected from the group consisting of
H and OMe, R3 is selected fi'om the group consisting of H and OH, and R4 is selected from the
group consisting of H and OH.
In one ment, R1 is H, R2 is OMe, R3 is H, and R4 is OH. In another ment, R1 is
OH. R2 is OMe, R3 is H, and R4 is OH. In another embodiment, R1 is OH, R2 is OMe, R3 is OH,
and R4 is H. In another embodiment, R. is H, R2 is H, R3 is H, and R4 is OH.
cally contemplated as anthracycline in the context of the present invention is epirubicin.
Epirubicin is an anthracycline drug which has the following formula:
and is marketed under the trade name Ellence in the US and rubicin or Epirubicin Ebewe
elsewhere. In particular, the term "epirubicin" refers to the compound (8R,IOS)
WO 46778
[(2 S,4S,5R,6S)aminohydroxymethyl-oxanyl]oxy-6,1 l-dihydroxy-B-(2-
favoured
hydroxyacetyl)- l -methoxy~8-methy1-9, l 0-dihydro-7H-tetracen-5,1 2-dion. Epirubicin is
as it s
over doxorubicin, the most popular anthracycline, in some chemotherapy regimens
to cause fewer side-effects.
According to the invention, the term. "platinum nd" refers to compounds containing
platinum in their structure such as platinum complexes and includes compounds such as
tin, carboplatin and oxaliplatin.
The term "cisplatin" or "cisplatinum" refers to the compound amminedichloroplatinum(II)
(CDDP) of the following formula:
,0, Pt» NH3
0/ \NH3
The term "carboplatin" refers to the compound cis—diammine( l ,1 -
cyclobutanedicarboxylato)platinum(II) of the following formula:
H3N\ /0
1Pt\
H3N o
The term "oxaliplatin" refers to a compound which is a platinum compound that is complexed to
a diaminocyclohexane carrier ligand of the following formula:
H2 0
In particular, the term platin" refers to the compound R)-cyclohexane-l,2-
diamine](ethanedioato-0,0')platinum(II). Oxaliplatin for injection is also marketed under the
trade name Eloxatine.
The term oside analog" refers to a structural analog of a nucleoside, a category that
includes both purine analogs and pyrimidine analogs. In particular, the term "nucleoside analog"
refers to fluoropyrimidine derivatives which includes fluorouracil and prodrugs thereof.
The term "fluorouracil" or "5-fluorouracil" (S-FU or fSU) (sold under the brand names Adrucil,
Carac, Efudix, Efudex and Fluoroplex) is a compound which is a pyrimidine analog of the
following formula:
In particular, the term refers to the compound 5-fluoro— l H-pyrimidine-2,4-dione.
The term "capecitabine" (Xeloda, Roche) refers to a chemotherapeutic agent that is a g
that is converted into S-FU in the tissues. Capecitabine which may be orally administered has the
ing fonnula:
In particular, the term refers to the compound pentyl [I-(3,4-dihydroxy—5-methyltetrahydrofuran-
2-yl)fluorooxo- l H-pyrimidinyl]carbamate.
Taxanes are a class of ene compounds that were first derived from natural sources such as
plants of the genus Taxus, but some have been synthesized artificially. The principal mechanism
of action of the taxane class of drugs is the disruption of microtubule on, thereby inhibiting
the process of cell division. Taxanes include docetaxel (Taxotere) and paclitaxel (Taxol).
According to the invention, the term "docetaxel" refers to a compound having the following
formula:
”35C
According to the invention, the term "paclitaxel" refers to a nd having the following
1 O formula:
According to the invention, the term othecin analog" refers to derivatives of the
compound camptothecin (CPT; (S)ethylhydroxy—lH-pyrano[3',4':6,7]indolizino[1,2-b]
quinoline-3,14-(4H,12H)-dione). Preferably, the term "camptothecin " refers to
compounds comprising the following structure:
According to the invention, preferred camptothecin analogs are inhibitors of DNA enzyme
topoisomerase I (topo I). Preferred camptothecin analogs according to the invention are
irinotecan and topotecan.
Irinotecan is a drug ting DNA from unwinding by inhibition of topoisomerase I. In
chemical terms, it is a semisynthetic analogue of the l alkaloid camptothecin having the
following formula:
00%;;
In particular, the term "irinotecan" refers to the nd 1 l-diethyl-3,4,12,14-tetrahydro-
4-hydroxy-3, l o l H—pyrano[3 ’,4’:6,7]-indolizino[l,2-b]quinolin-9—yl-[1,4’bipiperidine]-l ’-
carboxylate.
Topotecan is a topoisomerase inhibitor of the formula:
In particular, the term "topotecan" refers to the compound (S)-lO-[(dimethylamino)methyi]
ethyl-4,9-dihydroxy-lH-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
monohydrochloride.
According to the invention, an agent stabilizing or increasing expression of CLDNl 8.2 may be a
chemotherapeutic agent, in particular a chemotherapeutic agent established in cancer treatment
and may be part ofa combination of drugs such as a combination of drugs established for use in
cancer treatment. Such combination of drugs may be a drug combination used in chemotherapy,
and may be a drug combination as used in a chemotherapeutic regimen selected from the group
ting of EOX chemotherapy. ECF herapy, ECX chemotherapy, EOF
chemotherapy, FLO chemotherapy, FOLFOX chemotherapy, FOLFIRI chemotherapy,
chemotherapy and FLOT chemotherapy.
The drug combination used in EOX chemotherapy comprises of epirubicin, oxaliplatin and
capecitabine. The drug combination used in ECF chemotherapy comprises of epirubicin,
cisplatin and 5-fluorouracil. The drug combination used in ECX chemotherapy comprises of
epirubicin, cisplatin and capecitabine. The drug combination used in EOF chemotherapy
comprises of epirubicin, oxaliplatin and 5-fluorouracil.
Epirubicin is normally given at a dose of50 mg/m2, cisplatin 60 mg/m2, oxaliplatin 130 mg/m2,
protracted venous infusion of 5-fluorouracil at 200 mg/mZ/day and oral capecitabine 625 mg/m2
twice daily, for a total of eight 3-week .
acid and
The drug ation used in FLO chemotherapy comprises of 5- fluorouracil, folinic
oxaliplatin (normally 5-fluorouracil 2,600 mg/m2 24-h infusion, folinic acid 200 mg/mZ and
oxaliplatin 85 mg/m2, every 2 weeks).
FOLFOX is a chemotherapy n made up of folinic acid (leucovorin), 5-fluorouracil and
follows: Day 1: oxaliplatin. The ended dose schedule given every two weeks is as
Oxaliplatin 85 mg/m2 IV infusion and leucovorin 200 mg/m2 [V on, followed by 5-FU 400
mg/m2 IV bolus, ed by 5-FU 600 mg/m2 IV infusion as a 22-hour continuous infusion;
Day 2: Leucovorin 200 mg/m2 [V on over 120 minutes, followed by S-FU 400 mg/m2
bolus given over 2-4 minutes, ed by S-FU 600 mg/m2 IV infusion as a 22-hour continuous
infusion.
The drug combination used in FOLFIRI chemotherapy comprises of 5-fluorouracil, leucovorin,
and irinotecan.
The drug combination used in DCF chemotherapy comprises of xel, tin and 5-
tl uorouracil.
The drug combination used in FLOT chemotherapy comprises of docetaxel, oxaliplatin, 5-
fluorouracil and folinic acid.
The term "folinic acid" or vorin" refers to a compound useful in synergistic combination
with the chemotherapy agent 5-tluorouracil. Folinic acid has the following formula:
In particular, the term refers to the compound (ZS){[4-[(2-aminoformyloxo-5,6,7,8—
tetrahydro- l H—pteridinyl)methylamino]benzoyl]amino } pentanedioic acid.
According to the invention, an an antibody having the ability of binding to .2 may be
administered in combination with, i.e. simultaneously with, followed by and/or following, an
agent stimulating 75 T cells.
76 T cells (gamma delta T cells) ent a small subset of T cells that possess a distinct T cell
receptor (TCR) on their surface. A majority ofT cells have a TCR composed of two rotein
chains called a- and B-TCR chains. In st, in 75 T cells, the TCR is made up of one 7-chain'
and one 8-chain. This group ofT cells is usually much less common than 043 T cells. Human 75 T
cells play an important role in stress-surveillance ses like infectious diseases and
autoimmunity. Transformation-induced changes in tumors are also suggested to cause stress-
surveillance ses mediated by 75 T cells and enhance antitumor immunity. lmportantly,
after antigen engagement, activated 76 T cells at lesional sites provide cytokines (e.g. INF7,
TNFa) and/or chemokines mediating recruitment of other effector cells and Show immediate
effector functions such as xicity (via death receptor and tic granules ys) and
ADCC.
The majority of 78 T cells in peripheral blood express the V79V52 T cell receptor (TCR75).
V79V52 T cells are unique to humans and primates and are assumed to play an early and
essential role in sensing ”danger" by invading pathogens as they expand dramatically in many
acute infections and may exceed all other lymphocytes within a few days, e.g. in tuberculosis,
salmonellosis, ehrlichiosis. brucellosis, tularemia. listeriosis, toxoplasmosis, and malaria.
76 T cells d to small non-peptidic phosphorylated antigens (phosphoantigens) such as
pyrophosphates synthesized in bacteria and isopentenyl pyrophosphate (IPP) produCed in
mammalian cells through the mevalonate pathway. Whereas IPP production in normal cells is
not sufficient for activation of 76 T cells, dysregulation of the nate y in tumor cells
leads to accumulation of IPP and 75 T cell activation. IPPs can also be therapeutically increased
by aminobisphosphonates, which inhibit the mevalonate pathway enzyme famesyl
pyrophosphate synthase (FPPS). Among others, zoledronic acid (ZA, zoledronate, ZometaTM,
Novartis) represents such an aminobiphosphonate, which is already clinically administered to
ts for the treatment of osteoporosis and metastasic bone disease. Upon treatment of
PBMCs in vitro, ZA is taken up especially by monocytes. IPP accumulates in the monocytes and
they differentiate to n-presenting cells stimulating development of 75 T cells. In this
setting, the addition of interleukin-2 (IL-2) is preferred as, growth and survival factor for
activated 76 T cells. Finally, certain alkylated amines have been described to activate V'y9V52 T
cells in vitro, however only at millimolar concentrations.
According to the invention, the term "agent stimulating 75 T cells" relates to nds
stimulating development of 75 T cells, in ular Vy9V52 T cells, in vitro and/or in vivo, in
particular by inducing activation and expansion of 78 T cells. Preferably, the term relates to
compounds which in vitro and/or in vivo increase isopentenyl pyrophosphate (IPP) ed in
ian cells, ably by inhibiting the mevalonate pathway enzyme famesyl
pyrophosphate synthase (FPPS).
One particular group of compounds stimulating 76 T cells are bisphosphonates, in particular
nitrogen-containing bisphosphonates (N-bisphosphonates; aminobisphosphonates).
For example, suitable bisphosphonates for use in the invention may include one or more of the
following compounds including analogs and tives, pharmaceutical salts, hydrates, esters,
conjugates and prodrugs thereof:
[I-hydroxy(1H-imidazol-l-yl)ethane-l.l-diyl]bis(phosphonic acid), onic acid, e. g.
zoledronate;
oro-phosphono-methyl)phosphonic acid, 6. g. clodronate
{l-hydroxy[methyl(pentyl)amino]propane-l.l-diyl}bis(phosphonic acid), ibandronic acid,
e.g. ibandronate
(3-amino-l-hydroxypropane— l,l-diyl)bis (phosphonic acid), onic acid, 6. g. pamidronate:
' 30
(l-hydroxy-l-phosphono-Z-pyridinyl-ethyl)phosphonic acid, onic acid, e. g. onate;
(l-Hydroxy-Z-imidazo[l,2-a]pyridinyl-l-phosphonoethyl)phosphonic acid, minodronic acid;
[3—(dimethylamino)=l-hydroxypropane~l.1-diyl]bis(phosphonic acid), olpadronic acid.
[4-amino-l-hydroxy-l-(hydroxy-oxido-phosphoryl)-butyl]phosphonic acid, alendronic acid, e.g.
alendronate;
[(Cycloheptylamino)methylene]bis(phosphonic acid), onic acid;
(l-hydroxyethan-l,1-diyl)bis(phosphonic acid), etidronic acid, e. g. etidronate; and
{[(4-chlorophenyl)thio]methylene}bis(phosphonic acid), tiludronic acid.
According to the invention, zoledronic acid (INN) or zoledronate (marketed by Novartis under
the trade names Zometa, Zomera, Aclasta and Reclast) is a ularly preferred
bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as
multiple myeloma and te cancer, as well as for treating osteoporosis. It can also be used to
metastases.
treat hypercalcemia of malignancy and can be helpful for treating pain from bone
In one particularly preferred embodiment, an agent stimulating 78 T cells according to the
invention is administered in combination with IL-2. Such combination has been shown to be
particularly effective in mediating expansion'and activation of 7952 T cells.
Interleukin-2 (IL-2) is an interleukin, a type of ne signaling molecule in the immune
system. It is a protein that attracts lymphocytes and is part of the body's natural response to
microbial infection, and in minating between foreign (non-sell) and self. IL-2 mediates its
s by binding to lL-2 receptors, which are expressed by lymphocytes.
The lL-2 used according to the invention may be any lL—2 supporting or enabling the stimulation
of y5 T cells and may be derived from any species, ably human. [1-2 may be ed,
recombinantly produced or tic lL-2 and may be naturally occurring or modified IL-2.
According to the invention the term "antiemetic" relates to a compound, composition or drug that
is effective against vomiting and/or nausea. In one embodiment, the antiemetic includes a 5-HT3
receptor antagonist and/or a neurokinin 1 (NKl) receptor antagonist.
-HT3 receptor antagonists block serotonin receptors in the central nervous system and
gastrointestinal tract. Examples thereof include, but are not limited to Ondansetron (Zofran)
which can be administered in an oral tablet form, oral dissolving tablet form, or in an injection,
Dolasetron (Anzemet) which can be administered in tablet form or in an injection, etron
(Kytril, Sancuso) which can be administered in tablet (Kytril), oral solution (Kytril), injection
(Kytril), or in a single transdermal patch to the upper arm (Sancuso), Tropisetron (Navoban)
which can be administered in oral capsules or in injection form, Palonosetron (Aloxi) which can
be administered in an injection or in oral capsules and Mirtazapine (Remeron).
NKl or nists e, but are not limited to Aprepitant (Emend).
A preferred combination of a 5-HT3 receptor nist and a NKl receptor antagonist is a
combination of Ondansetron (Zofran) and tant (Emend).
Further antiemetics which can be used according to the ion, in particular in combination
with a 5-HT3 receptor antagonist and/or a NKl receptor antagonist include but are not limited to
Metoclopramide (Reglan) which acts on the GI tract as a pro-kinetic, Lorazepam, Atropin,
Alizapride an, Plitican, Superan, Vergentan) and Dimenhydrinate (Dramamine, Driminate,
Gravol, Gravamin, Vomex, osan).
ACCording to the invention, an antispasmodic (synonym: spasmolytic) can be administered.
According to the ion the term "antispasmodic" relates a compound, composition or drug
that suppresses muscle spasms. Preferably, an antispasmodic is useful for smooth muscle
contraction. Preferred according to the invention are antispasmodics which are effective in
treating spasmodic activity in the ive system. Thus, preferred asmodics are effective
in the relief of gastro-intestinal spasms.
Antispasmodics include. but are not limited to butylscopolamine which is also known as
scopolamine butylbromide, butylhyoscine and hyoscine butylbromide. It is marketed under the
trade name Buscopan by Boehringer Ingelheim GmbH, Germany.
According to the invention, a parasympatholytic can be administered. According to the invention
the term "parasympatholytic" relates to a nd, composition or drug that reduces the
activity of the parasympathetic nervous system. Parasympatholytics include, but are not limited
to Atropine.
According to the invention the term "proton-pump tor” relates to a compound, composition
or drug whose main actiOn is a pronounced and long-lasting ion of c acid production.
Proton-pump inhibitors include benzimidazole derivatives and opyridine derivatives.
Examples of proton-pump inhibitors include, but are not limited to Omeprazole (brand names:
Gasec, Losec, Prilosec, Zegerid, ocid, Lomac, Omepral, Omez,), Lansoprazole (brand names:
Prevacid, Zoton, Monolitum, lnhibitol, Levant, Lupizole), Dexlansoprazole (brand name:
x, Dexilant), Esomeprazole (brand names: Nexium, x, esso), Pantoprazole (brand
names: Protonix, Somac, Pantoloc, Pantozol, Zurcal, Zentro, Pan, loc, Tecta),
Rabeprazole (brand names: Acipl—lex, Pariet, Erraz, Zechin, Rabecid, Nzole-D, Rabeloc, Razo)
and llaprazole (brand names: , Lupilla, Adiza).
According to the invention, other compounds, compositions or drugs can be administered which
have a protective effect on gastric mucosa, in particular if a nonsteroidal anti-inflammatory drug
(NSAID) is administered.
For example, other compounds, compositions or drugs can be administered to prevent the
common e effect of gastric ulceration of NSAIDs, in particular to prevent NSAID induced
gastric ulcers. In one embodiment, Misoprostol can be administered which is a synthetic
prostaglandin E1 (PGEl) analog that is used for the prevention ofNSAID induced gastric ulcers.
Misoprostol acts upon gastric parietal cells, inhibiting the secretion of gastric acid via G-protein
coupled receptor mediated inhibition of ate cyclase, which leads to decreased intracellular
cyclic AMP levels and decreased proton pump ty at the apical surface of the parietal cell.
Furthermore, Omeprazole proved to be at least as effective as Misoprostol in the treatment of
NSAID induced ulcers but significantly better tolerated.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of drugs that provide sic and
antipyretic (fever-reducing) effects, and, in higher doses, anti-inflammatory effects. The term
"nonsteroidal" distinguishes these drugs from steroids. The most prominent members of this
group of drugs are aspirin, ibuprofen, and naproxen.
One of the main adverse drug reactions (ADRs) associated with NSAle relate to the
gastrointestinal (GI) effects of NSAIDs. These effects are in many cases severe enough to pose
the risk of ulcer perforation and upper gastrointestinal bleeding. NSAID patients experience
dyspepsia. NSAID-associated upper gastrointestinal adverse events, irritation of the
gastrointestinal (GI) tract and GI ulceration. NSAIDs cause a dual t on the GI tract: the
acidic molecules directly irritate the c mucosa, and inhibition of COX-1 and COX-2
reduces the levels of protective prostaglandins. tion of prostaglandin synthesis in the GI
tract causes increased gastric acid secretion, diminished bicarbonate ion, shed mucus
secretion and diminished trophic effects on epithelial mucosa. Thus, NSAIDs are preferably not
administered according to the invention. Paracetamol or "acetaminophen" which is not classified
as a NSAID because it only exerts weak nflammatory effects can be administered as
analgesic ing to the invention, however, it may not be efficient for pain management and
thus, administration of an NSAID could become necessary, in particular to avoid administration
of opiods.
Commonly, gastric (but not necessarily intestinal) adverse effects can be reduced through
suppressing acid production, by concomitant use of a proton pump inhibitor, e.g. Omeprazole,
razole; or the glandin analogue Misoprostol.
The term "antigen" relates to an agent such as a protein or peptide comprising an epitope against
which an immune response is directed and/or is to be ed. In a preferred embodiment, an
n is a tumor-associated antigen, such as CLDN18.2, i.e., a constituent of cancer cells which
may be derived from the cytoplasm, the cell surface and the cell nucleus, in particular those
antigens which are produced, preferably in large ty, intracellular or as surface antigens on
cancer cells.
In the context of the present invention, the term "tumor-associated n" preferably relates to
proteins that are under normal conditions specifically expressed in a limited number of tissues
and/or organs or in specific developmental stages and are expressed or aberrantly expressed in
one or more tumor or cancer tissues. In the context of the present invention, the tumor-associated
antigen is preferably associated with the cell surface of a cancer cell and is preferably not or only
.30 rarely expressed in normal tissues.
The term "epitope" refers to an antigenic determinant in a molecule, i.e., to the part in a molecule
that is recognized by the immune system, for example, that is ized by an antibody. For
e, epitopes are the discrete, three-dimensional sites on an antigen, which are recognized
W0 2014/146778
by the immune system. Epitopes y consist of chemically active surface groupings of
les such as amino acids or sugar side chains and usually have c three dimensional
structural characteristics, as well as specific charge characteristics. Conformational and non-
conformational epitopes are distinguished in that the binding to the former but not the latter is
lost in the ce of denaturing solvents. An epitope ofa protein such as CLDN18.2 preferably
comprises a continuous or tinuous portion of said protein and is preferably n 5 and
100, preferably between 5 and 50, more preferably between 8 and 30, most preferably between
and 25 amino acids in length, for example, the epitope may be preferably 8, 9, 10, 11, 12, 13,
14, 15, l6, 17, 18, 19, 20, 21, 22. 23, 24, or 25 amino acids in length.
The term "antibody" refers to a glycoprotein comprising at least two heavy (H) chains and two
light (L) chains inter-connected by disulfide bonds, and includes any molecule comprising an
binding portion thereof. The term "antibody" includes onal antibodies and
antigen
fragments or derivatives of antibodies, including, without limitation, human antibodies.
humanized antibodies, chimeric antibodies, single chain dies, e.g., scFv's and antigen-
binding antibody fragments such as Fab and Fab' nts and also includes all inant
forms of antibodies, e.g., antibodies expressed in prokaryotes, unglycosylated antibodies, and
derivatives as described herein. Each heavy chain is
any antigen-binding antibody nts and
comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain
constant region. Each light chain is comprised of a light chain le region (abbreviated
herein further as VL) and a light chain constant region. The VH and VL regions can be
subdivided into regions of hypervariability, termed complementarity determining regions (CDR),
interspersed with regions that are more conserved, termed framework regions (FR). Each VH
and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-
terminus in the following order: FRI, CDRI, FR2, CDR2, FR3, CDR3, FR4. The variable
regions of the heavy and light chains contain a binding domain that interacts with an antigen.
The constant regions of the antibodies may mediate the binding of the immunoglobulin to host
s or s. including various cells of the immune system (e.g., effector cells) and the first
component (Clq) of the classical complement system.
The antibodies bed herein may be human antibodies. The term "human antibody", as used
herein, is intended to include antibodies having variable and constant regions derived from
human gerrnline globulin sequences. The human antibodies described herein may
include amino acid residues not encoded by human germline immunoglobulin sequences (e.g.,
mutations introduced by random or pecific mutagenesis in vitro or by somatic mutation in
viva).
The term "humanized antibody" refers to a molecule having an antigen binding site that is
substantially derived from an immunoglobulin from a non-human species, wherein the remaining
immunoglobulin structure of the molecule is based upon the structure and/or sequence of a
human immunoglobulin. The antigen binding site may either comprise complete variable
domains fused onto constant domains or only the mentarity determining regions (CDR)
grafted onto appropriate framework regions in the variable domains. Antigen binding sites may
be wild-type or modified by one or more amino acid tutions. e.g. modified to resemble
human immunoglobulins more closely. Some forms of zed antibodies preserve all CDR
sequences (for example a humanized mouse antibody which ns all six CDRs from the
mouse antibody). Other forms have one or more CDRs which are altered with respect to the
original antibody.
The term "chimeric antibody" refers to those antibodies wherein one portion of each of the amino
acid sequences of heavy and light chains is homologous to cOrresponding sequences in
antibodies derived from a particular s" or belonging to a particular class, while the
remaining t of the chain is gous to corresponding sequences in another. Typically
the le region of both light and heavy chains mimics the variable regions of antibodies
derived from one species of mammals, while the constant portions are homologous to sequences
of antibodies derived from another. One clear advantage to such ic forms is that the
variable region can conveniently be derived from presently known sources using readily
available B-cells or hybridomas from non-human host organisms in combination with constant
regions derived from, for example, human cell preparations. While the variable region has the
advantage of ease of preparation and the specificity is not affected by the source, the nt
region being human. is less likely to elicit an immune response from a human subject when the
antibodies are injected than would the nt region from a non human source. However the
definition is not limited to this particular e.
The terms "antigen-binding portion" of an dy (or simply "binding portion") or "antigen-
binding fragment" of an antibody (or simply "binding fragment") or similar terms refer to one or
more nts of an antibody that retain the ability to specifically bind to an antigen. It has
been shown that the antigen-binding function of an antibody can be performed by fragments of a
2014/000719
ength antibody. Examples of g fragments encompassed within the term "antigenbinding
portion" of an antibody include (i) Fab fragments, monovalent fragments consisting of
the VL, VH, CL and CH domains; (ii) 2 fragments, bivalent fragments comprising two Fab
fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragments consisting of the
VH and CH domains; (iv) Fv fragments consisting of the VL and VH domains of a single arm of
an antibody, (v) dAb fragments (Ward et al., (1989) Nature 341: 544-546), which consist of a
VH domain; (vi) isolated complementarity determining regions (CDR), and (vii) combinations of
two or more ed CDRs which may optionally be joined by a synthetic linker. Furthermore,
although the two domains of the Fv fragment, VL and VH, are coded for by separate genes, they
can be , using recombinant methods, by a synthetic linker that s them to be made as
a single protein chain in which the VL and VH regions pair to form monovalent molecules
(known as single chain Fv (scFv); see e. g., Bird et al. (1988) Science 242: 423-426; and Huston
et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such single chain antibodies are also
intended to be encompassed within the term "antigen-binding fragment" of an antibody. A
further example is binding-domain immunoglobulin fusion ns comprising (i) a binding
domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, (ii) an
globulin heavy chain CH2 constant region fused to the hinge , and (iii) an
immunoglobulin heavy chain CH3 constant region fused to the CH2 constant . The
binding domain polypeptide can be a heavy chain variable region or a light chain variable region.
The binding-domain globulin fusion proteins are further disclosed in US 2003/0118592
and US 2003/0133939. These antibody fragments are obtained using conventional techniques
known to those with skill in the art, and the fragments are screened for utility in the same manner
as are intact antibodies.
The term "bispecific molecule" is ed to include any agent, e.g., a protein, peptide, or
protein or peptide complex, which has two different binding specificities. For example, the
molecule may bind to, or interact with (a) a cell e antigen, and (b) an Fc receptor on the
surface of an effector cell. The term "multispecific molecule" or "heterospecific molecule" is
intended to include any agent, e.g., a protein, peptide, or protein or peptide complex, which has
more than two different g specificities. For example, the molecule may bind to, or interact
with (a) a cell surface antigen, (b) an Fc receptor on the surface of an effector cell, and (c) at
least one other component. Accordingly, the invention includes, but is not limited to, bispecific,
trispecitic, tetraspecitic, and other multispecific molecules which are directed to CLDN18.2, and
to other targets, such as Fc receptors, on effector cells. The term "bispecific antibodies" also
includes ies. Diabodies are bivalent, bispecific antibodies in which the VH and VL
s are expressed on a single ptide chain, but using a linker that is too short to allow
for pairing between the two domains on the same chain, y forcing the domains to pair with
complementary domains of another chain and creating two antigen binding sites (see e.g. ,
Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448; Poljak, R. J ., et al. (1994)
Structure 2: 1121-1123).
An antibody may be conjugated to a therapeutic moiety or agent, such as a cytotoxin, a drug
(e.g., an immunosuppressant) or a radioisotope. A cytotoxin or cytotoxic agent includes any
agent that is detrimental to and, in particular, kills cells. Examples include taxol, cytochalasin B,
gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine,
vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone,
mithramycin, actinomycin D, l-dehydrotestosterone, glucocorticoids, procaine, tetracaine,
lidocaine, propranolol, and puromycin and analogs or homologs thereof. Suitable therapeutic
agents for forming antibody conjugates include, but are not limited to, antimetabolites (e.g.,
methotrexate, 6-mercaptopurine, 6-thioguanine, bine, tludarabin, ouracil
decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, lan,
carrnustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, -dibromomannitol,
streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin),
anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g.,
dactinomycin (formerly actinomycin), bleomycin, mithramycin, and mycin (AMC). and
itotic agents (e. g., vincristine and vinblastine). In a preferred embodiment, the therapeutic
agent is a cytotoxic agent or a radiotoxic agent. In another ment, the therapeutic agent is
an immunosuppressant. In yet another embodiment, the therapeutic agent is GM-CSF. In a
red ment, the therapeutic agent is doxorubicin, cisplatin, bleomycin, sulfate,
carmustine, mbucil, cyclophosphamide or ricin A.
Antibodies also can be conjugated to a radioisotope, e.g., iodine-131, yttrium-9O or indium-l l 1,
to generate cytotoxic radiopharrnaceuticals.
The antibody ates of the invention can be used to modify a given biological response, and
the drug moiety is not to be construed as limited to classical chemical therapeutic . For
example, the drug moiety may be a protein or polypeptide possessing a desired biological
activity. Such ns may include, for example, an enzymatically active toxin, or active
fragment thereof, such as abrin, ricin A, pseudomonas in, or diphtheria toxin; a protein
such as tumor necrosis factor or interferon-y; or, biological response modifiers such as, for
example, lymphokines, interleukin-1 ("IL-l"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),
granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating
factor ("G-CSF"), or other growth factors.
Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g.,
Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in
Monoclonal Antibodies And Cancer y, Reisfeld et al. (eds. ), pp. 243-56 (Alan R. Liss,
Inc. 1985); Hellstrom et al., "Antibodies For Drug ry", in Controlled Drug Delivery (2nd
Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers
Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological
And Clinical ations, Pincheraet al. (eds. ), pp. 475-506 (1985); "Analysis, Results, And
Future ctive Of The Therapeutic Use Of Radiolabeled Antibody In Cancer y", in
Monoclonal Antibodies For Cancer Detection And y, Baldwin et al. (eds), pp. 303-16
(Academic Press 1985), and Thorpe et al., "The Preparation And xic Properties Of
Antibody-Toxin ates", Immunol. Rev., 62: 119-58 (1982).
As used herein, an antibody is "derived from" a particular germline ce if the antibody is
obtained from a system by immunizing an animal or by screening an immunoglobulin gene
y, and n the ed antibody is at least 90%, more preferably at least 95%, even
more preferably at least 96%, 97%, 98%, or 99% identical in amino acid sequence to the amino
acid sequence d by the germline immunoglobulin gene. Typically, an antibody derived
from a particular germline sequence will display no more than 10 amino acid ences, more
preferably, no more than 5, or even more preferably, no more than 4, 3, 2, or 1 amino acid
difference from the amino acid sequence encoded by the germline immunoglobulin gene.
As used herein, the term "heteroantibodies" refers to two or more antibodies, derivatives thereof,
or antigen binding regions linked together, at least two of which have different specificities.
These different specificities include a binding specificity for an Fc receptor on an effector cell,
and a binding specificity for an antigen or epitope on a target cell, e. g., a tumor cell.
The antibodies described herein may be monoclonal antibodies. The term "monoclonal antibody"
as used herein refers to a preparation of antibody molecules of single molecular composition. A
monoclonal antibody displays a single binding specificity and affinity. In one embodiment, the
monoclonal dies are produced by a hybridoma which includes a B cell obtained from a
non-human animal, e.g., mouse, fused to an immortalized cell.
The antibodies described herein may be recombinant antibodies. The term "recombinant
isolated
antibody", as used herein. es all antibodies that are prepared, expressed, created or
by recombinant means, such as (a) antibodies isolated from an animal (e.g., a mouse)
that is
transgenic the globulin genes or a hybridoma
or transchromosomal with respect to
prepared rom, (b) antibodies ed from a host cell transformed to express the antibody,
e.g., from a transt‘ectoma, (c) antibodies isolated from a recombinant, combinatorial antibody
library, and (d) antibodies prepared, expressed, created or isolated by any other means that
involve splicing ofimmunoglobulin gene sequences to other DNA sequences.
Antibodies described herein may be derived from different species, including but not limited to
mouse, rat, rabbit, guinea pig and human.
such
dies described herein include onal and monoclonal antibodies and include IgA
[gAl or [gA2, lgGl, lgGZ, IgG3, lgG4, IgE, IgM, and IgD antibodies. In
as various
embodiments, the antibody is an IgGl antibody, more particularly an lgGl, kappa or lgGl,
lambda isotype (i.e. IgGl, K, A), an IgGZa antibody (e.g. IgG2a, K, )t), an IgG2b antibody (e.g.
lgGZb. K. 7»), an IgG3 antibody (e.g. lgG3, K. K) or an lgG4 antibody (e.g. IgG4, K, A).
The term "transfectoma", as used herein, includes recombinant eukaryotic host cells expressing
or fungi,
an antibody, such as CHO cells, NS/O cells, HEK293 cells, HEK293T cells, plant cells,
including yeast cells.
As used herein, a ologous antibody" is defined in relation to a transgenic organism
producing such an antibody. This term refers to an antibody having an amino acid sequence or an
encoding nucleic acid sequence ponding to that found in an organism not consisting of the
transgenic organism, and being lly d from a species other than the transgenic
organism.
and heavy chains of
As used herein. a "heterohybrid antibody" refers to an antibody having light
chain associated
different organismal origins. For example, an antibody having a human heavy
with a murine light chain is a heterohybrid antibody.
described herein which for
The inVention includes all antibodies and derivatives of antibodies as
the purposes of the invention are encompassed by the term "antibody". The term "antibody
derivatives" refers to any modified form of an antibody, e.g., a conjugate of the antibody
another agent or antibody, or an dy nt.
used herein, is
The antibodies described herein are ably isolated. An "isolated antibody" as
intended to refer to an antibody which is substantiallyfree of other antibodies having ent
to CLDN18.2 is
antigenic specificities (e.g., an isolated antibody that specifically binds
CLDNl 8.2). An isolated
substantially free of antibodies that specifically bind antigens other than
or‘variant of human CLDN18.2 may,
antibody that specifically binds to an epitope, isoform
other species (e.g., CLDNI 8.2
.15 however, have cross-reactivity to other related antigens, e.g., from
free of other ar
species homologs). er, an isolated antibody may be substantially
"isolated"
al and/or chemicals. In one embodiment of the invention, a combination of
ed in
monoclonal antibodies relates to antibodies having different specificities and being
a well defined composition or mixture.
The term "binding" according to the invention preferably relates to a specific binding.
According to the present ion, an antibody is capable ofbinding to a predetermined target
it has a significant affinity for said ermined target and binds to said predetermined target
standard assays. "Affinity" or “binding affinity" is often measured by equilibrium dissociation
to a predetermined
constant (K0). Preferably, the term "significant affinity" refers to the binding
'6 M or lower, 10'7 M or lower, 10'
target with a iation constant (1(0) of 10‘5 M or lower,
or lower, 10'9 M or lower. 10'l0 M or lower, lO'H M or lower, or 10"2 M or lower.
An antibody is not (substantially) capable ofbinding to a target if it has no significant affinity
said target in
said target and does not bind cantly, in particular does not bind detectably, to
standard assays. Preferably, the antibody does not detectably bind to said target if present in a
concentration of up to 2, preferably 10, more ably 20, in particular 50 or 100 ug/ml or
. Preferably, an antibody has no significant affinity for a target if it binds to said target
with a KD that is at least 10-fold, lOO-fold, 103—rold, 104-fold, 105-fold, or lOé-fold higher than
of binding. For
the K0 for binding to the predetermined target to which the antibody is capable
example, if the [(9 for binding of an antibody to the target to which the antibody is capable
binding is 10'7 M, the K0 for g to a target for which the antibody has no significant affinity
would be is at least 10'6 M, 10‘5 M, 10“ M, 10‘3 M, 10'2 M. or 10" M.
An dy is ic for it binding to said
a predetermined target if is capable of
predetermined target while it is not capable of binding to other targets, i.e. has no significant
affinity for other targets and does not significantly bind to 'other targets in standard assays.
According to the invention, an antibody is specific for CLDN18.2 if it is capable of binding to
CLDN18.2 but is not (substantially) capable of binding to other targets. Preferably, an antibody
is specific for CLDN18.2 if the affinity for and the binding to such other s does not
bovine
significantly exceed the affinity for or binding to CLDN18.2-unrelated proteins such as
serum albumin (BSA), casein, human serum albumin (HSA) or non-claudin transmembrane
proteins such as MHC molecules or transferrin receptor or any other specified ptide.
with a Kn
ably, an antibody is specific for a predetermined target if it binds to said target
that is at least 10-fold, IOO-fold, 103-fold, 104-fold, 105-fold, or lot—fold lower than the [(0 for
g to a target for which it is not specific. For example, if the K0 for binding of an antibody
to the target for which it is specific is 10'7 M, the K0 for binding to a target for whichiit is not
specific would be at least 10'“ M, 10‘5 M, 10“ M, 10'3 M, 10'2 M, or 10‘l M.
method;
Binding of an dy to a target can be determined mentally using any suitable
for e, Berzofsky et al., "Antibody-Antigen Interactions" In Fundamental
see,
Immunology, Paul, W. E., Ed., Raven Press New York, N Y , Kuby, Janis Immunology,
Affinities
W. H. Freeman and Company New York, N Y (1992), and methods described herein.
such as by equilibrium dialysis; by
may be readily determined using conventional techniques,
using the BIAcore 2000 instrument, using general procedures outlined by the manufacturer; by
radioimmunoassay using abeled target antigen; or by another method known to the skilled
artisan. The affinity data may be analyzed, for example, by the method of Scatchard et al., Ann
NY. Acad. ScL, 51:660 (1949). The measured affinity of a particular antibody-antigen
interaction can vary if measured under different conditions, e.g., salt concentration, pH. Thus,
ements of affinity and other antigen-binding parameters, e.g., KD, IC50, are preferably
made with standardized solutions of dy and antigen, and a standardized buffer.
As used herein. pe" refers to the antibody class (e.g., IgM or IgGl) that is encoded by
heavy chain constant region genes.
As used herein, "isotype switching" refers to the phenomenon by which the class, or isotype, of
an antibody changes from one lg class to one of the other lg classes.
The term "naturally occurring" as used herein as applied to an object refers to the fact that an
object can be found in nature. For example, a polypeptide or polynucleotide sequence that is
present in an sm (including viruses) that can be isolated from a source in nature and which
' has not been intentionally d by man in the laboratory is naturally ing.
The term "rearranged" as used herein refers to a configuration of a heavy chain or light chain
immunoglobulin locus wherein a V segment is positioned immediately adjacent to a 0-1 or .I
segment in a conformation encoding essentially a te VH or VL domain, respectively. A
rearranged immunoglobulin (antibody) gene locus can be identified by comparison to germline
DNA; a rearranged locus will have at least one ined er/nonamer homology
element.
The term "unrearranged" or ine configuration" as used herein in reference to a V segment
refers to the configuration wherein the V segment is not recombined so as to be immediately
adjacent to a D or] segment.
According to the invention an antibody having the ability of binding to CLDN18.2 is an dy
capable of binding to an epitope present in CLDN18.2, preferably an epitope located within the
ellular domains of CLDN18.2, in particular the first extracellular domain, preferably amino
acid positions 29 to 78 of CLDN18.2. In particular embodiments, an antibody having the ability
ofbinding to CLDN18.2 is an antibody capable of binding to (i) an epitope on CLDN18.2 which
is not present on .1, preferably SEQ ID NO: 3, 4, and 5, (ii) an epitope localized on the
CLDN18.2-loop1, preferably SEQ ID NO: 8, (iii) an epitope localized on the CLDN18.2-loop2,
preferably SEQ ID NO: 10, (iv) an epitope localized on the CLDN18.2-loopD3, preferably SEQ
ID NO: 1 1, (v) an epitope, which encompass CLDN18.2-loop] and CLDN18.2-loopD3, or (vi) a
non-glycosylated epitope zed on the CLDN18.2-loopD3, preferably SEQ ID NO: 9.
According to the invention an antibody having the ability of binding to CLDN18.2 preferably is
an antibody having the ability of binding to CLDN18.2 but not to CLDN18.1. Preferably, an
dy having the ability of g to CLDN18.2 is specific for CLDN18.2. Preferably, an
antibody having the y of g to .2 ably is an antibody having the ability
of binding to CLDN18.2 expressed on the cell surface. In particular red embodiments, an
antibody having the ability of binding to CLDN18.2 binds to native epitopes of CLDN18.2
present on the surface of living cells. Preferably, an antibody having the ability of binding to
CLDN18.2 binds to, one or more peptides selected from the group consisting of SEQ ID NOS: 1,
3-11, 44, 46, and 48-50. Preferably, an dy having the ability of binding to CLDN18.2 is
10_ specific for the afore ned proteins, peptides or immunogenic fragments or tives
f. An antibody having the ability of binding to .2 may be obtained by a method
comprising the step of immunizing an animal with a protein or peptide comprising an amino acid
sequence selected from the group consisting of SEQ ID NOS: 1, 3-11, 44, 46, and 48-50, or a
nucleic acid or host cell expressing said protein or e. Preferably, the dy binds to
cancer cells, in ular cells of the cancer types mentioned above and, preferably, does not
bind substantially to non-cancerous cells.
Preferably, binding of an antibody having the ability of binding to CLDN18.2 to cells expressing
CLDN18.2 induces or mediates killing of cells expressing CLDN18.2. The cells expressing
CLDN18.2 are preferably cancer cells and are, in particular, selected from the group consisting
of tumorigenic gastric, esophageal, pancreatic, lung, ovarian, colon, hepatic, head-neck, and
gallbladder cancer cells. Preferably, the antibody induces or mediates killing of cells by inducing
one or more of complement dependent cytotoxicity (CDC) mediated lysis, antibody dependent
cellular cytotoxicity (ADCC) mediated lysis, apoptosis, and inhibition of proliferation of cells
expressing CLDN18.2. Preferably, ADCC mediated lysis of cells takes place in the presence of
effector cells, which in particular embodiments are selected from the group consisting of
monocytes, mononuclear cells, NK cells and PMNs. Inhibiting proliferation of cells can be
measured in vitro by determining proliferation of cells in an assay using eoxyuridine (5-
Z-deoxyuridine, BrdU). BrdU is a synthetic nucleoside which is an analogue of thymidine
and can be incorporated into the newly synthesized DNA of replicating cells (during the S phase
of the cell cycle), substituting for thymidine during DNA replication. Detecting the incorporated
chemical using, for example, antibodies specific for BrdU indicates cells that were actively
replicating their DNA.
In red embodiments, antibodies described herein can be characterized by one or more of
the following properties:
a) specificity for CLDN18.2;
b) a binding affinity to CLDN18.2 of about 100 nM or less, preferably, about 5-10 nM or less
and, more preferably, about [-3 nM or less,
c) the ability to induce or mediate CDC on CLDN18.2 positive cells;
d) the ability to induce or mediate ADCC on CLDN18.2 positive cells;
e) the ability to inhibit the growth ofCLDN18.2 positive cells;
0 the ability to induce apoptosis ofCLDN18.2 positive cells.
in a particularly red embodiment, an antibody having the ability of binding to CLDN18.2
is produced by a hybridoma ted at the DSMZ (Mascheroder Weg lb, 31824
Braunschweig, Germany; new address: Inhoffenstr. 73, 31824 Braunschweig, Germany) and
having the following ation and accession number:
1 5 a. 182-D1106-055, accesssion no. DSM ACC2737, deposited on r 19, 2005
b. 182-Dl 6, accesssion no. DSM ACC2738, deposited on October 19, 2005
c. 182-Dl 106-057, accesssion no. DSM ACC2739, deposited on October 19, 2005
d. 182-D1106-058, accesssion no. DSM ACC2740, deposited on October 19, 2005
e. 106-059, sion no. DSM ACC2741, deposited on October 19, 2005
2 O f. 106-062, accesssion no. DSM ACC2742, deposited on r 19, 2005,
g. 182-Dl 106-067, accesssion no. DSM ACC2743, deposited on October 19, 2005
h. 182—D758-035, accesssion no. DSM ACC2745, deposited on Nov. 17, 2005
i. 182-D758-036, accesssion no. DSM ACC2746, deposited on Nov. 17, 2005
j. 182-D758-040, accesssion no. DSM ACC2747, deposited on Nov. 17, 2005
2 5 k. l82-D1 106-061, accesssion no. DSM ACC2748, deposited on Nov. 17, 2005
l. 106-279, accesssion no. DSM ACC2808, deposited on Oct. 26, 2006
m. 182-Dl 106-294, accesssion no. DSM ACC2809, ted on Oct. 26, 2006,
n. l82-Dl 106-362, accesssion no. DSM ACC2810, deposited on Oct. 26, 2006.
Preferred antibodies according to the invention are those produced by and obtainable from the
above-described hybridomas; Le. 3761 l in the case of 182-D1 106-055, 37H8 in the case of 182-
D1 106-056. 3805 in the ease of 182-Dl 106-057, 38H3 in the case of 182-D1 106-058, 39Fll in
the case of l82-Dl 106-059, 43All in the case of l82~Dl 106-062, 61C2 in the case of 182-
D1106-O67, 2685 in the case of 182-D758-035, 26D12 in the case of l82-D758-036, 28D10 in
the case of 182-D758-O40, 42E12 in the case of 182-D1106-061, 125E1 in the case of 182-
D1106-279, 163E12 in the case of 106-294, and 175D10 in the case of 182-D1106-362;
and the chimerized and humanized forms thereof.
Preferred chimerized dies and their sequences are shown in the following table.
chimerized
clone mAb lsotype variable region antibody
heavy
chain 43A1 l 182-D1 106-062 SEQ ID NO:29 SEQ ID NO:14
163E12 182-Dl 106-294 IgG3 SEQ ID NO:3O SEQ ID NO:15
125E1 182-Dl 106-279 IgG2a SEQ ID NO:3I SEQ ID NO:16
166E2 l82-Dl 106-308 IgG3 SEQ ID NO:33 SEQ ID NO:18
l75D10 182-D1106-362 IgGl SEQ ID NO:32 SEQ ID NO:17
45C1 l82-D758-187 IgGZa SEQ ID NO:34 SEQ ID NO:19
43A1 1 l82-D1106-062 SEQ ID NO:36 SEQ 10 N02]
163E12 106-294 IgK SEQ ID NO:35 SEQ ID NO:20
125E1 182-D1106-279 IgK SEQ [0 NO:37 SEQ 10 N022
166E2 182308 ng SEQ ID NO:40 SEQ 10 NO:25
175010 l82-D1106-362 IgK SEQ 10 NO:39 SEQ ID N024
45c1 182187 ng SEQ ID NO:38 SEQ ID N023
4501 1820758187 IgK SEQ ID NO:4l SEQ 10 NO:26
45C1 182187 IgK SEQ ID NO:42 SEQ 10 N027
45C] 182-D758-187 IgK SEQ ID NO:43 SEQ 10 NO:28
In preferred embodiments, antibodies, in particular chimerised forms of antibodies according to
the invention include antibodies comprising a heavy chain constant region (CH) comprising an
amino acid ce derived from a human heavy chain constant region such as the amino acid
sequence represented by SEQ ID NO: 13 or a fragment f. In further preferred
embodiments, dies. in particular chimerised forms of antibodies according to the invention
include dies comprising a light chain constant region (CL) comprising an amino acid
sequence derived from a human light chain constant region such as the amino acid sequence
represented by SEQ ID NO: 12 or a fragment thereof. In a particular preferred embodiment,
antibodies, in particular chimerised forms of antibodies according to the invention include
antibodies which se a CH comprising an amino acid sequence derived from a human CH
such as the amino acid sequence represented by SEQ ID NO: 13 or a fragment thereof and which
se a CL comprising an amino acid sequence derived from a human CL such as the amino
acid sequence represented by SEQ ID NO: 12 or a fragment thereof.
In one embodiment, an antibody having the ability of binding to CLDN18.2 is a chimeric
mouse/human IgGl monoclonal antibody comprising kappa, murine variable light chain, human
kappa light chain constant region allotype Km(3), murine heavy chain variable region, human
IgG1 constant region, allotype Glm(3).
In certain preferred embodiments, chimerised forms of antibodies include antibodies comprising
a heavy chain comprising an amino acid sequence ed from the group consisting of SEQ
N05: 14, 15, 16, 17, 18, 19, and a fragment thereof and/or comprising a light chain comprising
an amino acid sequence selected from the group consisting of SEQ ID NOS: 20, 21, 22, 23, 24,
25, 26, 27, 28, and a nt thereof.
In certain preferred ments, chimerised forms of antibodies include antibodies comprising
a combination of heavy chains and light chains selected from the following possibilities (i) to
(ix):
(i) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 14 or a
fragment thereof and the light chain comprises an amino acid sequence ented by SEQ ID
NO: 21 or a fragment thereof,
(ii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 15 or a
fragment f and the light chain comprises an amino acid sequence represented by SEQ ID
NO: 20 or a fragment thereof,
(iii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 16 or a
nt thereof and the light chain comprises an amino acid sequence represented by SEQ ID
NO: 22 or a fragment thereof,
(iv) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 18 or a
fragment thereof and the light chain ses an amino acid sequence represented by SEQ ID
NO: 25 or a fragment f,
(v) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 17 or a
fragment thereof and the light chain comprises an amino acid sequence ented by SEQ ID
NO: 24 or a nt thereof,
(vi) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 19 or a
nt thereof and the light chain comprises an amino acid sequence represented by SEQ ID
NO: 23 or a fragment thereof,
(vii) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 19 or a
fragment thereof and the light chain comprises an amino acid sequence represented by SEQ ID
NO: 26 or a fragment thereof,
(viii) the heavy chain comprises an amino acid sequence ented by SEQ ID NO: 19 or a
nt thereof and the light chain comprises an amino acid sequence represented by SEQ ID
NO: 27 or a fragment thereof, and
(ix) the heavy chain comprises an amino acid sequence represented by SEQ ID NO: 19 or a
fragment thereof and the light chain comprises an amino acid ce represented by SEQ ID
NO: 28 or a fragment thereof.
The dy according to (v) is particularly preferred.
"Fragment" or "fragment of an amino acid sequence" as used above relates to a part of an
antibody sequence, i.e. a sequence rwhich represents the antibody ce ned at the N-
and/or C-terminus, which when it replaces said antibody sequence in an antibody retains binding
of said antibody to CLDN18.2 and preferably functions of said dy as described herein, e. g.
CDC mediated lysis or ADCC mediated lysis. Preferably, a fragment of an amino acid sequence
comprises at least 80%, preferably at least 90%, 95%, 96%, 97%, 98%, or 99% of the amino acid
es from said amino acid sequence. A fragment ofan amino acid sequence selected from the
group consisting of SEQ ID NOs: 14, 15, l6, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, and 28
preferably relates to said sequence wherein 17, 18, 19, 20, 21, 22 or 23 amino acids at the N-
terminus are removed.
In a preferred embodiment, an antibody having the ability of binding to CLDN18.2 comprises a
heavy chain variable region (VH) comprising an amino acid sequence ed from the group
consisting ofSEQ ID N05: 29, 30, 31, 32, 33, 34, and a fragment thereof.
In a preferred embodiment, an antibody having the y of binding to CLDN18.2 comprises a
light chain variable region (VL) comprising an amino acid sequence selected from the group
consisting ofSEQ ID NO: 35, 36, 37, 38, 39, 40, 41, 42, 43, and a fragment thereof.
In certain preferred embodiments, an antibody having the ability of binding to CLDN18.2
comprises a ation of heavy chain variable region (VH) and light chain variable region
(VL) selected from the following possibilities (i) to (ix):
(i) the VH comprises an amino acid sequence ented by SEQ ID NO: 29 or a fragment
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 36 or a
nt f,
(ii) the VH ses an amino acid sequence represented by SEQ ID NO: 30 or a fragment
thereof and the VL ses an amino acid sequence represented by SEQ ID NO: 35 or a
fragment thereof,
(iii) the VH comprises an amino acid sequence represented by SEQ ID NO: 31 or a fragment
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 37 or a
fragment thereof,
(iv) the VH comprises an amino acid sequence ented by SEQ ID NO: 33 or a fragment
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 40 or a
fragment thereof,
(v) the VH comprises an amino acid sequence ented by SEQ ID NO: 32 or a fragment
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 39 or a
fragment thereof,
(vi) the VH comprises an amino acid sequence represented by SEQ ID NO: 34 or a fragment
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 38 or a
nt thereof,
(vii) the VH comprises an amino acid sequence represented by SEQ ID NO: 34 or a fragment
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 41 or a
nt thereof,
(viii) the VB comprises an amino acid sequence represented by SEQ ID NO: 34 or a fragment
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 42 or a
fragment thereof,
(ix) the VH comprises an amino acid sequence represented by SEQ ID NO: 34 or a nt
thereof and the VL comprises an amino acid sequence represented by SEQ ID NO: 43 or a
fragment thereof.
The antibody according to (v) is particularly preferred.
WO 46778
CLDN18.2 comprises a
In a preferred ment. an antibody having the ability of g to
CDR3 selected
VH comprising a set of complementarity-detennining regions CDRl, CDR2 and
from the following embodiments (i) to (vi):
(i) CDRI: positions 45-52 of SEQ ID NO: 14, CDR2: positions 70-77 of SEQ ID NO:
CDR3: positions 116-125 of SEQ ID NO: 14,
(ii) CDRl: ons 45-52 of SEQ ID NO: 15, CDR2: positions 70-77 of SEQ ID NO:
CDR3: positions 116-126 of SEQ ID NO: 15,
16, CDR2: positions 70-77 of SEQ ID NO: 16,
(iii) CDRI: positions 45-52 of SEQ ID NO:
CDR3: positions 116-124 ofSEQ ID NO: 16,
(iv) CDR]: positions 45-52 of SEQ ID NO: 17, CDR2: positions 70-77 of SEQ ID NO:
CDR3: positions 116-126 of SEQ ID NO: 17,
(v) CDRl: positions 44-51 of SEQ ID NO: 18, CDR2: positions 69-76 of SEQ ID NO:
CDR3: positions 115-125 of SEQ ID NO: 18,. and
(vi) CDRl: positions 45-53 of SEQ ID NO: 19, CDR2: positions 71-78 of SEQ ID NO: 19,
CDR3: ons 117-128 of SEQ ID NO: 19.
CLDN18.2 comprises a
In a preferred embodiment, an antibody having the ability of binding to
and CDR3 selected
VL comprising a set of complementarity-determining regions CDRl, CDR2
from the following embodiments (i) to (ix):
(i) CDRI: positions 47-58 of SEQ ID NO: 20, CDR2: positions 76-78 of SEQ ID NO:
CDR3: positions 115-123 ofSEQ ID NO: 20,
positions 49-53 of SEQ ID NO: 21,
(ii) CDRI: 21, CDR2: positions 71-73 of SEQ ID NO:
CDR3: ons 110-118 ofSEQ ID NO: 21,
(iii) CDRl: positions 47-52 of SEQ ID NO: 22, CDR2: positions 70-72 of SEQ ID NO: 22,
CDR3: positions 7 of SEQ ID NO: 22,
(iv) CDRI: positions 47-58 of SEQ ID NO: 23, CDR2: positions 76-78 of SEQ ID NO:
CDR3: positions 115-123 ofSEQ ID NO: 23,
positions 47-58 of SEQ ID NO: 24, CDR2: positions 76-78 of SEQ ID NO: 24, (v) CDRI:
CDR3: positions 115-123 ofSEQ ID NO: 24,
(vi) CDRl: positions 47-58 of SEQ ID NO: 25, CDR2: positions 76-78 of SEQ ID NO:
CDR3: positions 115-122 ofSEQ ID NO: 25,
26, CDR2: positions 76-78 of SEQ ID NO: 26, (vii) CDRI: positions 47-58 of SEQ ID NO:
CDR3: positions 115-123 of SEQ ID NO: 26,
2014/000719
(viii) CDRI: positions 47-58 of SEQ ID NO: 27, CDR2: positions 76-78 of SEQ ID NO: 27,
CDR3: positions 115-123 of SEQ ID NO: 27, and
(ix) CDRI: positions 47-52 of SEQ ID NO: 28, CDR2: positions 70-72 of SEQ ID‘NO: 28,
CDR3: ons 109-117 of SEQ ID NO: 28.
In a preferred ment, an antibody having the ability of binding to CLDN18.2 comprises a
combination of VH and VL each comprising a set of complementarity-determining regions
CDRl, CDR2 and CDR3 selected from the following embodiments (i) to (ix):
(i) VH2 CDRl: positions 45-52 of SEQ ID NO: 14, CDR2: positions 70—77 of SEQ ID NO: 14,
CDR3: ons 116-125 of SEQ ID NO: 14, VL: CDRI: positions 49-53 of SEQ ID NO: 21,
CDR2: positions 71-73 ofSEQ ID NO: 21, CDR3: positions 110-118 of SEQ ID NO: 21,
(ii) VH1 CDRI: positions 45-52 ofSEQ ID NO: 15, CDR2: positions 70-77 of SEQ ID NO: 15,
CDR3: positions 116—126 of SEQ ID NO: 15, VL: CDRI: positions 47-58 of SEQ ID NO: 20,
CDR2: positions 76-78 of SEQ ID NO: 20, CDR3: positions 115-123 ofSEQ ID NO: 20,
(iii) VH: CDRI: positions 45-52 of SEQ ID NO: 16, CDR2: positions 70-77 of SEQ ID NO: I6,
CDR3: positions 4 of SEQ ID NO: 16, VL: CDRl: positions 47—52 of SEQ ID NO: 22,
CDR2: positions 70-72 of SEQ ID NO: 22, CDR3: positions 109-117 ofSEQ ID NO: 22,
(iv) VHi CDRl: positions 44-51 of SEQ ID NO: 18, CDR2: positions 69-76 of SEQ ID NO: 18,
CDR3: positions 115-125 of SEQ ID NO: 18, VL: CDRI: positions 47-58 of SEQ ID NO: 25,
CDR2: positions 76-78 of SEQ ID NO: 25, CDR3: positions 115-122 of SEQ ID NO: 25,
(v) VH2 CDRI: positions 45-52 of SEQ ID NO: 17, CDR2: ons 70-77 of SEQ ID NO: 17,
CDR3: positions [16-126 of SEQ ID NO: 17, VL: CDRI: positions 47-58 ofSEQ ID NO: 24,
CDR2: positions 76-78 of SEQ ID NO: 24, CDR3: positions 1 15—123 of SEQ ID NO: 24,
(vi) VH: CDRl: positions 45-53 of SEQ ID NO: 19, CDR2: positions 71-78 of SEQ ID NO: I9,
CDR3: positions 117-128 of SEQ ID NO: 19, VL: CDRI: positions 47-58 of SEQ ID NO: 23,
CDR2: ons 76-78 of SEQ ID NO: 23, CDR3: positions 115-123 ofSEQ ID NO: 23,
(vii) VH: CDRI: positions 45-53 of SEQ ID NO: 19, CDR2: positions 71-78 ofSEQ ID NO:19,
CDR3: ons 117-128 of SEQ ID NO: 19, VL: CDRl: positions 47-58 of SEQ ID NO: 26,
CDR2: positions 76-78 of SEQ ID NO: 26, CDR3: positions 115-123 of SEQ ID NO: 26,
(viii) VH: CDRl: positions 45-53 of SEQ ID NO: 19, CDR2: positions 71-78 of SEQ ID NO:
19, CDR3: positions 117-128 of SEQ ID NO: 19, VL: CDRI: positions 47-58 of SEQ ID NO:
27, CDR2: positions 76-78 of SEQ ID NO: 27, CDR3: positions 115-123 of SEQ ID NO: 27,
(ix) VH: CDRl: positions 45-53 of SEQ ID NO: 19, CDR2: ons 71-78 of SEQ ID NO:
CDR3: positions 117-128 of SEQ ID NO: 19, VL: CDRl: positions 47-52 of SEQ ID NO: 28,
ID NO: 28.
CDR2: positions 70-72 ofSEQ ID NO: 28, CDR3: positions 109-117 of SEQ
In further preferred embodiments, an antibody having the ability of binding to CLDN18.2
preferably comprises one or more of the complementarity-determining regions (CDRS),
and/or of
preferably at least the CDR3 variable region, of the heavy chain variable region (VH)
of a
the light chain variable region (VL) of a monoclonal antibody against CLDN18.2, preferably
monoclonal antibody against CLDN18.2 described herein, and preferably comprises one or more
at least the CDR3 variable
of the complementarity-detennining regions (CDRS), preferably
chain variable
region, of the heavy chain variable regions (VH) and/or light regions (VL)
bed herein. In one embodiment said one or more of the complementarity-determining
CDRl, CDR2
s (CDRs) are selected from a set of complementarity-determining regions
and CDR3 bed herein. In a particularly preferred embodiment, an antibody having
regions,
ability of binding to CLDN18.2 preferably comprises the complementarity-determining
CDRl, CDR2 and CDR3 of the heavy chain le region (VH) and/or of the light chain
of a onal
variable region (VL) of a monoclonal antibody against CLDN18.2, preferably
antibody against CLDN18.2 described herein, and preferably comprises the mentarity-
and/0r
deterrnining regions CDRl, CDR2 and CDR3 of the heavy chain variable regions (VH)
2O light chain variable regions-(VL) described herein.
CDRs or a combination
In one embodiment an antibody comprising one or more CDRs, a set of
of sets of CDRs as described herein comprises said CDRs together with their ening
both
framework regions. Preferably, the portion will also include at least about 50% of either or
first
of the first and fourth framework regions, the 50% being the C-terminal 50% of the
framework region and the N-terminal 50% of the fourth ork region. Construction of
residues N-
antibodies made by recombinant DNA techniques may result in the introduction of
introduced to facilitate cloning or other
or C-terminal to the variable regions encoded by linkers
invention
manipulation steps, including the introduction of linkers to join variable s of the
other variable domains (for
to r protein sequences including immunoglobulin heavy chains,
example in the production of diabodies) or protein labels.
combination
In one ment an antibody comprising one or more CDRs, a set of CDRs or a
framework.
of sets ofCDRs as described herein comprises said CDRs in a human antibody
Reference herein to an antibody sing with respect to the heavy chain thereof a particular
chain, or a particular region or sequence preferably relates to the situation wherein all heavy
chains of said antibody se said ular chain, region or sequence. This applies
correspondingly to the light chain of an antibody.
The term "nucleic acid", as used herein, is intended to include DNA and RNA. A c acid
is double-stranded DNA.
may be single-stranded or -stranded, but preferably
According to the invention, the term ”expression" is used in its most general meaning and
comprises the tion of RNA or of RNA and protein/peptide. It also comprises partial
expression of nucleic acids. Furthermore, expression may be carried out transiently or stably.
The teaching given herein with respect to specific amino acid ces, e. g. those shown in the
sequence listing, is to be construed so as to also relate to variants of said specific sequences
resulting in sequences which are functionally equivalent to said specific sequences, e. g. amino
acid sequences exhibiting properties identical or similar to those of the c amino acid
of an antibody to its target or to sustain
sequences. One important property is to retain binding
effector functions of an antibody. Preferably, a sequence which is a variant with respect to a
specific sequence, when it replaces the specific sequence in an antibody retains binding of said
dy to CLDN18.2 and preferably fimctions of said antibody as described herein, e.g. CDC
mediated lysis or ADCC mediated lysis.
It will be appreciated by those skilled in the art that in particular the sequences of the CDR,
ariable and variable regions can be d without losing the ability to bind CLDN18.2.
For e, CDR regions will be either identical or highly homologous to the regions of
antibodies specified herein. By y homologous" it is contemplated that from 1 to 5.
preferably from 1 to 4, such as 1 to 3 or 1 or 2 substitutions may be made in the CDRs. In
addition, the hypervariable and le regions may be modified so that they show substantial
homology with the regions of antibodies specifically disclosed herein.
For the purposes of the present invention, "variants" of an amino acid sequence comprise amino
acid insertion variants, amino acid addition variants, amino acid deletion ts and/or amino
acid substitution variants. Amino acid deletion variants that comprise the deletion at the N-
al and/or C-terminal end of the protein are also called N-terminal and/or C-terminal
truncation variants.
Amino acid insertion variants comprise insertions of single or two or more amino acids in a
particular amino acid sequence. In the case of amino acid sequence variants having an insertion,
amino acid sequence,
one or more amino acid residues are ed into a particular site in an
although random insertion with appropriate screening of the resulting product is also possible.
Amino acid addition variants comprise amino- and/or carboxy-terminal fusions of one or more
amino acids, such as l, 2, 3, 5, 10, 20, 30, 50, or more amino acids.
Amino acid deletion variants are characterized by the removal of one or more amino acids from
the sequence, such as by removal of l, 2, 3, 5, 10, 20, 30, 50, or more amino acids. The deletions
may be in any position of the protein.
Amino acid substitution variants are characterized by at least one residue in the ce being
removed and another residue being inserted in its place. ence is given to the modifications
being in positions in the amino acid sequence which are not conserved between homologous
proteins or peptides and/or to replacing amino acids with other ones having similar properties.
2O Preferably, amino acid changes in protein variants are conservative amino acid changes, i.e.,
substitutions of rly d or uncharged amino acids. A conservative amino acid change
involves substitution of one of a family of amino acids which are related in their side chains.
Naturally ing amino acids are generally divided into four families: acidic (aspartate,
glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, cine,
e, phenylalanine, nine, tryptophan), charged polar (glycine, asparagine,
glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and
tyrosine are sometimes classified jointly as ic amino acids.
Preferably the degree of similarity, preferably identity between a given amino acid sequence and
an amino acid sequence which is a variant of said given amino acid sequence will be at least
about 60%, 65%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%.
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. The degree of similarity or identity is given
preferably for an amino acid region which is at least about 10%, at least about 20%, at least
about 30%, at least about 40%, at least about 50%. at least about 60%. at least about 70%. at
least about 80%, at least about 90% or about 100% of the entire length of the reference amino
acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids,
the degree of similarity or identity is given preferably for at least about 20, at least about 40, at
least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least
about 160, at least about 180, or about 200 amino acids, preferably continuous amino acids. In
preferred embodiments, the degree of similarity or identity is given for the entire length of the
reference amino acid sequence. The alignment for determining sequence similarity, preferably
sequence identity can be done with art known tools, preferably using the best sequence
alignment, for example, using Align, using standard settings, preferably EMBOSS::needle,
Matrix: Blosum62, Gap Open 10.0, Gap Extend 0.5.
"Sequence similarity" indicates the percentage of amino acids that either are identical or that
represent conservative amino acid tutions. nce ty" between two amino acid
sequences indicates the percentage of amino acids that are identical between the sequences.
The term "percentage identity" is ed to denote a tage of amino acid residues which
are identical between the two sequences to be compared, obtained after the best alignment, this
percentage being purely statistical and the differences between the two ces being
distributed randomly and over their entire length. Sequence comparisons between two amino
acid sequences are conventionally carried out by comparing these sequences after having aligned
them optimally, said comparison being carried out by segment or by "window of comparison" in
order to identify and compare local regions of sequence similarity. The l alignment of the
sequences for comparison may be ed, besides manually, by means of the local homology
algorithm of Smith and an, 1981, Ads App. Math. 2, 482, by means of the local
homology algorithm of Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, by means of the
rity search method of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 85, 2444, or
by means of computer programs which use these algorithms (GAP, BESTFIT, FASTA, BLAST
P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group,
575 Science Drive, n, Wis.).
The percentage identity is calculated by determining the number of cal positions between
the two ces being compared, dividing this number by the number of positions compared
and multiplying the result obtained by 100 so as to obtain the percentage identity between these
two sequences.
The term "transgenic animal" refers to an animal having a genome comprising one or more
transgenes, preferably heavy and/or light chain transgenes, or transchromosomes (either
integrated or non-integrated into the animal's natural genomic DNA) and which is preferably
e of expressing the transgenes. For example, a transgenic mouse can have a human light
chain transgene and either a human heavy chain ene or human heavy chain
transchromosome, such that the mouse produces human anti-CLDNI8.2 antibodies when
immunized with CLDN18.2 antigen and/or cells expressing CLDN18.2. The human heavy chain
can be integrated into the chromosomal DNA of the mouse, as is the for
transgene case
transgenic mice, the human heavy chain
e.g., HuMAb mice, such as HCo7 or HC012 mice, or
transgene can be maintained extrachromosomally, as is the case for transchromosomal (e.g.,
KM) mice as described in WO 02/43478. Such transgenic and hromosomal mice may be
capable of producing multiple isotypes of human monoclonal antibodies to CLDN18.2 (e.g.,
igG, lgA and/or lgE) by undergoing V-D-J recombination and isotype switching.
"Reduce", "decrease" or it" as used herein means an overall decrease or the ability to Cause
an overall se, preferably of 5% or greater, 10% or greater, 20% or greater, more preferably
of 50% or greater, and most preferably of 75% or r, in the level, e.g. in the level of
expression or in the level of proliferation of cells.
Terms such as "increase" or ce" preferably relate to an increase or enhancement by about
at least 10%, preferably at least 20%, preferably at least 30%. more preferably at least 40%, more
preferably at least 50%, even more preferably at least 80%. and most preferably at least 100%, at
least 200%, at least 500%, at least 1000%, at least 10000% or even more.
Mechanisms of mAb action
Although the ing provides considerations regarding the mechanism underlying the
therapeutic efficacy of antibodies of the invention it is not to be considered as limiting to the
invention in any way.
The antibodies described herein ably interact with components of the immune system,
preferably through ADCC or CDC. Antibodies described herein can also be used to target
ds (e.g., radioisotopes, drugs or toxins) to directly kill tumor cells or can be used
istically with traditional chemotherapeutic agents, attacking tumors through
complementary mechanisms of action that may include anti-tumor immune responses that may
have been compromised owing to a herapeutic's cytotoxic side effects on T lymphocytes.
However, antibodies described herein may also exert an effect simply by binding to CLDN18.2
on the cell surface, thus, 6. g. blocking proliferation of the cells.
Antibody-dependent cell-mediated cytotoxicity
ADCC describes the cell-killing ability of effector cells as described herein, in particular
lymphocytes, which preferably requires the target cell being marked by an antibody.
ADCC preferably occurs when antibodies bind to ns on tumor cells and the antibody Fc
domains engage F0 receptors (FCR) on the surface of immune effector cells. l families of
Fc receptors have been identified, and specific cell tions teristically express defined
Fc receptors. ADCC can be viewed as a mechanism to directly induce a variable degree of
immediate tumor destruction that leads to antigen presentation and the induction of tumor-
ed T-cell responses. Preferably, in vivo induction of ADCC will lead to tumor-directed T-
cell responses and host-derived antibody responses.
Complement-dependent cytotoxicity
CDC is another illing method that can be directed by antibodies. IgM is the most effective
isotype for ment activation. IgG1 and lgG3 are also both very effective at directing CDC
via the classical complement-activation pathway. Preferably, in this cascade, the formation of
antigen-antibody complexes results in the uncloaking of multiple Clq binding sites in close
proximity on the CH2 domains of participating dy molecules such as lgG molecules (C lq
is one of three subcomponents of complement Cl). Preferably these uncloaked Clq g sites
convert the previously low-affinity Clq-lgG interaction to one of high avidity, which triggers a
cascade of events involving a series of other complement proteins and leads to the proteolytic
release of the or-cell chemotactic/activating agents C3a and C5a. Preferably, the
complement cascade ends in the formation of a membrane attack complex, which creates pores
in the cell membrane that facilitate free passage of water and solutes into and out of the cell.
dies described herein can be produced by a y of techniques, including conventional
monoclonal antibody methodology, e.g., the rd somatic cell hybridization technique of
Kohler and Milstein, Nature 256: 495 (1975). Although somatic cell ization procedures are
preferred, in principle, other techniques for producing monoclonal antibodies can be employed.
e.g., viral or oncogenic transformation of B-lymphocytes or phage display techniques using
libraries of antibody genes.
The red animal system for preparing hybridomas that secrete monoclonal antibodies is the
murine system. Hybridoma production in the mouse is a very well established procedure.
zation protocols and techniques for ion of immunized splenocytes for fusion are
known in the art. Fusion partners (e. g., murine myeloma cells) and fusion procedures are also
known.
Other preferred animal systems for preparing hybridomas that secrete monoclonal antibodies are
the rat and the rabbit system (e.g. described in r—Polet et al., Proc. Natl. Acad. Sci. USA.
9229348 ( 1995), see also Rossi et al., Am. J. Clin. Pathol. 124: 295 (2005)).
In yet another preferred embodiment, human monoclonal antibodies can be generated using
transgenic or transchromosomal mice carrying parts of the human immune system rather than the
HuMAb
mouse system. These transgenic and transchromosomic mice include mice known as
mice and KM mice, respectively, and are collectively referred to herein as "transgenic mice."
The production of human dies in such transgenic mice can be med as described in
detail for CD20 in W02004 035607
Yet another strategy for generating onal antibodies is to directly isolate genes encoding
antibodies from lymphocytes producing antibodies of defined specificity e.g. see k et al.,
1996; A novel gy for generating monoclonal antibodies from single, isolated lymphocytes
producing antibodies of defined specificities. For details of recombinant dy engineering
see also Welschof and Kraus, Recombinant antibodes for cancer therapy ISBN89603-9l8-8
and Benny K.C. Lo Antibody Engineering ISBN 1092-1.
To generate antibodies. "mice can be immunized with carrier-conjugated peptides derived from
the antigen sequence, i.e. the sequence against which the antibodies are to be directed, an
enriched preparation of recombinantly expressed antigen or fragments thereof and/or cells
expressing the antigen, as described. Alternatively, mice can be immunized with DNA encoding
the antigen or fragments thereof. In the event that immunizations using a d or enriched
preparation of the n do not result in dies. mice can also be immunized with cells
expressing the n. e.g., a cell line, to promote immune responses.
with
The immune response can be monitored over the course of the zation protocol
bleeds. Mice with sufficient
plasma and serum samples being obtained by tail vein or retroorbital
titers of immunoglobulin can be used for fusions. Mice can be boosted intraperitonealy or
of the spleen to
enously with n expressing cells 3 days before sacrifice and removal
increase the rate of c dy ing hybridomas.
and lymph node cells
To generate hybridomas producing monoclonal antibodies, splenocytes
cell line, such as
from immunized mice can be isolated and fused to an appropriate immortalized
can then be screened for the production of
a mouse myeloma cell line. The resulting hybridomas
antigen-specific dies. Individual wells can then be screened by ELISA antibody
secreting hybridomas. By Immunofluorescence and FACS analysis using antigen expressing
cells, antibodies with specificity for the antigen can be identified. The antibody secreting
antibodies can be
hybridomas can be replated, ed again, and if still positive for monoclonal
vitro to generate
subcloned by limiting on. The stable subclones can then be cultured in
antibody in tissue culture medium for characterization.
acombination of
Antibodies also can be produced in a host cell transfectoma using, for example,
recombinant DNA techniques and gene transfection methods as are well known in the art
(Morrison, S. (1985) Science 229: 1202).
be ligated into
For example, in one embodiment, the gene(s) of interest, e. g., antibody genes, can
the GS gene
an expression vector such as a eukaryotic expression plasmid such as used by
other expression
expression system disclosed in WO 87/04462, WO 89/01036 and EP 338 841 or
systems well knewn in the art. The purified plasmid with the cloned antibody genes can
introduced in eukaryotic host cells such as CHO cells, NS/O cells, HEK293T cells or HEK293
cells or alternatively other eukaryotic cells like plant derived cells, fungal or yeast cells. The
such
method used to introduce these genes can be s described in the art as
electroporation, lipofectine, lipofectamine or others. Afier uction of these antibody genes
cells
in the host cells, cells expressing the antibody can be fied and selected. These
their expression level and upscaled
represent the transt‘ectomas which can then be amplified for
and purified from these culture
to e antibodies. Recombinant antibodies can be isolated
supematants and/or cells.
Alternatively, the cloned antibody genes can be expressed in other expression systems, including
prokaryotic cells, such as microorganisms, e.g. E. coli. Furthermore, the antibodies can be
in eggs
produced in transgenic non-human animals. such as in milk from sheep and rabbits or
216: 165-
from hens. or in transgenic plants; see c. g. Verma, R., et a1. (1998) J. Immunol. Meth.
181; Pollock, et al. (1999) J. Immunol. Meth. 231: 147-157; and Fischer. R., et
a1. (1999) Biol.
Chem. 380: 825-839.
Chimerization
Murine monoclonal antibodies can be used as therapeutic antibodies in humans when
with toxins or radioactive isotopes. Nonlabeled murine antibodies are highly immunogenic
main man when repetitively d leading to reduction of the therapeutic effect. The
immunogenicity is mediated by the heavy chain nt regions. The immunogenicity of murine
antibodies in man can be reduced or tely avoided if respective antibodies are chimerized
of which are d
or humanized. Chimeric antibodies are antibodies, the different portions
from different animal. species, such as those having a variable region derived from a murine
antibody and a human immunoglobulin constant region. Chimerisation of antibodies is achieved
by joining of the le regions of the murine antibody heavy and light chain with the constant
region of human heavy and light chain (e.g. as described by Kraus et al., in Methods in
Molecular Biology series, Recombinant antibodies for cancer therapy lSBN-O918-8). In
human kappa-light chain
a preferred embodiment chimeric antibodies are generated by joining
chimeric
constant region to murine light chain variable region. In an also red embodiment
antibodies can be generated by joining human lambda-light chain constant region to murine light
chain variable region. The preferred heavy chain constant regions for generation of chimeric
antibodies are IgGl , lgG3 and IgG4. Other red heavy chain constant regions for generation
of chimeric antibodies are lgGZ, IgA, lgD and IgM.
Humanization
Antibodies interact with target antigens predominantly through amino acid residues that are
located in the six heavy and light chain complementarity ining regions (CDRs). For this
between dual antibodies
reason, the amino acid sequences within CDRs are more e
than sequences outside of CDRs. e CDR sequences are sible for most antibody-
antigen interactions, it is possible to express recombinant antibodies that mimic the properties of
ic lly occurring antibodies by constructing expression vectors that include CDR
onto framework sequences from
sequences from the specific naturally occurring antibody grafted
a different antibody with different prOperties (see, e.g., Riechmann, L. et al. (1998) Nature 332:
323-327; Jones, P. et al. (1986) Nature 321: 522-525; and Queen, C. et al. (1989) Proc. Natl.
Acad. Sci. U. S. A. 86: 10029-10033). Such framework ces can be obtained from public
DNA databases that e germline antibody gene sequences. These germline sequences will
differ from mature antibody gene sequences because they will not include tely assembled
variable genes, which are formed by V (D) J joining during B cell maturation. ine gene
sequences will also differ from the sequences of a high affinity secondary repertoire dy
dual evenly across the variable region.
The ability of antibodies to bind an antigen can be determined using standard binding assays
(e. g., ELISA, Western Blot, lmmunofluorescence and flow cytometric analysis).
To purify antibodies, selected hybridomas can be grown in two-liter spinner~flasks for
monoclonal antibody purification. Alternatively, dies can be produced in dialysis based
bioreactors. Supematants can be filtered and, if necessary, concentrated before y
chromatography with protein G-sepharose or protein A-sepharose. Eluted IgG can be checked by
gel electrophoresis and high mance liquid tography to ensure purity. The buffer
solution can be exchanged into PBS, and the concentration can be determined by 00280 using
1.43 extinction coefficient. The monoclonal dies can be aliquoted and stored at -80°C.
To determine if the selected monoclonal antibodies bind to unique epitopes, site-directed or
multi-site directed mutagenesis can be used.
To determine the isotype of antibodies, isotype ELISAs with various commercial kits (e.g.
Zymed, Roche Diagnostics) can be performed. Wells of microtiter plates can be coated with anti-
mouse lg. After blocking, the plates are reacted with monoclonal antibodies or purified isotype
controls, at ambient temperature for two hours. The wells can then be reacted with either mouse
lgGl, lgG2a, IgGZb or [gG3, IgA or mouse lgM-specific peroxidase-conjugated probes. After
washing, the plates can be developed with ABTS substrate (1 mg/ml) and analyzed at OD of
405-650. Alternatively, the lsoStrip Mouse onal Antibody lsotyping Kit (Roche, Cat. No.
1493027) may be used as described by the manufacturer.
In order to demonstrate ce of antibodies in sera of immunized mice or binding of
monoclonal antibodies to living cells expressing antigen, flow cytometry can be used. Cell lines
expressing naturally or after transfection antigen and negative controls lacking antigen
concentrations
sion (grown under standard growth conditions) can be mixed with various
1% FBS, and can be
of monoclonal antibodies in hybridoma supematants or in PBS containing
incubated at 4°C for 30 min. After washing, the APC- or 47—labeled anti IgG dy
the y antibody
bind to antigen-bound monoclonal antibody under the same conditions as
instrument using light
staining. The samples can be analyzed by flow cytometry with a FACS
and side scatter properties to gate on single, living cells. In order to distinguish antigen-specific
method of co-
onal antibodies from non-specific binders in a single measurement, the
and a
transfection can be employed. Cells transiently transfected with plasmids encoding antigen
be detected in a
fluorescent marker can be stained as described above. Transfected cells can
transfected cells
different fluorescence channel than antibody-stained cells. As the majority of
both transgenes, n-specific monoclonal antibodies bind entially to
express
in a comparable ratio
fluorescence marker expressing cells, whereas non-specific antibodies bind
used in
to non-transfected cells. An alternative assay using fluorescence microscopy may be
described
addition to or instead of the flow cytometry assay. Cells can be stained exactly as
above and examined by fluorescence microscopy.
In order to demonstrate ce of antibodies in sera of zed mice or binding of
monoclonal antibodies to living cells expressing antigen, immunofluorescence microscopy
afier transfection
analysis can be used. For example, cell lines expressing either spontaneously or
n and negative controls g antigen expression are grown in chamber
slides under
standard growth conditions in DMEM/FIZ medium, supplemented with 10 % fetal calf serum
Cells can then be
(FCS), 2 mM amine, 100 lU/ml penicillin and 100 pg/ml streptomycin.
fixed with methanol or paraformaldehyde or left untreated. Cells can then be reacted with
Alter washing, cells can be
monoclonal antibodies against the antigen for 30 min. at 25°C.
under
reacted with an Alexa555-labelled anti-mouse IgG ary dy (Molecular Probes)
the same conditions. Cells can then be examined by fluorescence microscopy.
Cell extracts from cells expressing antigen and appropriate ve controls can be prepared
subjected to sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis. After
blocked,
electrophoresis, the separated antigens will be transferred to nitrocellulose membranes,
antiand
probed with the monoclonal dies to be tested. IgG binding can be detected using
mouse IgG peroxidase and developed with ECL substrate.
Antibodies can be further tested for vity with antigen by Immunohistochemistry in a
manner well known to the skilled person, e.g. using paraformaldehyde or acetone fixed
cryosections or paraffin embedded tissue sections fixed with paraformaldehyde from non-cancer
tissue or cancer tissue samples obtained from ts during routine surgical procedures or from
mice carrying xenogratted tumors inoculated with cell lines expressing spontaneously or after
transfection n. For staining, antibodies reactive to n can be incubated
followed by horseradish-peroxidase conjugated goat anti-mouse or goat abbit antibodies
(DAKO) according to the vendors instructions.
Antibodies can be tested for their ability to mediate phagocytosis and killing of cells expressing
CLDN18.2. The testing of onal dy activity in vitro will e an initial screening
prior to testing in vivo models.
Antibody dependent cell-mediated cytotoxicity (ADCC):
Briefly, polymorphonuclear cells (PMNs), NK cells, monocytes, mononuclear cells or other
or cells, from healthy donors can be purified by Ficoll Hypaque density centrifugation,
followed by lysis of contaminating erythrocytes. Washed effector cells can be suspended in
RPMI supplemented with 10% heat-inactivated fetal calf serum or, alternatively with 5% heat-
inactivated human serum and mixed with 5'Cr labeled target cells expressing CLDN18.2,V at
various ratios of effector cells to target cells. Alternatively, the target cells may be labeled with a
fluorescence enhancing ligand ). A highly fluorescent chelate of Europium with the
ing ligand which is released from dead cells can be measured by a fluorometer. Another
alternative technique may utilize the transfection of target cells with luciferase. Added lucifer
yellow may then be oxidated by viable cells only. Purified anti-CLDN18.2 IgGs can then be
added at various concentrations. Irrelevant human IgG can be used as negative control. Assays
can be carried out for 4 to 20 hours at 37°C depending on the effector cell type used. Samples
lCr release
can be assayed for cytolysis by measuring or the presence of the EuTDA chelate in
the culture supernatant. Alternatively, scence resulting from the oxidation of lucifer
yellow can be a measure of viable cells.
Anti-CLDN18.2 monoclonal antibodies can also be tested in various combinations to determine
whether cytolysis is enhanced with multiple monoclonal antibodies.
Complement ent cytotoxicity (CDC):
Monoclonal anti-CLDN18.2 antibodies can be tested for their ability to mediate CDC using a
variety of known techniques. For example, serum for complement can be obtained from blood in
a manner known to the skilled person. To determine the CDC ty of mAbs, different
1Cr
methods can be used. release can for example be measured or elevated membrane
permeability can be assessed using a propidium iodide (PI) exclusion assay. Briefly, target cells
can be washed and 5 x lOs/ml can be incubated with various concentrations of mAb for 10-30
min. at room temperature or at 37°C. Serum or plasma can then be added to a final concentration
of 20% (v/v) and the cells incubated at 37°C for 20-30 min. All cells from each sample can be
added to the PI solution in a FACS tube. The mixture can then be analyzed immediately by flow
cytometry analysis using FACSArray.
In an alternative assay, induction of CDC can be determined on adherent cells. In one
embodiment of this assay, cells are seeded 24 h before the assay with a density of 3 x 104/well in
tissue-culture flat-bottom microtiter plates. The next day growth medium is removed and the
cells are incubated in triplicates with antibodies. Control cells are incubated with growth medium
or growth medium containing 0.2% saponin for the ination of ound lysis and
maximal lysis, respectively. After tion for 20 min. at room temperature supernatant is
d and 20% (v/v) human plasma or serum in DMEM rmed to 37°C) is added to the
cells and incubated for another 20 min. at 37°C. All cells from each sample are added to
propidium iodide solution (10 pig/ml). Then, tants are replaced by PBS containing 2.5
ug/ml ethidium bromide and fluorescence emission upon excitation at 520 nm is ed at
600 nm using a Tecan Safire. The percentage specific lysis is calculated as follows: % specific
lysis = scence sample-fluorescence background)/ (fluorescence maximal lysis-
fluorescence background) x 100.
Induction ofapoptosis and inhibition ofcell proliferation by monoclonal antibodies:
To test for the ability to initiate apoptosis, monoclonal anti-CLDN18.2 antibodies can, for
example, be ted with CLDN18.2 positive tumor cells, e.g., SNU-l6. DAN-G, KATO-III
or CLDN18.2 transfected tumor cells at 37°C for about 20 hours. The cells can be harvested,
washed in Annexin-V binding buffer (BD biosciences), and incubated with Annexin V
conjugated with FITC or APC (BD ences) for 15 min. in the dark. All cells from each
sample can be added to PI solution (10 )4ng in PBS) in a FACS tube and assessed immediately
by flow cytometry (as . Alternatively, a general inhibition of cell-proliferation by
2014/000719
monoclonal antibodies can be ed with commercially available kits. The DELFIA Cell
Proliferation Kit (Perkin-Elmer, Cat. No. ADOZOO) is a non-isotopic immunoassay based on the
measurement of 5-bromo-2’-deoxyuridine (BrdU) incorporation during DNA synthesis of
proliferating cells in microplates. Incorporated BrdU is detected using um labelled
monoclonal antibody. To allow antibody detection, cells are fixed and DNA denatured using Fix
solution. Unbound antibody is washed away and DELFIA inducer is added to dissociate
um ions from the labelled antibody into solution, where they form highly fluorescent
chelates with components of the DELFIA Inducer. The fluorescence measured - utilizing time-
resolved fluorometry in the detection - is proportional to the DNA synthesis in the cell of each
well.
Preclinical studies
Monoclonal antibodies which bind to CLDN18.2 also can be tested in an in vivo model (e.g. in
immune deficient mice carrying xenografted tumors ated with cell lines expressing
CLDN18.2, e.g. DAN-G, SNU-l6, or KATO-III, or after transfection, e.g. ) to
determine their efficacy in controlling growth of CLDN18.2-expressing tumor cells.
In vivo studies after xenografiing CLDN18.2 expressing tumor cells into immunocompromised
mice or other animals can be performed using antibodies described herein. Antibodies can be
administered to tumor free mice followed by injection of tumor cells to measure the effects of the
dies to prevent formation of tumors or tumor-related symptoms. Antibodies can be
administered to tumor-bearing mice to ine the therapeutic efficacy of respective
antibodies to reduce tumor growth, metastasis or tumor related symptoms. Antibody application
can be combined with application of other substances as cystostatic drugs, growth factor
inhibitors, cell cycle blockers, angiogenesis inhibitors or other antibodies to determine
synergistic efficacy and potential toxicity of combinations. To analyze toxic side effects
mediated by antibodies animals can be inoculated with antibodies or control reagents and
thoroughly igated for symptoms possibly related to CLDN18.2-antibody therapy. Possible
side effects of in vivo application of CLDN18.2 dies particularly include toxicity at
.2 expressing tissues ing stomach. Antibodies recognizing CLDN18.2 in human
and in other species, e.g. mice, are particularly useful to predict potential side effects mediated
by application of monoclonal CLDN18.2-antibodies in humans.
65 '
in detail in
Mapping of epitopes recognized by antibodies can be performed as bed
ISBN
"Epitope Mapping Protocols (Methods in Molecular Biology) by Glenn E. Morris
375-9 and in "Epitope Mapping: A Practical Approach" Practical ch Series, 248 by
Olwyn M. R. Westwood, Frank C. Hay.
suitable
The compounds and agents described herein may be administered in the form of any
pharmaceutical composition.
ceutical compositions are usually provided in a uniform dosage form and may be
form of a
prepared in a manner known per se. A pharmaceutical composition may e.g. be in the
solution or suspension.
A pharmaceutical composition may comprise salts. buffer substances, preservatives, carriers,
ts and/or excipients all of which are preferably pharmaceutically acceptable. The term
interact
"pharrnaceutically able" refers to the non-toxicity of a material which does not
with the action of the active component of the pharmaceutical composition.
Salts which are not pharrnaceutically acceptable may used for preparing pharmaceutically
this kind
acceptable salts and are included in the invention. Pharmaceutically acceptable salts of
comprise in a non limiting way those prepared from the ing acids: hloric.
hydrobromic, sulfLiric, . phosphoric," , acetic. salicylic, citric, formic, malonic,
succinic acids, and the like. Pharmaceutically acceptable salts may also be prepared as
alkali
salts.
metal salts or alkaline earth metal salts, such as sodium salts, potassium salts or calcium
Suitable buffer substances for use in a pharmaceutical composition include acetic acid in a salt,
citric acid in a salt, boric acid in a salt and phosphoric acid in a salt.
Suitable preservatives for use in a pharmaceutical composition include benzalkonium chloride,
chlorobutanol, n and thimerosal.
An injectible formulation may comprise a pharmaceutically acceptable excipient such as Ringer
Lactate.
WO 46778
nature,
The term "carrier" refers to an organic or inorganic component, of a natural or synthetic
enable application.
in which the active component is combined in order to facilitate, enhance or
According to the invention, the term "carrier" also includes one or more compatible solid or
to a
liquid fillers, diluents or encapsulating substances, which are suitable for administration
patient.
Possible carrier substances for eral administration are e.g. e water, Ringer, Ringer
and, in
lactate, sterile sodium de solution, polyalkylene s, hydrogenated naphthalenes
ular, biocompatible lactide polymers, lactide/glycolide copolymers
polyoxyethylene/polyoxy- propylene copolymers.
The term "excipient" when used herein is intended to indicate all'substances which may be
active ingredients such as, e.g.,
present in not
a pharmaceutical composition and which are
buffers,
carriers, binders, lubricants, thickeners, e active agents, vatives, fiers,
flavoring agents, or colorants.
conventional route,
The agents and compositions described herein may be administered via any
such by parenteral administration including by injection or infilsion. Administration is
preferably parenterally, intradermally
e.g. intravenously, rterially, subcutaneously, or
intramuscularly.
Compositions suitable for parenteral administration usually comprise a sterile aqueous or
which is preferably isotonic to the blood of the
nonaqueous preparation of the active compound,
isotonic sodium
recipient. Examples of compatible carriers and solvents are Ringer solution and
chloride solution. In addition, usually sterile, fixed oils are used as solution or suspension
medium.
The amounts. An
agents and compositions described herein are administered in ive
"effective amount" refers to the amount which achieves a desired reaction or a desired effect
alone or together with further doses. In the case of treatment of a particular disease or of a
ular condition, the desired reaction preferably relates to inhibition of the course of the
disease. This comprises slowing down the ss of the e and, in particular, interrupting
reaction in a ent of a disease or of a
or reversing the progress of the disease. The desired
ion may also be delay of the onset or a prevention of the onset of said disease or said
condition.
An ive amount of an agent or composition described herein will depend on the condition
be treated, the ness of the disease, the individual parameters of the patient, including age,
physiological condition, size and weight, the duration of treatment, the type of an accompanying
(if present), the specific route of administration and similar factors. Accordingly, the
therapy
doses administered of the agents described herein may depend on various of such parameters. In
the case that a reaction in a patient is insufficient with an initial dose, higher doses (or effectively
higher doses achieved by a different, more localized route of administration) may be used.
The agents and compositions described herein can be administered to patients, e.g., in vivo, to
treat or prevent a variety of disorders such as those described herein. Preferred patients e
human patients having disorders that can be corrected or ameliorated by administering the agents
and compositions described . This includes disorders ing cells characterized by an
d expression pattern of CLDN18.2.
For example, 'in one embodiment, antibodies described herein can be used to treat a t with
the presence of
a cancer disease, e.g., a cancer e such as described herein characterized by
cancer cells expressing CLDN18.2.
The ceutical compositions and methods of treatment described according to the ion
disease described herein.
may also be used for immunization or vaccination to prevent a
The present invention is further illustrated by the following examples which are not be construed
as limiting the scope of the invention.
EXAMPLES
Example 1: al first-in-human single-dose multi-center, phase I, open-label, i.v. infusion
escalation study evaluating the safety and tolerability of IMAB362 in hospitalized patients with
advanced gastroesophageal cancer
A clinical first-in-human single-dose multi-center, phase I, open-label, i.v. infusion escalation
study in humans with IMAB362 was performed to determine the maximum tolerated or
applicable single dose (MTD) of IMAB362, examine the safety, tolerability and adverse event
profile of IMAB362, determine the pharmacokinetics profile of single escalating doses of
IMAB362, determine the immunogenicity of a single dose ation of IMAB362, and
ine the ial antitumor activity of IMAB362 in patients with advanced
gastroesophageal (GE) cancer.
This study was designed as a first-in-human phase I, multi-center, non-randomized, inter-patient
single-dose escalation, open-label clinical study with a single enous infiasion of IMAB362
and a 4-week treatment free follow-up period.
To be included in the study, ts had to fulfill all of the following inclusion criteria:
- Metastatic, refractory or recurrent disease of advanced gastroesophageal cancer proven
by ogy
- CLDN18.2 sion confirmed by immunohistochemistry or availability of a tissue
sample of the tumor suitable for determination of CLDN18.2 expression
- Prior standard chemotherapy containing a fluoropyrimidine, a platinum compound and/or
epirubicine, and — if clinically appropriate — docetaxel
2O - At least I able site of the disease according to RECIST criteria (Computer
tomography (CT)—scans or Magnetic resonance tomography (MRT) not older than 6 weeks
before study entry)
- 18 years of age or older
- Written informed t afler being informed of the study
- ECOG performance status (PS) 0-1 OR Kamofsky 70-100%
- Life expectancy > 3 months
- Platelet count 2 100.000/mm3
- Hemoglobin Z 10 g/dl
- [NR < 1.5
- Bilirubin normal
° AST and ALT < 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases
are present)
' Creatinine < 1.5 x ULN
- For women with childbearing potential (last menstruation less than 2 years prior to
enrolment): Negative pregnancy test (B-HCG) at ne and using two highly effective methods
of contraception for 8 weeks afier the infusion of the study drug
- Male ts must use an accepted contraceptive method for 8 weeks after the infusion
of the study drug.
Patients presenting one or more of the following criteria were not to be included in the study:
- Pregnancy or breastfeeding
- Prior ic reaction or intolerance to a monoclonal antibody, including humanized and
ic antibodies
0 Prior inclusion in the present study
- Less than 3 weeks since prior anti-tumor chemotherapy or radiotherapy
- Other igational agents or devices concurrently or within 4 weeks prior to this study
- Other concurrent anticancer agents or therapies
- History of positive test for human immunodeficiency virus (HIV) antibody
0- Known hepatitis
- Uncontrolled or severe illness including, but not limited to, any of the following:
- Ongoing or active infection requiring parenteral antibiotics
- Symptomatic tive heart failure
— le angina pectoris
- Uncontrolled hypertension
- Clinically significant cardiac hmia
— Myocardial infarction within the past 6 months
- Gastric bleeding within last four weeks
- Symptomatic peptic ulcer
- Clinical symptoms of cerebral metastasis or documented metastasis
- Psychiatric illness or social situations that would preclude study compliance
° Concurrent administration of anticoagulation agents with vitamin K antagonists (e. g.
Coumadin)
° Concurrent administration of therapeutic doses of heparin (prophylactic doses are
acceptable).
From a total of 29 ts. 15 patients ed study medication and were allocated to one of
the dose cohorts (33, 100, 300, 600 or 1000 mg lMAB362/m3). These patients formed the safety
population (SP). As no potentially dose limiting toxicities occurred in any of the dose groups, no -
additional ts had to be tested to confirm potential dose limiting toxicities. Therefore, no
more than 3 patients in each dose cohort, i.e. 15 patients l, received study medication.
Patient tion to the different IMABS62 dose cohorts is given in Table 1, below.
Table l: Allocation of patients
IMAB362 dose cohort
300 mg/m
600 mg/m _3020-_04
1000 mg/m
No patient terminated the study prematurely, i.e. all patients completed the study according to
l 0 protocol.
A. SAFETY EVALUATION
[MAB362 was found to be safe and well tolerated.
Only 25 AEs (adverse events), which occurred in 8 of the patients were rated as treatment-
related. Treatment-related AEs were similar between the dose groups. More than half of these
AEs were gastrointestinal disorders (mostly . ng). Only one of these related AEs
was rated as severe (vomiting), whereas all others were mild or moderate. All related AEs
red, except for one case of dysgeusia (CTC grade 1 ) with unknown outcome and a
case ofincreased GGT (CTC grade 2 (moderate)) which did not recover.
No dose limiting toxicity (DLT), defined as a treatment-related AE that ed during or
within four weeks after the study drug infusion and was either grade 3 toxicity t for
nausea, vomiting, and ia) or grade 4 or 5 toxicity (according to CTC version 3.0), was
observed in any of the dose groups. Accordingly, the maximum tolerated or applicable single
dose (MTD) of IMAB362 determined in the present study is 1000 mg/mz.
No related SAE and no suspected cted serious adverse reaction (SUSAR) occurred in the
present study.
Only 7 patients had at least one laboratory value out of reference range assessed as grade 3
(severe). No dose-effect relationship and no clear relatedness to the study drug was observed. No
laboratory values ofCTC grade 4 (life-threatening) or 5 ) were reported.
In conclusion, no relevant differences in AB profile and other safety parameters between the
dose groups could be seen. Generally speaking, IMAB362 given in a single dose was observed to
be safe and olerated with nausea and vomiting being the most common related adverse
event.
B. EVALUATION OF PHARMACOKINETICS AND IMMUNOGENICITY
For determination of drug concentration the IMAB362 serum levels of all patients were
measured immediately before the infusion of study medication, at the end of the infusion, at 3, 8,
12 and 24 hours after the end of the infusion and on days 3 (V3), 5 (V4), 8 (V5), 15 (V6) and 29
(v7).
An overview of the IMAB362 serum levels in the course of the study for each patient is given in
Table 2. For unknown reasons for one patient (no. 1201) in the 300 mg/m2 dose group a low
IMAB362 serum level (12.633 ug/ml) was measured already before infusion of the study drug
(V2, day 0).
Table 2: Time course of IMAB362 serum level [pg/ml] per patient
IMA8362 V2 V2 V2 V2 V3 V4 V5 V6 V7
dose Oh 8h post 1 2h 24h day 2 day 5 day 8 day day
29
group post infusio post post (:1) (:1) (i (t
infusio infusio n infusio infusio 2) 7)
n n n n
0103 33 mg/m HI“-
0104 33 mg/mmm
0201 33 mg/m
0105 100 mg/m"W
000 NM0 0)0N -wl
_--lill 12.6 6 3
403"mm-m43.9 20.9 11.4
1101”mm65.3 42.7 36.8
1201 300 mg/m 63.7 47.7 33.3
0204 600 mg/mm- 87.5 52.9
0 020) 600 mg/m
1202 600 mg/m 242.2
1000
0106 493.7 488.9 465.9 452.7 367.8 259.9 158.8
mg/m
1000
0112 359.0 “375.9 356.5 311.0 273.1 220.6 192.8 154.1
mg/m
479.7 435.9 366.7 331.6 343.9 279.7 193.9 155.3 105.9
* Peak concentration (Cmax) of each patient is printednin bold
The mean observed peak trations (Cmax) per dose group are shown in Table 3. Increasing,
mean values for Cmax correspond to the increasing infusion dosages of IMAB362.
Table 3: Peak trations (Cmax) of IMAB362 during study - y of
descriptive statistics
IMA8362 dose group
---W
300 mg/m
600 mg/m
1000 mg/m
A graphical presentation of the mean blood concentrations of IMAB362 during the study is given
in Figure 1.
Highest IMAB362 levels were measured from directly at the end of infusion to up to 8 hours
after end ofinfusion. At 3 hours after end of infusion the mean IMAB362 concentration was 14.1
ug/mL in the 33 mg/m2 group, 50.7 ug/mL in the 100 mg/m2 group, 164.2 ug/mL in the 300
mg/m2 group, 307.8 ug/mL in the 600 mg/m2 group, and 502.6 ug/mL in the 1000 mg/m2 group.
Pharmacokinetics of IMAB362 is dose-dependent. t dose levels were observed within the
first 8 hours after the 2 hours infusion. The mean half-life of IMAB362 was 8.5 days overall,
g from about 5 to about 12 days in the different dose cohorts.
We determined from in vitro mode-of-action studies that at IMAB362 trations of 50
ug/ml robust execution of anti-tumor cell effects via ADCC, CDC and inhibition of proliferation
can be ed and that ECso values of ADCC and CDC, which are considered as main mode of
actions, are even covered with half of this concentration level. Based on this knowledge, 300
mg/m2 and 600 mg/m2 dose levels were identified for closer assessment in multiple dose studies
with IMAB362. Patients who had received 300 mg/m2 and 600 mgm2 IMAB362 were clearly
above these levels at day 8 (V5) and close to 50 ug/ml at day 15 (V6).
There was no evidence for anti-drug antibodies in patients after this single dose of IMAB362.
C. EVALUATION OF ANTITUMORAL ACTIVITY
The primary measure for assessment of ial moral activity was the tumor status
according to RECIST on 1.0) fication at 2 to 5 weeks after IMAB362 infusion
(V6/V7). As all patients completed the study according to protocol, assessments were done
exclusively at V7, i.e. 4 to 5 weeks after drug infusion. All patients were evaluated by CT.
Three patients had no measurable e (patients 1101 and 1201 had no target lesion, for
patient 0302 the respective data were unavailable) but were included into population for analysis
of antitumoral activity, as this was not a formal efficacy evaluation.
2014/000719
Overall, for none of the patients a complete or partial se could be assessed. Stable disease
was observed for one of the 15 patients in the 600 mg/m2 dose group. While in the treated
patients the percentage of tumor cells staining positive for CLDN18.2 ranged from 1% to 80%
(up to 50% tumor cells with nous staining), 90% or more of the tumor cells of this
patient stained positive for CLDN18.2 with a large fraction of the tumor cells exhibiting
membranous staining. Two patients in the 300 mg/m2 group did also not progress and as they
had no target lesion they were not evaluable for ive tumor response and were rated as non-
CR, non-PD. The duration of the SD was about 2 months. The duration of non-CR, non-PD were
about two months and 6 weeks, respectively.
An overview of the overall response by patient is given in Table 4.
Table 4: Tumor status (overall response) at V7 by patient
IMAB362 dose cohort Tumor status at V7
oomomz
1000 mg/m2
* Patients without measurable disease (patients 1 101 and 1201 had no target , for patient 0302 the respective
data were unavailable)
The different ters contributing to the assessment of tumor status (overall response) are
described in the following.
Regarding the change in sum of longest diameters (target lesion), status of non-target lesions
after IMAB362 treatment, occurrence of new lesions, an overview of the evaluation results afier
[MAB362 treatment (assessed at V7) is provided in Table 5.
Table 5: Evaluation of parameters for ment of tumor status at V7 by patient
IMA3362 dose group Patient no. Percentage Unequivocal New lesions
change in sum of progression of a
longest diameter non-target
in tar-et lesion
33 mg/m2 0103 +3o.2%
0203 +35.1% No non-target
lesion
. 1 101 No target lesion Unavailable
data
0302 lable data Unavailable
data
0205 -2.8% No rget yes
lesion
The percentage change in sum of longest diameters of target lesion from V1 to V7 did not show
any clear difference for different treatment doses.
For non-target lesions an vocal progression (from V1 to V7) was reported more frequently
in patients in the lower dose levels but not in the 600 mg/m2 and 1000 mg/m2 dose levels.
In one patient in the 300 mg/m2 group (0403) an unequivocal progression was observed in non-
target lesion and a decrease in the longest diameter in one target lesion lymph node.
With regard to new lesions no preference for one of the dose groups was observed.
In case of ts 0302 (600 mg/m2 dose group) and 0205 (1000 mg/m2 dose group) the
occurrence of new lesions was the reason for the assessment of overall response as progressive
disease.
For assessment of the status of the non-target lesions ing to RECIST, the level of the
serum tumor antigens CA 125, CA 15-3, CA 19-9, and CEA was determined by the central
laboratory at V2 (day 1, prior to infusion), V6 and V7.
An overview of the serum tumor markers for the 3 patients with an overall response of at least
stable disease is given in Table 6.
Table 6: Serum tumor markers during the study of patients with l response
of at least stable disease
Dose group Tumor marker Time point Level Out of refe-
Patient ID rence range
V2 (prior inf.) 21.2 U/mL
V6 20.6 UlmL
V7 27.7 UlmL
V2 (prior inf.) 21.3 U/mL
V6 21.0 U/mL
V7 21.3 U/mL
V2 (prior inf.) < 0.6 U/mL
V6 < 0.6 U/mL
V7 < 0.6 U/mL
V2 (prior inf.) 1.7 ng/mL
V6 2.0 ng/mL
V7 2.1 ng/mL
1201 V2 (prior inf.) 13.5 U/mL
V6 13.7 U/mL
V7 11.5 U/mL
V2 (prior inf.) 11.6 UlmL
V6 11.3 U/mL
V7 11.3 UlmL
V2 (prior inf.) 68.0 UlmL
V6 68.8 UlmL
V7 63.0 U/mL
V2 (prior inf.) 3.2 ng/mL
V6 2.6 ng/mL
V7 3.0 ng/mL
V2 (prior inf.) 59.2 U/mL
V6 50.2 UlmL
V7 35.1 UlmL
V2 (prior inf.) 477.5 U/mL
V6 372.3 U/mL
V7 310.4 UlmL
V2 (prior inf.) > 10000 U/mL
V6 5667 U/mL
V7 3979 UlmL
V2 (prior inf.) 40.3 ng/mL
V6 25.2 ng/mL
V7 19.4 ng/mL
Of the 3 patients with stable disease or Non-CR/Non-PD according to imaging two patients had
stable tumor marker levels in the observation period. One patient (0204) showed profound
decrease of all 4 tumor markers afier ent. Most of the patients with progressive e, in
contrast, experienced an increase of tumor marker levels.
The tumor status (according to RECIST classification) at 4 to 5 weeks after IMAB362 infusion
(V6/V7) was compared to baseline. Overall, for none of the patients a complete or partial
dose group) showed stable
response could be assessed. One of the 15 patients (in the 600 mg/m2
disease at study end. Two patients in the 300 mg/m2 dose group with non-measurable disease
showed non-CR/non—PD. In line with this, tumor marker levels of these three patients either
stayed stable (2 patients) or even decreased profoundly (1 patient). Most of the patients with
progressive disease showed increase of tumor marker levels over time.
Regarding the parameters buting to the assessment of tumor status (overall response), a
decrease in one lesion was observed in the dose group 300 mg/mz. At screening (V1), 13 of the
patients had a total of 32 non-target s. Afler IMAB362 treatment (asseSsed at V7) an
unequivocal progression of a non-target lesion was ed for a total of 5 patients, 3 in the
33 mg/m2 dose group, 1 in the 100 mym2 group and l in the 300 mg/m2 dose group. For none of
these 5 patients the overall response was assessed as progressive disease only due to the
progression of their non-target lesions. A total of 17 new lesions were observed in the course of
the study, evenly distributed over the dose groups. In case of 2 patients (in the 600 mg/m2 and
1000 mg/m2 dose groups) the. ence of new lesions was the reason for the assessment of
overall response as progressive disease.
er, ancillary data was collected in selected ts, showing that the patients serum
components and the patients PBMCs are fully functional and potent in mediating the major
lMAB362 modes of action CDC and ADCC, respectively.
In conclusion, hints for moral activity e disease, tumor marker se) were
observed in the 300 mg/m2 and 600 mg/m2 dose groups. Due to the small sample size of the dose
groups, it is difficult to conclude on trends for efficacy.
C. OVERALL CONCLUSIONS
This trial was designed as first-in-human phase I, multi-center, ndomized, inter-patient
single-dose tion, open-label clinical study with a single intravenous infusion of IMAB362
and a 4-week treatment-free follow-up period.
A total of 15 patients received study medication and were allocated to one of the dose cohorts
(33, 100, 300, 600 or 1000 mg IMAB362/m2). The dose groups can be regarded as comparable.
No relevant imbalances concerning the demographic data and baseline characteristics could be
observed.
Regarding the primary objective of the study, no dose limiting ty (DLT) was observed in
any of the dose groups. Therefore, the applicable single dose of IMAB362 in the present study
was 1000 mg/mz. IMAB362 was safe and well-tolerated with nausea and vomiting being the
most common related e events.
The AE profile and the AE incidence was found to be similar in the different dose groups. No
apparent ences between the dose groups could be observed in numbers of individual
patients with clinically significant deteriorations in any hematological, biochemistry or
coagulation parameters.
Regarding the potential antitumor activity of 2 according to RECIST criteria, a
complete or partial response could not be observed for any of the patients. One of the 15 patients
(in the 600 mg/m2 dose group) showed stable disease at study end. Two patients in the
300 mg/m2 dose group with non-measurable disease showed non-CR/non—PD. Of these 3 patients
with stable e according to imaging two had stable tumor marker levels in the observation
. One patient showed nd decrease of all 4 tumor markers alter treatment.
This and the pharmacokinetic studies, showing that targeted serum levels for IMAB362 are
achieved at 600 mg/m2 dose levels, support that this dose should be evaluated further.
Moreover, ancillary data confirms that the ts’ immune ors are fully functional and
potent in mediating the major IMAB362 modes of action CDC and ADCC, respectively.
e 2: Drug potency
The aims of the in vitro analyses performed for this Phase I clinical study included an analysis if
(i) effector cells present in patient blood are able to induce IMAB362-dependent ADCC, (ii) the
complement system of the patient is able to induce IMAB362-dependent CDC and (iii) the
ability of IMAB362 to induce ADCC and CDC is altered after administration in patients.
Different types of assays were performed to study the tic activity induced by IMAB362
after administration in patients in . The assays were either performed with patient serum or
patient PBMCs isolated from blood samples (Table 7). For comparison and to verify
functionality of CDC and serum ADCC assays, a human serum pool ated from healthy
human subjects), in which fresh IMAB362 was serially diluted, was included in parallel in each
assay. To test onality of ADCC assays with PBMCs, blood cells isolated fiom a healthy
donor were used as positive control in the same assay for each patient.
A. MATERIALS AND METHODS
For the different in vitro assays patient serum samples were collected prior to on of
IMAB362 and l, 7, 14 and 28-32 days after IMAB362 antibody administration (Table 7). They
were used as a source of IMAB362 antibody and complement in CDC or as antibody source in
serum ADCC assays. Pre-infusion serum of patients was used as “no IMAB362” ve
control and for dilution of patient serum s to adjust the 'IMAB362 concentration to 0.5
ug/ml. Fresh blood samples were ted 14 days afier infiJsion (7 days for patient 0203) and
were used as a source of effector cells for ADCC assays.
Table 7: Overview of serum and blood samples collected for each patient. n.o.: serum
sample was not obtained from clinical study site
SufiLect “$333162 infiirgeion Semfmusfigzaineg after 0:03:22: on
[mg/m2] °" ay
(y/n) day
0201 as y 1
2014/000719
Blood samples were collected from patients (Table 7), serum was harvested and serum aliquots
these samples was performed in
were prepared and immediately stored at -80°C. Analysis of all
one single experiment after collection of all 24 serum samples.
For ADCC, fresh blood samples (15 ml NagEDTA) were used to isolate PBMCs and ADCC
assays were performed the next day.
tested ex
The capability ofpatients’ PBMCs to induce ADCC in conjunction with IMAB362 was
from the patients
vivo by using fresh 15 ml Nag—EDTA anti-coagulated blood samples obtained
were
14 days (7 days for patient 0203) afier IMAB362 administration. PBMCs ofblood samples
for 24h
isolated upon arrival using Ficoll density nt centrifugation. PBMCs were cultivated
and ADCC assays were med the next day with luciferase-transfected CLDN18.2—positive
NUGC4 human gastric cancer cells as targets in conjunction with various concentrations of
exogenously added IMAB362. PBMCs were added in an EIT ratio of 20:1 and assays were
tested in the
incubated for 24h at 37°C, 5% C02 PBMCs ed from a healthy donor were
same setting in parallel to analyze validity of the assay (positive assay control). This PBMC
from
stock was stored in liquid N2 and for each ADCC assay with patients’ PBMCs. an aliquot
this PBMC stock was thawed and ed in parallel.
Characterized materials used were:
0 CLDN18.2 positive target cells: transiently luciferase-transfected NUGC4-10cHl lElO
stomach cancer cells
0 Positive control effector cells: PBMCS obtained from a healthy donor (frozen Ng-stock
lD: 276-SMS—09-00706, 4e7c/vial, MNZ, 08.07.07.SJA)
0 Functional control antibody: 2 in serial dilutions (0.4 11ng -126.5 pig/ml)
o Assay negative control antibody: Istotype control (Rituximab, 126.5 pig/ml)
The ability of patient serum components to induce complement-dependent cytotoxicity (CDC)
conjunction with 2 was analyzed ex vivo over time. Serum samples were ted and
stored at ~80°C and all patient samples were assayed in parallel in the same experiment.
In addition to pre-infusion serum to which a fixed amount of 0.5 14ng IMAB362 (representing
the in vitro EC50 concentration) was added exogenously, also samples collected 1, 7, 14 and 28-
32 days after 2 administration were tested, in which circulating 2 had to be
adjusted to 0.5 ug/ml (CDC with normalization). The final serum concentration in each assay
was adjusted to 20%. Luciferase-transfected CHO-Kl cells stably transfected with CLDN18.2
were used as targets. For comparison a serum pool of healthy human donors spiked with
IMAB362 was tested.
terized materials used were:
0 CLDN18.2 positive target cells: Stably transfected CHO-Kl p740 luci #2A5 cells.
0 Assay positive control: IMAB362 serial dilutions (1:3.16) prepared in human serum pool
from healthy donors, resulting in final trations ranging from 31.6 11ng to 10.0
rig/ml.
0 Functional control antibody: IMAB362 ed to 0.5 11ng final assay concentration in
each patient pre—infusion serum sample.
0 Assay negative control antibody: e control antibody diluted in human serum pool
(Rituximab).
The kinetics of the overall cytotoxicity mediated by IMAB362 in human circulation, integrating
its capability to induce ADCC and CDC, was analyzed in an "one tube" assay.
Serum of each patient collected 7, l4 and 28-32 days afier i.v. administration of IMAB362, and
thus comprising complement factors of the patient plus circulating IMAB362, was tested in this
assay. Serum was applied in each assay to a final serum concentration of25% (v/v). PBMCS of a
healthy control were added as effector cells, whereas NUGC-4 cells served as target cells with an
EzT ratio of4021.
In an additional setting, the serum was heat-inactivated destroying the ment activity. This
second assay thus exclusively reflects ADCC activity induced by IMAB362 present in the
patient serum.
During the Phase I study, serum samples were ted and stored at -80°C. All patient s
were d in parallel in the same experiment.
Characterized materials used were:
- CLDN18.2 ve target cells: Stably luciferase-transtected NUGC-4 lOCHl 1 luci
eGFP #2 stomach cancer cells.
0 Effector cells: PBMCs from a healthy donor (fresh buffy coat).
0 Functional control antibody: IMAB362 serial dilutions (0.26 ng/ml - 200.0 ug/ml) spiked
in human serum pool.
0 Sample positive l: Patient fusion serum sample spiked with IMAB362 (200.0
rig/ml) (representing EC3()-|()0 for IMAB362 in this setting).
o Assay negative control antibody: lsotype control antibody in human serum pool
(Rituximab).
The ability of IMAB362 to ct and activate complement present in the patient serum and to
induce complement-dependent cytotoxicity (CDC) afier prolonged circulation in t blood
was analyzed ex vivo 1, 7, l4 and 28-32 days after IMAB362 stration. The assay was
performed by directly using the patient serum samples in the assay (CDC without
normalization). As a positive control pre-infusion serum to which a fixed amount of 10 pg/ml
IMAB362 (representing the in vitro EC90400 concentration) was added exogenously. The final
serum concentration in each assay was adjusted to 20%. Luciferase-transtected CHO-K1 cells
stably ected with CLDN18.2 were used as targets. For comparison a serum pool of healthy
human donors spiked with IMAB362 was tested.
During the Phase I study serum samples were collected and stored at -80°C. All patient samples
were assayed in parallel in the same ment.
Characterized materials used were:
0 CLDN18.2 positive target cells: S‘tably transfected CHO-Kl p7401uci #2A5_cells.-
0 Functional control antibody: IMAB362 serial dilutions (1:3.16) prepared in human serum
pool from healthy donors. resulting in final concentrations ranging from 31.6 ng/ml to
.0 pg/ml.
«- Sample positive control: fusion patient serum samples each spiked with IMAB362
(l0.0 ) in (in vitro CDC-EC()()_|00 concentration).
0 Assay ve control antibody: Isotype control antibody diluted in human serum pool.
B. RESULTS
Capability of patients’ PBMCs to mediate ADCC
In order to analyze the capability of patient immune cells to lyse CLDN18.2 expressing tumor
cells, -gastric cancer cells. endogenously expressing .2, were incubated with
increasing concentrations of IMAB362 and with patient PBMCs. Assays with PBMCs from a
healthy donor were included as functional l.
t PBMCs showed IMAB362-dose dependent lysis rates with a maximum of27 to 77% at a
concentration of ~30 rig/ml. This is not significantly different (unpaired t-test) from the maximal
lysis rates of 14 to 56% obtained with y control PBMCs tested in the same assays (Figure
2). ADCC activity was most profound for patient 0204.
These data show. that PBMCs of gastric cancer patients are not inferior in inducing ADCC of
human CLDN18.2 positive gastric cancer cells in ction with 2 as compared to
PBMCs obtained from healthy donors.
lity of the ts’ ment system to induce CDC
The ability of patient complement to interact with IMAB362 present in the serum and to induce
CDC was tested. The pre-infusion serum samples were spiked with fresh 0.5 pig/ml IMAB362
and CDC ty was compared to the same antibody concentration spiked in human serum
pool. antibody samples were incubated with CHO-Kl p740 luci #2A5 cells and lysis was
determined after 80 min by measuring rase activity.
All patients were capable to induce significant CDC within 80 min (Figure 3). For 5 out of 6
patients maximum lysis rates ranging from 50 to 71% were observed. This is comparable to data
we obtained by parallel testing with pooled sera from healthy controls (64.5%). Noteworthy,
patient 0204 showed highest CDC activity with fresh IMAB362 (93.9%).
Capability of soluble effectors in the patient serum to induce cell killing with enously
circulating IMAB362
Next, the ability of patients‘ serum to interact with i.v. stered IMAB362 over the time
span of its circulation in the patient was investigated by testing serum samples ted at
different time points after IMAB362 administration in CDC assays on CLDN18.2 positive CHO-
Kl target cells. Serum samples were the source for patient-specific soluble effectors including
complement as well as for IMAB362. IMAB362 concentrations in serum samples were
determined by ELISA (vivoScience) (Table 8) and adjusted to a final IMAB362 concentration of
0.5 14ng (median ECSO of IMAB362) using the corresponding pre-infusion serum of each
patient as diluents. As IMAB362 concentrations differ depending on treatment dose and time
point of blood collection. the dilution factor for the samples differed considerably between
patients ranging from 4.6fold to 688fold. A serum pool from healthy donors (HSC) was used as a
control (Figure 4).
As compared to the ve control (pre-infusion serum of the tive patient + fresh
IMAB362) killing activity is retained within the first 24h, whereas cytolytic activity of serum
samples collected one week later is decreased, which is progressing further in the following
weeks (Figure 4). Even so, considerable cytotoxicity was executed by patients serum even 2
weeks after administration of IMAB362. The loss in CDC activity after 28-32 days is significant
and most pronounced in ts treated with low doses of IMAB362 (Figure 4). In patients
treated with high doses (0204; 600 mg/m2 and 0205; 1000 mg/mz) CDC ty appeared to be
better conserved over the time period investigated. Based on tly available data, the
underlying mechanism for this decline is not understood so far.
2014/000719
63563
.mxmmmm E
000 «3912. 2233:0050 REE—5095: 9:33
new ago
ooo< E
East? Nomm<s= 988
0.: :ozmhcmucoo guisoiu
33: 5». 000
352. .303 .8519: 5
0:5 <m3m 5:25 «39:2.
as 355530
=5.th 5 22.3
.m 03289;
E $392):
53:3 53223.50 35:2: 2.33
32:3 8582:
E .33
mcosmbcuocoo cozmzcmogoP 9:; «89:2. 20.535
”EEC—:23
momm<§ 6: «89:2. E2535
.8363
2%.." and
Effect ofserum ents on IMAB362 induced cytotoxicity
ADCC activity of mABs may be d in the presence of human serum. The effect of the
patients sera on ADCC activity was investigated. To this aim, serum of each patient collected 7,
14 and 28-32 days after IMAB362 administration and thus representing complement s of
the patient plus ating i.v. administered IMAB362 was used. All patient serum samples were
diluted to 25% (v/v) final serum tration and the remaining IMAB362 tration in
each patient assay sample was calculated (Table 8). PBMCs from one healthy donor were used
as effectors and NUGC-4 cells as target cells (E:T ratio=40:1) in this ADCC assay. All assays for
all patients were performed in parallel in one single experiment using the same conditions, target
cells and donor PBMCs to ensure comparability. As functional assay control the healthy human
serum pool was spiked with IMAB362 (200.0 ug/ml). As additional positive control the
individual patient pre-infusion serum samples were spiked with 200.0 ug/ml IMAB362
senting in vitro EC80-100 for IMAB362 in this system).
We observed in all assays that IMAB362 antibodies present in patient serum after administration
are highly active and induce cytotoxicity (Figure 5). Biological activity of IMA3362 was
ed over 28-32 days after administration with specific killing still being above 48% in all
dose groups. Overall differences between dose goups were surprisingly modest, suggesting a
saturation effect. In patients d with lower doses (33-300 mg/mz) a moderate decrease in
specific killing from 77.7—87.4% down to 48.3-66.8% was observed over time correlating with
the decrease in the antibody concentrations in the serum (Figure 5 upper panel). Highest activity
stably maintained over time was ed in patients treated with 600 or 1000 mg/m2 IMAB362
(Figure 5 lower panel). - -,..
. - --
This assay was repeated with serum samples, in which ment s were inactivated by
incubating them at 56°C for 30 min. Cytotoxicity with nactivated patient serum samples
was lower as compared to those obtained with untreated serum samples in all cases. Similar
decreases were also observed with the heat-inactivated pool from healthy donors (HSC, Figure
in summary, these data indicate that patient serum does not inhibit ADCC capability of soluble
serum components but instead add to IMAB362 d total cytolytic activity.
Kinetics of IMAB362 mediated CDC in patient serum
In order to determine the kinetics of CDC lity of IMAB362 in serum from patients of the
different dose groups serum samples were collected 1, 7, 14 and 28 days after .IMAB362
administration.
Again, this serum served as source for complement as well as for 2. Final serum
concentrations were adjusted to 20% (v/v) final volume. The final IMAB362 concentrations in
each CDC assay sample are listed in Table 7. As positive control, patient pre-infusion samples
were spiked with fresh IMAB362 antibody to a final concentration of 10 ug/ml (in vitro EC95 of
IMAB362 in this CDC assay system). Furthermore, for functional control of the CDC assay,
serial dilutions of [MAB362 (0.032-10 ) were prepared in human serum pool. A
'10 standardized assay with CHO-K1 cells stably transfected with CLDN18.2 and luciferase were
used as target cells. All serum samples were thawed and tested in parallel in the same
experiment.
CDC activity correlates well with the antibody concentration in each serum sample (Figure 7).
Most antly, the data suggests that diated txic activity is maintained over 4
weeks. In particular, patients ofhigh dose groups show no drop ofCDC activity over this time.
Summary and Conclusions
Patients with CBC appear not to be impaired in their capability to induce both ADCC and CDC
of CLDN18.2 expressing target cells in conjunction with IMAB362. Noteworthy, max. specific
lysis seen in ADCC and CDC and ECso measured for ADCC were t for patient 0204, who
had the most prominent clinical and serum tumor antigen response.
Ex vivo analysis of CDC with circulating [MAB362 at different time points after its,
administration showed that still 2 weeks after administration there is sufficient active [MAB362
circulating in the patients to induce profound ADCC and CDC.
CDC activity of patients in conjunction with ating IMAB362 is reduced over time for so far
unknown reasons.
Example 3: es
Cytokine serum levels may serve as indicators of the immune status of a patient. In this clinical
trial the objective of analyzing cytokines was primarily for supporting safety monitoring. We
reviewed nes within this ancillary is from the viewpoint of defining potential
biomarker candidates.
ne levels were determined on day 1 prior to IMAB362 on and on days 3 and 5 of the
treatment cycle. Studied cytokines comprised proinflammatory (IL-1, IL-6, IL-12, IFNy, TNFa)
and anti-inflammatory (IL-4, IL-10) cytokines and cytokines necessary for growth and function
ofT cells (IL-2) and NK cell proliferation (IL-2, IL-15).
Cytokines were analyzed by ELISA and flow cytometry (Interlab). Cytokines were analyzed
according to Interlab SOP-MU-IMM.M.0144. 05 “Flow x Cytokin- Check 1L4, I‘L6,
[L13. TNF-alpha, IFN-gamma, MCP-l, ILlO 1L2, ILl-B, IL12p70, 1L8, IL17A, IL23” and SOP-
MU-IMM.M.0151.02 ,,Humanes Interleukin 15“.
Cytokine serum levels of IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-15, IFNy, and TNFa were
analyzed for 14 out of 15 patients (Table 9). No cytokine levels were determined for patient 0403
(300 . Only serum cytokine level values, which were above nce range, were
analyzed for temporal changes. Reference range values were defined by Interlab (see CSR GM-
[MAB-001).
2014/000719
Table 9: Cytokine serum levels on Day 1, Day 3 and Day 5
Cytokine serum levels of all patients were measured on Dayl, Day 3 and Day 5. The reference
limit were set to the
range for each cytokine is indicated. Values below or above the detection
respective detection limit for calculations.
—IIEEI 0104 mmmmmmwmm 0106 [MIME]
Dose m- m ——m_-nt-_rr__m_
(Reference
range m Proinflammatory nes [pglmL]:
- -/m_L
n—-—_———_—_—__—
1L-1 u__—_--——_-—-_
(<52) n—_-———_—_———__
"Wm-1a64 2
IL-6 “WI-1!
(<45)“Wm—
n———————————-_-
lL-12 u_———_———_—————
n—_—-—_—_—__——
IFNv n_—-___——————--
(<45.0)“W
TNFa n__———___———_——
(<17.5)W
nflammato c okines [ - mL :
n-M'
IL-4 n_——————_——_———
(20.8) “mm—_—
lL-10n-Wm
(<6.0)“_M
Cytokines for T-cell and NK cell on and proliferation [pglmL]:
lL-Z "Wm-mm
(<20.0) n—_—____——_—-——
n_———_-——-_—-_—
n——_-—__-——_——_
lL-1 5“_W
(<10)“W
Rrointlammatorywcytokine levels (IL-1, IL-6, lL-12, lFNy, TNFa) were above the respective
reference ranges in 9 out of 14 patients (0104, 0105, 0201, 0203, 0204, 01 12, 1202, 0112, 0205).
IFNy levels were elevated in two patients (0201, 1202), TNFa level was elevated in one of these
two patients (0201). In both patients lFNy and TNFa levels were elevated before administration
of IMAB362 and decreased on the following days. IL—6 levels were elevated in eight patients
(0104, 0105, 0203, 1101, 0204, 0112, 1202, 0205). No clear pattern in IL-6 level changes with
respect to IMAB362 administration and dose-effect relationship becomes evident. lL-6 levels of
patient 0204 (600 mg/m2 IMAB362) were not ed prior to administration but increased
considerably 2 days after infusion, a n not displayed by any other patient. IL-1 and IL-12
levels stayed within the respective nce range for all patients.
Anti~inflammatory cytokine levels (IL-4, lL-lO) were above the respective reference range in 6
out of 14 patients (0103, 0104, 0201, 0202, 0203. 1101). [L-lO levels were elevated in six
ts (0103, 0104, 0201, 0202, 0203, 1101), lL-4 levels were elevated in two of these patients
(0201, 0202). Fluctuations of anti-inflammatory cytokine levels show no clear pattern with
respect to administration of IMAB362 and dose-effect relationship.
The cytokines for T-cell and NK cell function and proliferation IL-2 and IL-15 levels were above
the respective nce range in 9 out of 14 patients (0104, 0201, 0202, 0203, 1101, 1201, 0204,
1202, 0205). IL-2 levels were above nce range in six patients (0201, 0202, 0203, 1101,
1202, 0205), IL-lS levels were above reference range in five patients (0104, 0202, 1201, 0204,
1202). Seven out of nine patients (0104, 0201, 0202, 0203, 1201, 1202, 0205) with elevated IL-
2/lL-15 levels pre-administration displayed a cytokine level decrease on subsequent days: lL-
2/IL-15 levels were above respective reference range prior to IMAB362 administration and
decreased on the second and fourth day after 2 administration. The most pronounced
decrease in this group was observed for the IL-2 serum concentrations. In all five patients (0201,
()202, 0203, 1202, 0205) with increased 1L-2 pre-infusion levels a decrease to less than 50% of
respective fusion levels was observed on the fourth day alter stration. This decrease
could be observed also in one patient (0201) with a considerably elevated IL-2 level (354 pgmL)
before administration of 33 mg/m2 [MAB362.
A different lL-2 concentration profile was shown by patient 1101 (300 mg/m2 IMAB362) with
lL—2 levels in reference range before infusion and 2 days later but ed lL-2 concentration on
the fourth day after infusion.
The lL-15 level was decreased on the fourth day after administration in all four patients (0104,
0202, 1201, 1202) with elevated IL-15 pre-infusion . This concentration profile is very
similar to the observed IL-2 concentration profile although the relative level decrease is not as
nced.
No dose-effect relationship can be discerned for any of the analyzed cytokines.
Summarizing the above, analysis of pre-treatment levels of patients showed that IL-6, lL-lO, IL-
2, IL- 15 are elevated in a substantial fraction oflate stage patients with gastroesophageal e.
In contrast. none or only single patients had elevated levels of IL-1, IL-l2, IL-4, lFNy, and
TNFa.
WO 46778
Analysis of alteration of ne levels within the first 5 days alter IMAB362 treatment led to
following observations. In all five ts with elevated IL-2 levels, these levels were found to
decline profoundly, with four of five patients reaching normal reference values. Similarly, in all
four patients with elevated IL-15 levels a moderate decrease alter IMAB362 administration was
observed. se of elevated levels after treatment were also seen for single ts with
elevated levels of lFNy and TNFu, respectively. IL-6, in contrast, increased after IMAB362
administration, with four patients pre-treatment and 7 of 14 patients on day 5 post-treatment
showing lL-6 above reference levels.
Example 4: ational, multicenter, open-label, phase Ila, multiple dose study evaluating the
efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of
the stomach or the lower esophagps
An international, multicenter, open-label, phase Ila, multiple dose study was performed to
- investigate the efficacy and safety of multiple doses of IMAB362 in ts with advanced
adenocarcinoma of the stomach or the loweresophagus. The primary objective of this study was
to study the rate of remission (CR, PR) according to . The secondary objectives of this
study were: frequency and severity of adverse events ing to CTCAE v3.0 and tolerability
of multiple doses of IMAB362, ssion-free survival time (PFS): The time from start of the
first infusion to date of first observed disease progression or death due to any cause (whichever
occurs first), immunogenicity by analysis of human anti-chimeric antibodies, quality of life,
clinical benefit (CR,_,PR and SD accordinghto RECIST), and pharmacokinetics of IMAB362 by
serum levels.
Patients underwent screening for determination of presence of the 2 target CLDN18.2 in
their tumor. CLDN18.2 status was determined by immunohistochemistry with an anti-claudin-18
antibody, to be conducted according to a standardized protocol. Patient with tumors with at least
50% of the cells were stained with at least 2 + (double intensity) staining ity were enrolled
into this trial. The inclusion and exclusion criteria were d during the screening visit (V1).
Patients were recruited from university hospitals specialized in the treatment of gastroesophageal
cancer.
ts had to fulfill all of the ing inclusion criteria:
Metastatic, refractory or recurrent e of advanced adenocarcinoma of the stomach or
lower esophagus proven by histology
CLDN18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor
tissue sample in at least 50% of the tumor cells with a ng intensity of at least 2+ (on a
scale from 0 to 3+)
At least 1 measurable site of disease according to RECIST criteria (CT scans or MRI not
older than 2 weeks before visit 2)
Age 2 18 years
Written Informed consent
ECOG performance status (PS) 0—1 or Kamofsky Index 70-100%
Life expectancy > 3 months
Platelet count 2 l00_.000/mm3
Hemoglobin 2 10 g/dl
Bilirubin normal
AST and ALT < 2.5 times ‘upper limit of normal (ULN) (5 times ULN if liver metastases are
present)
Creatinine < 1.5 x ULN
For women with earing potential (last menstruation less than 2 years prior to
enrolment): Negative pregnancy test (B-HCG) at baseline and using two highly effective
methods of contraception during the treatment phase and for 8 weeks afier the last infusion of
the" study drug
Male patients whose sexual partners were women of child bearing potential had to use an
ed contraceptive method during the treatment phase and for 8 weeks after the last
infusion of the study drug
Patients meeting any one or more of the following exclusion ia were not eligible for study
entry:
Pregnancy or breastfeeding
Prior severe allergic on or intolerance to a monoclonal antibody, including humanized
or chimeric antibodies
Less than 3 weeks since prior chemo- or radiation therapy
Other investigational agents or devices concurrently or within 4 weeks prior to this study
Other concurrent anticancer therapies (not for the indication under study treatment)
0 Known HIV infection or known active hepatitis (A, B, C)
o Concurrent agulation with n K antagonists (e. g. Coumadin, Marcumar)
0 Therapeutic doses of heparin (prophylactic doses are accepted)
0 Uncontrolled illness including, but not limited to any of the following:
o Ongoing or active infection requiring parenteral antibiotics
o Symptomatic congestive heart failure
0 Unstable angina pectoris
o Uncontrolled hypertension
0 Clinically significant cardiac hmia
o Myocardial infarction within the past 6 months
0 Gastric ng within last four weeks
0 Symptomatic peptic ulcer
0 Clinical symptoms of cerebral metastasis
0 Psychiatric illness or social situations that would preclude study ance
All patients of all cohorts received repeated doses of IMAB362 every two weeks on visits 2, 5, 6,
7 and 8 (5 applications). The dose escalation procedure comprehended the following cohorts
with two ent doses (antibody/ body e area) of IMAB362:
Cohort l: 300 mg/m2
Cohort 2: 600 mg/m2
Cohort 32 600 mg/m2
The antibody solution was given as a 2 h intravenous infusion every two weeks. It was important
that the time of infusion was not less than 2 hours. For the infusion, an infusion system (c. g.
InfusomatE fmS ) had to be used in order to control the infusion time. The infusion set red
with the study drug, which was tested for compatibility by the manufacturer, had to be used for
the drug application. The time of the infusion of the study drug had to be in the morning. A
qualified physician had to be available for the time during the infusion and 24 hours thereafter.
Thirty-seven patients received at least one treatment. Unfortunately for 3 of them the
documentation is not completely in the database so that 34 patients will be included in the all
patients treated set (APT set) and will be used for the safety analysis. Four, 6 and 24 ts
were allocated respectively to cohort l with 300 mg/m2 IMAB362, cohort 2 with 600 mg/m2
IMAB362 and cohort 3 with 600 mg/m2 lMAB362.
During the treatment phase one patient in cohort 1, three patients in cohort 2, and 12 patients in
cohort 3 discontinued the study before having received 5 infusions of IMAB362 and completed
visit 9 (incl. second tumor imaging) two weeks after the 5‘h infusion. These patients have been
replaced.
Two patients in cohort 2 did not have measurable disease at baseline and were excluded from
efficacy analysis. Minor protocol deviations such as baseline tumor evaluation >14 days earlier
than Visit 2 (n=3; 8.8 %), obin <10 g/dl (n=5; 14.7 %), abnormal values for bilirubin
(n=3, 8.8 %), ALT or AST > 2.5 ULN (>5 ULN in case of liver metastases) ((n=2; 5.9 %), a
value for creatinine >l.5 ULN (n=l; 2.9 %) and prolonged time windows (>15 days) between
screening period and start of treatment (n=2; 5.9 %) occurred, but did not lead to exclusion from
within the last 6 months. A waiver was
any is. One patient had a myocardial tion
granted.
Since in cohort 2 and 3 the patients received the same dose of 600 mg/mz, it was decided to
analyze these ts as one group. All ts (n=34) of the APT set were Caucasian. The
median age was 62 (range of 45-65 years) in the 300 mgm2 dose group and 61 (range of 42-77
years) in the 600 mg/m2 dose group.
An overview of the localization of the cancer and the result of the histopathological grading is
shown in Table 10. The median time period n first diagnosis and screening visit for this
study was 16 months (min 2.7 / max 56). The HER2/neu expression status was mostly unknown
for the patients except for 5 patients treated with 600 mg/mz. One of these 5 ts was
HER2/neu positive.
TNM classification was specified for cancer of the stomach (n=16) and the gus or
gastroesophageal junction . In the APT set 25 % of the patients presented with primary
tumors of the stomach classified with T1 or 2, 31 % presented with T3, 25 % with T4 primary
tumors and for 19 % it was unknown. Sixty-Nine (69) % of the patients in the APT set had at
least one or two infiltrated lymph nodes indicated by the N1 classification and 56 % of the
ts suffered from peripheral metastases (M1) at the time of diagnosis. Sixty-nine (69) % of
patients with cancer of the esophagus or gastroesophageal junction were diagnosed with 2 T3. At
least one or two infiltrated lymph nodes (N1) were reported for 84 % of the patients. In addition
84 % of the patients presented with peripheral metastases.
2014/000719
Table 10: Overview of location and type of tumor at first diagnosis
(One patient had esophageal and stomach cancer; several patients had stomach cancer affecting
different parts of the stomach)
300 mg/m2 600 mg/m2 APT set
N M) N M) N (%)
Number of patients “
Esophagus ' —2(6.7) 2(6.7)
Gastroesophageal Junction 1 (25.0) 1 6 (53.3) 17 (50.0)
distal 4 4
cardia 8 8
subcardia 2 3
unspecified 2 2
Stomach 13 (43.3) 16 (47.1)
fundus 2 2
corpus 6 6
antrum 3 3
pylorus - -
ified 6 9
Type of tumor
intestinal 8
diffuse 7
Signet ring cell CA 4
mixed 4:10:00 1
unspecified 12 15
Histopathological grading
G2 10 10
62-3 3
G3 15
G3-4 1
Unknown 5
On a MedDRA SOC basis, the most frequent clinically relevant previous diseases were surgical
procedures in 25 patients (73.5%), chemotherapy in 30 patients ) and radiation in 7
patients (79.4%). In most cases, the surgery consisted of the surgical removal of organs (like
gastrectomy (72%), oesophagectomy (16%), lymphadenectomy (32%), ystectomy .
All patients, except four, had at least one previous y for their study disease. On a WHO
DD ATC basis, the most frequently used drugs were pyrimidine analogues (fluorouracil and/or
capecitabine), platinum compounds atin and/or oxaliplatin), and detoxifying agents for
antineoplastic treatment (calcium folinate and/or folinic acid). Other previous medicinal
ents (ending at the day of infusion at the latest) were also documented.
A total of 30 of the 34 patients (88.2%) had at least one concomitant disease, i.e. a disease that
was ongoing at the day of infusion of study medication. On a MedDRA SOC basis, the most
common ses were ‘gastrointestinal disorders’ in 19 patients (56%), al disorders‘ in
12 ts (35%), ‘metabolism and nutrition disorders’ in 10 patients (29%) and
‘musculoskeletal and tive tissue disorders’ in 8 patients (23.5%). Concomitant therapies
were mainly drugs for acid related disorders (17 ts; 50%), analgesics (12 patients; 35.3%)
and medication for GI disorders (10 patients; 29.4%).
A. SAFETY EVALUATION
Because the injections of the study medication were administered by the investigators at the
study centers, and the patients had to stay in the hospital for observation for at least 24 hours and
up to 72 hours, the overall compliance according to the study protocol was d. The
assignment of the eligible subjects to the dose cohorts was exactly performed as ed by the
study protocol (supervised by the DSMB). The study duration, defined as time from the date of
screening visit part 1 to last study day ranged from min. 18 to max. 355 days. The median study
duration was 106 days. 16 patients terminated the study prematurely before target visit 9.
Patients in all dose groups had a median number of4.5 to 5 infusions of IMAB362. The median
duration of one IMAB362 infusion in the APT set was 125 minutes. There was one patient with
a duration of less than the 120 minutes ed in the protocol. This patient stopped the
infusion due to vomiting, and prematurely discontinued the study.
The safety is was carried out for the APT set comprising all 34 patients who received at
least one dose of 300 mg/m2 (n=4) or 600 mg/m2 (n=30). Two-hundred-forty-one (241) adverse
events by physician’s description were coded according to MedDRA dictionary and translated
into preferred terms. Adverse events according to preferred terms have been counted only once
for each patient (also if the same adverse event occurred more than once for that patient during
the study). The highest NCI-CTC grade occuning in each patient was recorded. Thirty-two (32,
94 %) patients had at least one adverse event (regardless of relationship) during the study. No
e event was documented for 2 patients. Overall 6 patients (18 %) did not ence a
possibly drug related adverse event. One-hundred—four (104) drug related adverselevents by
preferred terms were reported for '28 patients. Eight (8) possibly drug related serious e
events were reported for 4 patients. The number of patient in the lower dose group (300 mg/mz)
was too small to allow detailed comparison between both dose groups. The nce of patients
with d e events in the 300 mg/m2 cohort and the 600 mg/m2 group (cohort 2 and 3)
are 75 and 83 % respectively.
In total, AEs from the SOCs ‘gastrointestinal disorders’ (27/34 patient 79.4%), ‘general disorders
and administration site conditions’ (26/34 patients, 76.5%) were reported most frequently. On a
MedDRA PT basis, the most frequently documented AEs were ‘nausea’ (57 events in
18 patients), ing’ (52 events in 16 ts) and ‘fatigue’ (20 events in 14 patients). In total
only 192 of the recorded AEs were assessed by the investigators as related to study medication.
These treatment-related AEs were classified in 104 different preferred terms and were observed
in 28/34 patients.
Most related adverse events were mild to moderate. There were 8 (23.5%) patients with
moderate drug-related ent emergent events and 12 (35.3%) patients with severe related
treatment emergent events.
Drug related AEs of severe intensity were ed for 2 patients in the 300 mg/m2 dose group,
vomiting and in one patient concomitant nausea. In the 600 ring/m2 dose group 10 patients
experienced severe drug related adverse events, 6 patients with vomiting of whom 3 patients
experienced in addition nausea, one patient with ensitivity (allergic reaction), one patient
with salivary hypersecretion one patient with dehydration, and one patient with hypoalbuminia.
The latter two patients also reported vomiting and . Two patients suffered a related
ensitivity (allergic reaction) during study drug infusion, one of which was classified as
moderate and one as severe. Both patients recovered after infiision was stopped.
In all reported treatment-emergent events study drug action was necessary for 12/34 patients due
to an AB. In 7 (21 %) cases an AB led to permanent study discontinuation. The underlying
e event was drug related in 3 sensitivity (allergic reaction) (n=2), vomiting and
abdominal pain) and not drug related in the other four patients (general physical health
deterioration (n=3), pneumonia). In one patient dose was reduced and in another patient dose
administration was delayed by 4 days due to serious vomiting with nausea. In three patients the
infusion was interrupted/prolonged. Twenty-seven patients (79%) received concomitant therapy
due to an AB. Eleven ts were hospitalized.
There were 13 patients with 31 SAEs documented. One patient died during the second screening
phase of the study. Twelve patients had other serious adverse events, which were study drug
related in four patients. Vomiting, nausea and related adverse events like GI hemorrhage and
exsiccosis were judged by the investigators as related to study medication. There were 4 SARs,
and 2 SUSARs (vomiting and vomiting with GI hemorrhage) in the present study. The final
outcome was death in seven cases. None of the deaths were classified by the investigators as
related to study medication.
One patient was a 45 old Caucasian male in good general condition (ECOG performance status
grade 1, Kamofsky index 80 %) with slim dietary status (BMI 19.3).
The patient ed infusions with 300 mgm2 IMAB362 every two weeks on 04 Nov, on 22
Nov and the third on 06 Dec 2011. Before the study the t had already suffered from nausea
and vomiting grade 1. On 07 Nov 2010 vomiting grade 3 was diagnosed
. As it was assessed as
serious, the t had to be hospitalized. When vomiting changed into grade 1 on 17 Nov 2010
and finally stopped completely, the patient could be discharged from the hospital
on the same
day. Before the second and third IMAB362 infusion the t was treated with a potent
premedication (alizapride, aprepitant, opramide, dimehydrinate) as prophylaxis for nausea
and vomiting, so that he did not suffer from nausea or vomiting again. The investigator assessed
the vomiting as related to study drug. The report was ed by the sponsor on 19 Jan 201 l and
the SAE judged as not expected but related to study drug and therefore reported as a SUSAR.
One patient was a 77 ld Caucasian male. He was in a very good l condition (ECOG
Performance : grade 0, Kamofsky Index: 100 %) with normal dietary status (BMI 24) at
screening. Before the study, the patient already suffered from nausea and he was therefore
treated as needed with metoclopramide. The patient received only one application of 600 mg/m2
IMAB362 on 09 Nov 2011, as the study had to be urely discontinued due to death. A
pleural effusion in the left lung was diagnosed by X-ray before the infusion and reported as SAE. .
The next morning, emesis set on. After administration of pantoprazole and 8 mg
ondansetron i.v., vomiting sed and haematemesis recovered the same day. Vomiting
decreased from grade 3 to grade 2 and finally stopped on 12 Nov 2011. so that the patient could
be discharged from hospital on 13 Nov 2011. The investigator assessed the event as related to
study drug. The report was received by the sponsor on 10 Nov 2011 and the event judged as not
expected but related to study drug and therefore reported as SUSAR. The general ion of
the patient worsened, he’developed renal failure and unfortunately died on 6 Dec 201 1.
One patient was a 42 year-old Caucasian male in very good general condition (ECOG
mance status grade 0; Kamofsky index: 100%) with a well-nourished dietary status (BMI
26). The patient received two infusions of 600 mg/m2 IMAB362. On 20 Mar 2012 the t
received the first study drug application. As he suffered from nausea and s vomiting, the
infusion rate had to be reduced after 35 minutes of infusion. The symptoms were treated with 40
mg pantoprazole and 3 mg granisetron and 2 vials i.v. butylscopolamine and 80 mg i.v.
aprepitant. This serious adverse event led to prolonged hospitalization. The investigator assessed
this event as related to study drug. The SAE report was received by the
sponsor on 21 Mar 2012
and the event judged as expected and related to study drug. A few days later, on 24 Mar 2012 the
patient had to be hospitalized again due to serious dehydration, which was caused by nausea and
vomiting. Furthermore the patient suffered from pain in the epigastrium. He received 1 g i.v.
metamizol, a buprenorphine patch and ons for rehydration. On 30 Mar 2012 the symptoms
were relieved and the patient rehydrated. The investigator assessed this event as not d to
study drug. The SAE report was received by the r on 26 Mar 2012 and the event judged as
not expected and not related to study drug. On 03 Apr 2012 the patient received the second
infusion. which led again to the AEs nausea and vomiting. He was treated with 30 drops p.o.
metoclopraminde and l vial i.v. dimenhydrinat. As the symptoms worsened on 05 Apr 2012,
they were ed as serious. In on the patient was troubled with dysphagia and thus
strongly reduced food-intake. On 15 Apr 2012 the symptoms were gone. The investigator
assessed this event as related to study drug. The SAE report was received by the
sponsor on 19
Apr 2012 and the event judged as expected and d to study drug.
One patient was a 73 year-old Caucasian male in good general ion (ECOG performance
status grade 1; Kamofsky index: 90%) with a well-nourished dietary status (BMI 26). From 08
Nov 2011 till 03 Jan 2012 the t received the five planned study drug applications of 600
mg/m2 IMAB362 every two weeks. On 08 Nov 2011 the patient received the first application of
IMAB362. During and afier this infusion. he suffered from nausea and vomiting. The symptoms
became serious on 09 Nov 2011. After treatment with metoclopramide the symptoms resolved
one day later. The investigator assessed the event as related to study drug. The SAE report
received by the sponsor on 10 Nov 2011 and the event judged expected and related to study
drug. On 6 Dec 2011 was the third infusion. The patient suffered from moderate vomiting and
mild nausea d with clemastine, ranitidine, and ondansetron. The vomiting lasted
one day.
The nausea continued for 7 days. The study was terminated on 16 Jan 2012 due to disease
progression. No follow up visit was performed.
In conclusion, IMAB362 was found to be safe and well tolerated in a heavy ated
tion of patients with advanced adenocarcinoma of the stomach, esophagus or
gastroesophageal junction. In total, AEs from the SOCs ‘gastrointestinal disorders’ (27/34
patient 79.4%), ‘general disorders and administration site conditions’ (26/34 ts, 76.5%)
were reported most frequently.
On a MedDRA PT basis, the most frequently documented AEs were ‘nausea’ (57 events in
18 patients), ‘vomiting’ (52 events in 16 patients) and ‘fatigue’ (20 events in 14 patients).
In total 192 of the ed AEs were assessed by the investigators as d to study
medication. These treatment-related AEs were observed in 28 of the 34 patients. Eighty-three
(83) percent of these related AEs were gastrointestinal disorders (68 %, 130 AEs) recorded in 25
patients and general disorders ( 15%, 29 AEs) ed in 16 ts.
On a MedDRA PT basis most related adverse events were mild to moderate with nausea (50 %),
vomiting (47 %), fatigue (27 %), abdominal pain (15 %), peripheral oedema (15 %),decreased
te (12 %) and diarrhea ( 12 %.) occurring in more than 10 % of the patients.
Two patients suffered a related hypersensitivity (allergic reaction) during study drug infusion,
one of which was classified as moderate and one as severe. Both patients recovered after
infusion was stopped.
No al study drug related laboratory values of CTC grade 4 (life-threatening) or 5 (death)
have been reported.
There were 12 (35.3%) patients with severe related treatment emergent . Drug related AEs
of severe intensity were reported for 2 patients in the 300 mgm2 dose group, vomiting and in
one patient concomitant nausea. In the 600 mg/m2 dose group 10 patients experienced severe
drug related adverse events, 6 patients with vomiting of whom 3 patients experienced in addition
nausea, one t with hypersensitivity (allergic reaction), one t with salivary
hypersecretion, one patient with dehydration, and one patient with hypoalbuminia. The latter two
patients also reported vomiting and nausea.
At the time of analysis 13 patients have recovered from all drug related adverse , 2 ts
were recovering, 11 patients did not recover from at least one AE and for 2 the status was
unknown. Of the l 1 patients where at least one drug related adverse event was not recovered 9
had gastrointestinal disorders (4 nausea, 2 vomiting);
There were 13 patients with 31 SAEs documented, including 7 deaths. One patient died during
the screening phase, i.e. prior to the start of study drug infusion, and was therefore classified as
screening event. In four patients ent emergent gastrointestinal SAEs like vomiting (n=4),
nausea (n=2), exsiccosis (n=l) and GI haemorrhage (n=l) were judged as treatment related. One
of these patients with vomiting was treated with 300 mg/m2 the other three were treated with 600
mg/m2 IMAB362. Three of these four patients recovered except one who died due to a not
related renal failure.
The incidence of drug related adverse events was comparable between the 300 and 600 mg/m2
dose group with 75 % and 83 % of the patients, respectively. The frequency and severity of
- nausea, vomiting and fatigue was also comparable between both dose . There was no clear
relationship n the dose and frequency/severity of adverse events.
The adverse event profile with most AEs ed for the gastrointestinal tract matches with the
underlying disease and also the CLDN18.2 expression profile. It is suggested that nausea and
vomiting are an on-target effect since .2 is also expressed on gastric epithelial cells (in
tight junctions).
Generally ng, IMAB362 given in multiple doses of300 and 600 mg/m2 was observed to
be safe and well-tolerated with vomiting and nausea being the most common related adverse
event.
B. TION OF PHARMACOKINETICS AND IMMUNOGENICITY
Preliminary drug concentration data for repeated dose application of IMAB362 is ble for
the four patients of the first and 34 patients of the second and third cohort, who received 300
mg/m2 and 600 ngm2 IMAB362, respectively.
Table 11: Cm“ (maximum serum drug concentration) following first and fifth
[MAB362 administration
cmax after lst infusion cmax after 5th infusion
[us/ml] [us/ml]
1179.2“l
$2.1
$7.1
13.2
1011-05
1013-02
1005-10
1001-24
1001-27
1004-07
1004-10
100411
1005-18
1005-27
1005-29
1005-34
1006-03
1006—05
1007—09
1011~09
1011—16
1011-17
1011-20
2003-08
2003-10
2003- 13
2003-15
2003— 16
“ high CV results from
one outlier in the triplicate measurement
Blood samples have been drawn prior to every infusion. After the first infusion additional
samples were taken at the end of the infusion and l. 1.5, 2, 3, 4, 6, 12, 24 hours, 3 and 6 days
after the end of the infusion. After the last infusion samples were taken at the end of the infusion
and l, 1.5, 2 hours and 14 days as well as 4 to 8 weeks after the end of the last infusion. No
analyte could be detected in the pre—dose samples from individual patients allocated to cohort l-
After the first IMAB362 on, cmax values ranged between 208.9 ug/mL and 349.6 ug/mL for
the first cohort. For the second and third , taken together, cmax values ranged between
269.1 ug/mL and 575.1 ug/mL after the first application.
In serum samples taken at subsequent time points (V3 to V5), a time dependent reduction of the
concentration of IMAB362 was observed (Figure 8). At visit 5 before the second infilsion,
minimum serum levels between 11.3 ug/mL and 36.8 ug/mL (mean value 22.5 i 10.5 ugmL)
were determined for cohort l and 17.0 ug/mL and 100.2 ug/mL (mean value 54.5 i 29.0 ug/mL)
for cohort 2 and 3 taken together.
At visit 8 (day 57) before fifih infusion minimum serum levels between 32.4 ug/mL and 67.1
ug/mL (mean value 46.1 d: 18.5 ug/mL) were determined for cohort 1 and 28.3 ug/mL and 301.6
ugmL (mean value 147.2 3: 93.1 ug/mL) for cohort 2 and 3 (Table 12).
After infusion at visit 8, cmax values ranged between 259.1 ug/mL and 326.5 ugmL for the first
cohort and 278.1 ug/mL and 642.6 ug/mL for cohort 2 and 3 (Table 1 1).
For cohort 1, mean Cmax values were determined 90 min after the first IMAB362 infusion (270.6
1- 63.9 ug/mL) and 90 min afier the fifth infusion (279.2 d: 27.7). For cohort 2 and_3 together,
mean Cmax values were determined at the end of the first IMAB362 on (340.8 :1: 80.2
ug/mL) and 60 min afier the fifth on (443.3 d: 97.7) (Table 12).
In summary, measured serum levels of 2 showed, that in the patients treated with 300
mg/m2 the serum concentration of IMAB362 drops below the desired level of 50-100 ug/ml in
between 2-weekly cycles. At a dose of 600 mg/mz, in contrast, in the vast majority of patients
IMAB362 serum levels were above 50 ugml, even 2 weeks afier the first application. Seven to
29 days (mean value 15 days) afier the 5th stration, the dose level was above 50 ug/ml
(mean value 151.3 i 90.1 ug/mL).
Table 12: Descriptive pharmacokinetic data of ed administration of 300 and 600
mg/m2 IMAB362
- Meanisd concentration (ugml) of IMAB362 in serum of 4 patients treated with repeated doses
of 300 mg/m2 t l) and up to 30 patients (30 patients first infusion, 12 patients fifth
infusion) treated with repeated doses of 600 mg/m2 (cohort 2 and cohort 3 together).
—Concentration (mean t sd) IMA3362 [pg/ml]
Dose IMABBGZ 300 mg/ml 600 mg/m2
cm, after 1“ infusion 270.5 i 63.9 340.8 a. 80.2
se level before 2"“ infusion
Pre-dose level before 3'" infusion
Pre-dose level before 4‘“ infusion
se level before 5m infusion
after 5‘" administration
A mild accumulation of IMAB362 was observed from cycle to cycle. lation s
ranged from 1,03 fold to 3,52 fold based on the first pre-dose value before second infusion
(mean value 2,04).
Table 13: lation of IMAB362 after repeated infusions
To determine accumulation factors, IMAB362 concentration ratios before visits 6, 7, 8 and 9.x
(responder treatment) and before second infusion (visit 5) were calculated.
Accumulationtactonm-
Patient 101105 --—-—-
Patient 400111
Patient 100510 :15 ---—-_——-_-__
Patient 100124 #15 --—-—-
Patient 100410 #15 ------
' ----—--
Patient 100529 P02
Patient 100603 ~ F02 -—_----
Patient 100605 P02
Patient 101109 #15 ——--—_-—----—-
Patient10112015——__—-_-
Patient 200310 ———--——
WO 46778
In conclusion, pharmacokinetics of IMAB362 was found to be dose-dependent.
After the first IMAB362 infusion, cmax values ranged between 208.9 ug/mL and 349.6 ug/mL for
the first . For the second and third cohort, taken together, cmax values ranged between
269.1 ug/mL and 575.1 pg/mL after the first ation.
In serum samples taken at subsequent time points (V3 to V5), a time dependent ion of the
concentration of IMAB3 62 was observed. At visit 5 before the second on, minimum serum
levels between 11.3 pg/mL and 36.8 pg/mL (mean value 22.5 :1: 10.5 ug/mL) were determined
for cohort 1 and 17.0 ug/mL and 100.2 ug/mL (mean value 54.5 i 29.0 ug/mL) for cohort 2 and
3 taken together.
At visit 8 (day 57) before fifih infusion minimum serum levels between 32.4 ug/mL and 67.1
ugmL (mean value 46.1 d: 18.5 ug/mL) were determined for cohort l and 28.3 ug/mL and 301.6
ug/mL (mean value 147.2 :1: 93.1 ug/mL) for cohort 2 and 3.
Afier 5‘h infusion at visit 8, cmax values ranged between 259.1 pg/mL and 326.5 pg/mL for the
first cohort and 278.1 pg/mL and 642.6 ug/mL for cohort 2 and 3.
For cohort 1, mean Cmax values were determined 90 min after the first IMAB362 infusion (270.6
d: 63.9 ug/mL) and 90 min afier the fifth infusion (279.2 1- 27.7). For cohort 2 and 3 together,
mean Cmax values were determined at the end of the first IMAB362 infusion (340.8 :1: 80.2
pg/mL) and 60 min after the fifth infusion (443.3 :1: 97.7).
In summary, measured serum levels of IMAB362 showed, that in the ts treated with 300
myml the serum concentration of IMAB362 drops below the desired level of 50-100 ug/ml in
between 2-weekly cycles. At a dose of 600 mg/ml, in contrast, in the vast majority of patients
2 serum levels were above 50 ug/ml, even 2 weeks after the first application. Seven to
29 days (mean value 15 days) after the 5‘h administration, the dose level was above 50 pg/ml
(mean value 151.3 t 90.1 pg/mL).
C. EVALUATION OF ANTITUMORAL ACTIVITY
Full analysis set (FAS):
Included all subjects who have received study medication at least once and for whom efficacy
data upon treatment were available.
At the time of analysis 50 patients have been enrolled at a dose of600 mg/mz. Nine of them have
been included recently and no further data is available at the moment due to their recent
enrolment. For ten patients no second tumor imaging has been performed and these patients are
therefore not included in the FAS set. The FAS set ses 31 patients.
The median age was 57 years with a range from 35 to 77. Patients of the FAS set had a median
Kamofsky—Index of 90 % (range from 70 - 100 %). The vast majority (81 %) of the patients has
been pretreated with at least one chemotherapy regimen. Six (6) patients did not have a previous
chemotherapy regimen.
Table 14: Details on previous chemotherapy regimens in the FAS set (n=3l).
Platinum
Taxanes
tabine Compound
No of
.atlents 25 81% 23 74% 14 45% 26%8 8 26% 6 19%
The median number of previous chemotherapy ns was 2.0 (range 0 to 5). Chemotherapy
regimens for gastroesophageal cancer mostly consist of various combinations of 5-FU tive.
platinum compound, taxanes, epirubicin, irinotecan, trastuzumab for HERZ/neu positive patients
and other igational agents. In the FAS set 81 % of ts had at least once 5-FU or
capecitabine and 74 % were treated with a platinum nd at least once prior to inclusion.
Six (6, l9 %) patients have been pretreated with trastuzumab or other investigational agents. Six
(6. 19 0/o) patients also had herapy before study start.
Due to the late stage ofthe disease the patients had a median of 2.0 metastatic sites (range from
1.0 to 4.0). Most prominent were lymph nodes (19 pts, 61 %); liver (13 pts, 42 %); ascites (8 pts,
26 %) and peritoneum (7 pts, 23 %).
The overall disease control rate was 39 % (Table 15). Four patients had confirmed partial
for these patients
response, and 8 patients had a stabilization of disease. The first re-assessment
took place 8 to l 1 weeks after first infusion, except for two patients, for whom it the first tumor
re-assessment was done after 6 weeks, respectively.
Table 15: Best response evaluation according to RECIST, FAS set
In 6 of the 12 patients with clinical disease control at least one tumor marker (CEA; CA19-9;
CA125; CA15—3) which was elevated at baseline dropped by 35 to 76 % throughout the study.
three ts all tumor markers were below the cut-off value and for one patient no tumor
marker results were available.
Interestingly also 4 patients with progressive disease as best response had a tumor marker
decrease between 29 and 54 % during the study.
Partial responses were reached after 2.3 months treatment (two ts), 6.5 months (one
lasted
patient) and 4.8 months (one patient) tively. The PR was continued for one patient,
another 4.4 months, which leads to a PFS of 9.2 months for this t. For the other three
patients confirmations were done after 6 (one patient) and 12 weeks (two patients), respectively.
More s can be found in Table 16.
Table 16: Detailed evaluation of the FAS set on a per patient basis
n.a. 4 data not available yet; n.d. — not detectable. - censored since event did not take place
until Nov. 2012 or exact date is n at the moment. Last date of follow-up has been used
Have not been counted in the text due to that.
every case. # - tumor marker is below cut-off.
Pat-Mm.
w n—-
1013-02 9 s—n-—-
1011-09
1001-24
1006-03 17 3 3 3 70 SD PR (—34 %) CA125 -37 % 34'
1007-09 11 1 2 3 73 so so (n.a.) CA15_3 42%" 23'
2003-15 11 0 3 3 80 PD PR (-35 %) CA125 -35% 22"
CA19-9 -76%
2003-16 11 1 4 2 90 PD PR (-39 %) CA125 -75%
1005-34 5 4 3 2 50 SD SD (+17 %) CEA -35%
2002-07 5 O 1 2 50 PD
I'mPow» -
1005-13 5 anPD (+63 °/o) increase 10
s “nun
a u-n-
CA15_3-40%
1005-10 5 4 2 PD (-2 %) CA125 -54%
IIIn—n _n-
CEA -29%
6 5 PD(‘26 % CA15 .3 -28°/o
a -fl-fl--
“nu—n-
mun-n-
-_-—--fl-
nun-n-nn-
m-----
III-m
The median progression free survival for patients in the FAS set was 10 weeks (min. 4 weeks;
max. 40 weeks). Due to restricted availability of events the median progression tree survival for
patients with clinical benefit (PR + SD) shown in Figure 9 has d value. ts without
clinical benefit (PD) had a median progression free survival of 9 weeks (min. 4 weeks; max. 1 1
weeks) (Figure 9).
best response) or
There was no differences between patients with clinical benefit (PR or SD as
progressive disease (PD as best response) with regard to age (mean of 56 vs. 59 years), no
of 89 vs. 88 %).
- previous chemotherapy regimen (mean of 1.9 vs. 2.1), ky-Index (mean
sites was lower in the responder group with a mean of 1.9 in Only the number of metastatic
comparison to 2.3 in the non-responder group. The difference is not statistically significant.
clinical benefit
The intensity (mean and max) of IHC staining was similar between patients with
and ssive disease. The number of cells stained was different between both groups.
in the
m number of cells d and the mean number of cells stained were higher
-10 patients with clinical benefit with a mean of 77 % vs. 67 % and 71 % vs. 60 %, respectively.
with clinical
Differences were also observed regarding location of the metastases. In the ts
% vs. 1 l
benefit the frequency of pleural effusion (25 % vs. 5 %), peritoneal carcinomatosis (42
disease as best
%) and ascites (42 % vs. 16 %) was higher compared to patients with progressive
much lower (17 % vs. 58 %) in ts with
response. The presence of liver ases was
clinical .
Per Protocol Set (PP):
The PP population included all patients who completed the treatment section (up to visit 9)
without any major protocol deviation.
and nine
Of the 31 patients in the FAS set two had a major protocol violation (no target lesion)
patients did not complete the study protocol until visit 9. and therefore they had less than the 5
ed infusions of IMAB362. The PP set comprises 20 patients.
The median age was 60 years with a range from 35 to 77. Patients of the PP set had a median
Kamofsky-Index of 90 % (range from 70 - [00 %). The vast majority (80 %) of the patients has
been ated with at least one chemotherapy regimen. Four (4) patients did not have a
previous chemotherapy regimen.
Table 17: Details on previous chemotherapy regimens in the PP set (n=20).
I Platinum
TaxanesMM
Capecitabine Compound
patients 1 6 80% 15 75% 11 55% 4 20% 5 25% 5 25%
WO 46778 2014/000719
The median number of previous chemotherapy regimens was 2.0 (range 0 to 5). Chemotherapy
regimens for gastroesophageal cancer mostly consist of s combinations of5-FU derivative,
platinum compound, taxanes, epirubicin, irinotecan, trastuzumab for HERZ/neu positive patients
and other investigational agents. In the PP set 80 °/o of ts had at least once 5-FU or
capecitabine and 75 % were treated with a um compound at least once prior to inclusion.
Five (5, 25 %) patients have been pretreated with trastuzumab or other investigational .
More details can be found in Table 17. Five (5, 25 %) patients also had herapy before study
start.
Due to the late stage of the disease the patients had a median of 3.0 metastatic sites (range from
1.0 to 4.0). Most prominent were lymph nodes (13 pts, 65 %); liver (9 pts, 45 %); ascites (6 pts,
%) and lung (5 pts, 25 %).
The overall disease control rate was 50 %. Four patients had confirmed partial response and 6
stabilization of disease. The first re-assessment for these patients took place 8 to 11 weeks after
first infusion, except for one patient, for’whom the first tumor re-assessment was done after 6
weeks, respectively (Table 18).
Table 18: Best response evaluation according to RECIST, PP set.
Total? '
. 20‘ .7 100
[n 6 of the 10 patients with clinical disease control at least one tumor marker (CEA; CAl9-9;
CA125; CA15-3) which was elevated at baseline dropped by 35 to 76 % throughout the study. In
two patients all tumor markers were below the cut-off value and for one patient no tumor marker
results were ble.
Interestingly also 3 patients with progressive disease as best response had a tumor marker
decrease between 29 and 54 % during the study.
Partial responses were reached after 2.3 months treatment (two patients), 6.5 months (one
patient) and 4.8 months (one patient) respectively. The PR was continued for one t, lasted
another 4.4 months, which leads to a PFS of 9.2 months for this patient. For the other three
patients ations were done after 6' (one patient) and 12 weeks (two patients), respectively.
More details can be found in Table 19.
2014/000719
Table 19: Detailed evaluation of the PP set on a per patient basis
n.a. — data not available yet; n.d. - not detectable. - censored since event did not take place
until Nov. 2012 or exact date is unknown at the . Last date of follow-up has been used in
counted in the text due to that.
every case. # - tumor marker is below cut-off. Have not been
1 IIII-I
IIIII-
IIIIIu—I-IIIII-—-
IIIIIwoe-es IIIII-
CA15_3 42%"
1007-09 so (na. ) CA125-27%"
2.... IIIIII- I
CA19-9 —76%
2003—16 PR (--39 %) CA125 -75% 22*
CEA -3S%
CA15_3 40%
1005-10 5 4 2 3 53 PD PD (-2 %) CA125 -54%
1004-11 5 1 3 2 4O n.a. PD(+32 %) CA19_9 32%
1011-05 5 1 2 2 58 n.a. PD(+72 %) increase
CEA -29%
1011-16 5 2 1 3 75 PD PD(-25 %) CA15_3 -28% 9 3.8
2003-10 5 0 4 2 60 n.a. PD (+8 %) increase 10
"Inn -u-
mama _-u
' Measurements
were done earliest after 4 weeks and every 3-12 weeks thereafter throughout the
study.
The median progression free survival for patients in the PP set was 18 weeks (min. 9 weeks;
max. 40 weeks). Due to restricted availability of events the median progression free survival for
patients with al benefit (PR + SD) shown in Figure 10 has limited value. Patients without
clinical benefit (PD) had a median progression free al of 10 weeks (min. 9 weeks; max. 10
weeks) (Figure 10).
There was no differences between patients with clinical benefit (PR or SD as best response) or
progressive e (PD as best response) with regard to age (mean of 57 vs. 62 years), no of
previous chemotherapy regimen (mean of2.1 vs. 2.0), Kamofsky-lndex (mean of 88 vs. 88 %).
Only the number of metastatic sites was higher in patient with al benefit with a mean of 3.0
in comparison to 2.2 in patient t benefit. The difference is not statistically significant.
The intensity (mean and max) of [HG staining was r n patients with clinical benefit
and progressive disease. The number of cells stained was different between both groups. The
maximum number of cells stained and the mean number of cells stained were» higher in the
patients with clinical benefit with a maximum of 76 % vs. 66 % and a mean of 70 % vs. 66 %,
respectively.
Differences were also observed regarding on of the metastases. In the patients with clinical
benefit the frequency of pleural effusion (30 % vs. 10 %), peritoneal carcinomatosis (40 % vs. 0
%) and ascites (40 % vs. 20 %) was higher compared to patients with ssive disease as best
response. The presence of liver metastases was much lower (20 % vs. 70 %) in patients with
clinical benefit.
In conclusion. the tumor status (according to RECIST) at 2 weeks afier the 5‘h 2
infusion (V9) was compared to baseline. For 31 patients (FAS) at least one staging afier baseline
was available. Patients were enrolled at a terminal stage ofdisease with a median of 2.0 previous
chemotherapies and 2.0 metastatic sites.
A ed partial response was assessed in four patients leading to a overall response rate of
l3 %. Three of them are currently ongoing and duration could not be calculated. Additionally,
eight patients had a stabilization of disease leading to a disease control rate of 39 %. At the time
of is the ssion free survival of these [2 patients with clinical benefit ranged from 6
and 40 weeks. Median could not calculated since event was not recorded for 7 of these patients
was elevated at baseline
so far. In 9 of the patients with clinical benefit at least one tumor marker
and dropped by -35 to -76 % in 6 of them concomitantly. Interestingly also 4 patients with
progressive disease as best response had a decrease between -29 and -54 % of at least one of the
elevated tumor markers during course of the study. The overall median‘progression free survival
was 10 weeks with a range of 4 to ~ 40 weeks.
In patients with al benefit (4 PR + 8 SD = 39%) the incidence of peritoneal omatosis,
pleural effusion and ascites was higher, and the incidence of liver ases was lower than in
patients without benefit. On the other hand one patient with a continued partial se had
frequent liver metastases.
With the current data set it seems that ts with a clinical benefit had a higher number of
cells with positive IHC staining.
Moreover, ancillary data was collected in ed patients, showing that the patients serum
components and the patients PBMCs are fully functional and potent in mediating the major
IMAB362 modes ofaction CDC and ADCC, respectively.
In conclusion, anti-tumor activity (partial response, stable disease, tumor marker decrease) has
been observed and IMAB362 warrants further investigation.
D. OVERALL CONCLUSIONS
This trial was designed as a phase IIa, multi-center, non-randomized, inter-patient multiple-dose
escalation, abel clinical study with 3 cohorts. Patients eligible for this al trial were
requested being refractory to standard treatment or being without accepted therapy.
For this interim report 34 ts were evaluable for safety analysis (APT set) thereof 4 were
enrolled in cohort 1 (300 , 6 in cohort 2 (600 mg/ml) and 20 in cohort 3 (600 mg/mz).
IMAB362 given in a le dose schedule was safe and well-tolerated in heavy pretreated
patients with gastro-esophageal cancer, with nausea and vomiting being the most common
related e event. Most adverse events were mild to moderate. There were only two patients
with allergic reactions. one of moderate degree, one severe. There were no grade 4 and grade 5
adverse events (including laboratory parameters) in this phase IIa study and the previous phase I
study. That IMAB3 52 did so far not cause grade 4 related AEs is remarkable, since the majority
of registered monoclonal antibodies are associated with life threatening grade 4 and 5 side
effects. The indication metastatic breast cancer for bevacizumab has been revoked by the FDA in
November 201 I. after initial inary approval in 2008. Bevacizumab did not prolong life and
' 114
caused severe high blood pressure and hemorrhaging, with bowel perforation and nasal septum
perforation. Cetuximab causes acne-like rashes and grade 3—4 infusion reactions, anaphylaxis and
cardiac arrest, necessitating anti-histamine diphenhydramine prophylaxis before treatment.
Trastuzumab is still widely used, while it causes symptomatic cardiac dysfunction in 2 to 7% of
patients, which is known for more than 10 years.
The primary measure for the assessment of potential antitumoral activity was the tumor status
according to RECIST. There were 31 patients who had at least this one evaluation after baseline,
and they were therefore included in the FAS. Four PR and 8 SD in 31 (RR 13 %, DCR of 39 %)
heavily pretreated patients compares very well with se results in other phase II studies
with approved targeted monotherapy as secondary or late stage treatment.
VCetuximab an EGFR antagonist achieved a RR of 3 % (with additional 7 % SD) in late stage
(majority had 2 or more metastatic sites and previous therapies) GEC measured after 8 weeks in
a phase II trial with thirty patients. In a second study with 55 late stage patients mab led to,
0/0 RR and additional 11 % of SDs measured after 8 weeks. r se rates were
achieved in EGFR positive, refractory mCRC patients where cetuximab was approved later in
this indication.
Sunitinib and erlotinib were tested in late stage GEC patients in different phase II studies with in
total some 150 ts. The DCR after 6-8 weeks varied between 16 and 39 % and the response
rate was reported between 3 and 7 %, respectively.
The phase [I objective response rate for trastuzumab as ary therapy in breast cancer was
I l % with in addition 9 % SD of 2 6 months. For erlotinib in pretreated lung cancer a response
rate of9 % was ed. Sorafenib achieved a RR between 2 % to 18 % in two phase [I trials in
renal cancer and for temsirolimus a R of 7 % was reported in a renal cancer trial. Later these
targeted therapy compounds were further ped in combination with herapy and
became registered in these tions.
lMAB362 is a safe and effective antibody. As expected from the exquisite tissue-specificity of
the targeted surface molecule and the high precision binding of the antibody, the investigational
drug is well tolerated in comparison with other marketed targeted therapy. Moreover, in several
patients ce for clinical activity has been ed. comparable or better to phase [I results
of other already marketed ed therapies.
Example 5: IMAB362 induced nausea/vomiting
It was ed that IMAB362 induces /vomiting The
up to NCI-CTC grade 3.
symptomatology can be described as follows: (i) not dose-dependent, (ii) acute onset, mostly
within the first s of infusion, may continue after finalization of on, (iii) starts with
in patients
epigastric cramps, alivation. (iv) vomiting may start without prodromi, (v) rare
increase from
with total gastrectomy, (vi) reaction at first on indicative versus symptoms
cycle to cycle.
total
The fact that these adverse reactions do rarely occur in patients, who have undergone
gastrectomy, suggests that the underlying mechanism is an on-target
effect. With IMAB362
vomiting is more nt than nausea and is often reported to occur without prodromal nausea.
of 2
Onset may be both acute as well as delayed. We hypothesize that small amounts
bind to restrictively accessible tight junction epitope. This results in a localized disruption
tissue reactions and
tight ons and leakage of gastric acid leaks into submucosa. Resulting
cramps initiate a nausea/vomiting cascade.
Thus, recommended countermeasures are efficient antiemetic prophylaxis gastric mucosa
protection.
medication. For both
For example. patients shall receive antiemetic prophylaxis prior to starting
laxis and curative intervention, a combination of a NK—l receptor (6. g.
Aprepitant/Emend) and a 5—HT3 receptor blocker (e. g. Ondansetron/Zofran) are recommended
is given for
and may be extended with additional compounds. Antiemetic tion preferably
at least the first three days of each cycle. Prophylactic administration of
butylscopolamin/buscopan shortly before each IMAB362 infusion may be considered.
this respect, proton pump
Any e for mucosal protection may reduce gastric symptoms. In
1-2 or
inhibitors and/or misoprostol may be used and may, for example, be administered on days
3 of each cycle. Nonsteroidal anti-inflammatory drugs (NSAIDS) should not be used, but
acetaminophen is allowed. If acetaminophen is not efficient for pain management NSAIDS can
NSAIDS
be used if required for pain ment to avoid opioid treatment. Patients receiving
are preferably treated with proton pump inhibitors and/or Misoprostol.
Thus, antiemetic prophylaxis and gastric mucosa protection may be started shortly before
IMABB62 infusion. For example, the following combination may be administered, intravenous
application being preferred:
- NK-l RA: e. g. Aprepitant/Emend (150 mg IV)
- 5-HT3 RA: e.g. Palonosetron (0.25mg IV), Ondansetron/Zofran (8mg
IV), Granisetron (3mg IV)
- butylscopolamin/buscopan
- Proton pump inhibitor: razol/Pantozol
ally, Metoclopramid/MCP, Lorazepam, and/or Atropin may also be administered.
IMAB362 is an antibody, which relies ntly on immunological modes of action, which
may be mised by immunosuppressive compounds. For this reason, steroids should be
avoided in antiemetic prophylaxis and only used, if other compounds have failed.
Furthermore, exposure to lMAB362 should be attentive. For example, close monitoring in first
-30 min is ended. If necessary, infusion rate should be slowed (e.g. up to 4b instead 2
h) and infusion breaks should be included.
Antiemetic medication as well as gastric mucosa protection could be continued for e. g. up to day
3 of each cycle.
WO 46778
Applicant‘s or agent's Internationalapplication No, .
tile reference 342-77 PCT
INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL
(PCT Rule I3hix)
A. The indications made below relate to the deposited microorganism or other ical material referred to in the ption
on page 44 .Iine 15
B. IDENTIFICATION OF T Further deposits are identified on an additional sheet
Name oi’depositary institution
DSMZ-Deutsche Sammlung von rganismen und Zelikulturen GmbH
Address of depositary institution (including pus/(II code and curmlijrl
Mascheroder Weg 1 b
38124 Braunschweig
Date ot‘dcposit ion Number
October 19, 2005 DSM ACC2737
C. ADDITIONAL INDICATIONS (leave blank lfnn/ applicable) This information is continued on an additional sheet D
- Mouse (Mus musculus) myeloma 98U,1 fused with mouse (Mus musculus) spienocytes
- Hybridoma secreting antibody against human ciaudin-18A2
D. ATED STATES FOR WHICH INDICATIONS ARE MADE (lfI/te itu/lcnliom (Ire lint/or u/l designatedSta/cs)
E. SEPARATE FURNISHING 0F INDICATIONS (/c'ui'c h/unlt i/‘rml applicable)
The indications listed below will he submitted to the International Bureau later (vpecr'lirlhcgcnem/nummofrhc indications cg, '34L'c‘6ii'l0"
N1Imhcr q/'I)qmsil ”)
For receiving Office use only For International Bureau use only
C] This sheet was ed with the international application DThis sheet was received by the International Bureau on:
Authorized officer Authorized officer
Form PCT/'RO/I34 (.Iulyl9982 reprint Januaryl 2004)
New International Patent ation
Ganymed Pharmaceuticals AG, et al.
,,THERAPY INVOLVING ANTIBODIES AGAINST N 18.2 FOR TREATMENT OF
CANCER”
Our Ref.: 342-77 PCT
Additional Sheet for Biological Material
fication of further deposits:
1) The Name and Address of tary institution for the deposits (DSM ACC2738, DSM
ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM
ACC-2745, DSM ACC2746, DSM 7, DSM ACC2748) are:
DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Mascheroder Weg 1b
3 8124 Braunschweig
2) The Name and Address of depositary institution for the deposits (DSM ACC2808, DSM
ACC2809, DSM ACC2810) are:
DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH
Inhoffenstr. 7 B
38124 Braunschweig
Date of desposits Accession Numbers The indications made below
relate to the deposited
microorganism in the
description on the following
page(s)
October 19, 2005
r 19, 2005
October 19, 2005 DSM ACC2742 page 44, line 20
r 19, 2005 DSM ACC2743 page 44, line 21
November 17, 2005
November 17, 2005
November 17, 2005
2014/000719
' 119
Additional Indications for all above mentioned deposits:
- Mouse (Mus musculus) myeloma P3X63Ag8U.l fused with mouse (Mus
musculus) splenocytes,
- Hybridoma secreting antibody against human claudin-18A2
3) Depositor:
All above mentioned depositions were made by:
Ganymed ceuticals AG
FreiligrathstraBe 12
55131 Mainz
Claims (18)
1. Use of an antibody having the y of binding to Claudin-18 splice variant 2 (CLDN18.2) for the ation of a medicament for treating a cancer disease of a patient, the treatment comprising administering to the patient the antibody at a dose of 300-1000 mg/m2 so as to provide a serum level of at least 40 µg/ml, wherein doses of the antibody are administered in time intervals of at least 7 days, wherein the antibody comprises an antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO: 32 and an dy light chain comprising the amino acid sequence shown in SEQ ID NO: 39.
2. The use of claim 1 n the serum level provided is between 40 µg/ml and 700 µg/ml.
3. The use of claim 1 or 2 n the serum level is provided for at least 7 days.
4. The use of any one of claims 1 to 3 wherein at least 50% of the cancer cells of the patient are .2 positive and/or at least 40% of the cancer cells of the patient are positive for surface expression of CLDN18.2.
5. The use of any one of claims 1 to 4 wherein the antibody is administered in multiple doses.
6. The use of claim 5 wherein the antibody is administered in at least 3 doses.
7. The use of any one of claims 1 to 6 wherein the ent comprises administering one or more ed from the group consisting of antiemetics, antispasmodics, parasympatholytics and agents which protect gastric mucosa.
8. The use of claim 7 wherein the treatment comprises administering to the patient a neurokinin 1 (NK1) receptor antagonist such as Aprepitant, a 5-HT3 receptor antagonist such as Ondansetron, Granisetron or Palonosetron, or a combination of two or more thereof, an antispasmodic such as butylscopolamine and a proton pump inhibitor such as Pantoprazole.
9. The use of any one of claims 1 to 8 wherein the antibody is administered by i.v. infusion.
10. The use of claim 9 wherein the i.v. infusion is over a time period of between 1 and 4 hours.
11. The use of any one of claims 1 to 10 wherein the antibody mediates cell killi ng by one or more of complement dependent cytotoxicity (CDC) ed lysis, antibody dependent cellular cytotoxicity (ADCC) mediated lysis, ion of sis and inhibition of proliferation.
12. The use of any one of claims 1 to 11 wherein the antibody is an antibody selected from the group consisting of (i) an antibody produced by and/or obtainable from a clone deposited under the accession no. DSM ACC2810, (ii) an antibody which is a chimerized or humanized form of the dy under (i), (iii) an antibody having the specificity of the antibody under (i), and (iv) an antibody comprising the antigen binding portion or antigen g site, in particular the le , of the antibody under (i) and preferably having the specificity of the antibody under (i).
13. The use of any one of claims 1 to 12 wherein the cancer is gastroesophageal cancer.
14. The use of any one of claims 1 to 13 wherein the cancer is metastatic, refractory or recurrent advanced gastroesophageal cancer.
15. The use of any one of claims 1 to 14 wherein the patient had prior therapy with at least one drug selected from the group ting of pyrimidine analogs, platinum compounds, epirubicine, docetaxel and detoxifying agents for antineoplastic treatment.
16. The use of any one of claims 1 to 15 wherein the patient has an ECOG performance status of between 0 and 1 and/or a Karnofsky Index of between 70 and 100%.
17. The use of any one of claims 1 to 16 wherein CLDN18.2 has the amino acid sequence according to SEQ ID NO: 1.
18. Use of an antibody having the ability of binding to Claudin-18 splice variant 2 (CLDN18.2) sing an antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO: 32 and an antibody light chain comprising the amino acid sequence shown in SEQ ID NO: 39 in the manufacture of a diagnostic preparation to determine the responsiveness to treating a cancer disease of a patient by administering the antibody at a dose of 300 to 1000 mg/m2 so as to provide a serum level of at least 40 µg/ml, and (i) determining the blood level of one or more markers selected from the group consisting of CA 125, CA 15- 3, CA 19-9, CEA, IL-2, IL-15, IL-6, IFNg, and TNFa wherein a decrease in the level of at least one of the markers selected from CA 125, CA 15-3, CA 19-9, CEA, IL-2, IL-15, IFNg, and TNFa and/or an se in the level of IL-6 following stration of the antibody indicates that the patient is responsive to treatment; or (ii) determining the percentage of CLDN18.2 positive cancer cells, wherein a level of at least 50% CLDN18.2 ve cancer cells indicates that the t is amenable to treatment or prevention of a cancer disease.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2013/000817 WO2014146672A1 (en) | 2013-03-18 | 2013-03-18 | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
EPPCT/EP2013/000817 | 2013-03-18 | ||
PCT/EP2014/000719 WO2014146778A1 (en) | 2013-03-18 | 2014-03-17 | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ710648A NZ710648A (en) | 2021-03-26 |
NZ710648B2 true NZ710648B2 (en) | 2021-06-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220184209A1 (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
AU2018201391B2 (en) | Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer | |
US10813996B2 (en) | Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer | |
EP2976360B1 (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
NZ710648B2 (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
RU2789478C2 (en) | Combination therapy using antibodies to claudin 18.2 for treatment of cancer | |
KR20240096827A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
NZ711060B2 (en) | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |